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Abstract 
Modern cancer treatment makes extensive use of clinical imaging 
methods for diagnosis and response assessment.  To this end, there is 
increasing desire to non-invasively measure various drugs and 
biomarkers inside a patient on a centimetre scale.  Despite undeniable 
preclinical progress and evaluation of many techniques, few new 
imaging drugs are emerging into pragmatic clinical cancer imaging. 
There are many drug targeting strategies, including target-affinity and 
activation-by-target.  Affinity selections can identify binders from 
combinatorial libraries of heteropolymers such as nucleic-acid sequences 
and peptides.  Using this approach, in combination with next-generation 
DNA sequencing, I identified sequences as binders of putative cancer 
biomarkers.  In addition, I investigated a target-activated fluorescent 
probe as a reporter of cancer-associated enzyme activation. 
Messenger RNA levels for Leucine-rich-repeat containing 15 
(LRRC15) are reported to be elevated in human, breast-cancer samples.  
I analysed a new antibody to LRRC15, which locates this protein in 
genetically triggered murine breast tumours and in their lysates on 
Western blot.  Antibody staining also showed a distinct pattern in 
sections of normal murine kidney, and protein expression in human 
breast-cancer samples. 
LRRC15 affinity selection of phage peptide and aptamer libraries was 
performed with immunopurified protein, and this identified consensus 
sequences.  However, specific binding of the peptides or aptamers to the 
target was not demonstrable. 
 
  v 
Alpha folate receptor overexpression has been described in many 
human tumours, particularly ovarian cancer.  Cell-lines to enable whole-
cell selection of binders to the folate receptor were developed.  Specific 
staining with a folate-fluorophore compound validated these.  Selection 
of peptide and aptamer binders showed early emergence of spurious 
dominant sequences, triggering abandonment of this approach.  The cell-
lines were used to test a folate-quantum dot conjugate, with 
disappointing results. 
Matrix Metalloproteinase-9 (MMP-9) activity in cancer has 
previously been described and pursued as a therapeutic target.  A novel 
probe to report activity of MMP-9 was tested using fragments of murine 
tissue, successfully differentiating normal murine fat pad from pieces of 
murine mammary tumour.  Significant off-target activation was also 
observed, particularly with kidney.  Recombinant proteins based on 
human MMP-2 and -13 also activated the probe.  Expression and activity 
of equivalent enzymes in the murine tissues and tumours were assessed 
using RT-PCR, Western blot, immunohistochemistry and zymography, 
but the basis of spurious activation remains obscure. 
In conclusion, a new antibody identifies LRRC15 in both human and 
murine breast cancers, and in the murine kidney.  Library affinity 
selections with LRRC15 and the alpha folate receptor developed 
consensus sequences, but were unsuccessful.  An MMP-9 activated 
probe successfully differentiated breast tumour from normal tissue but 
also showed significant off-target activation.  Non-invasive detection and 
measurement of cancer biomarkers remains an important topic, likely to 
see much progress in coming decades.  Some of the practical difficulties 
in developing reagents to achieve this are discussed. 
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1.1 Clinical Imaging of Cancer - What is it for? 
Cancer is a wide category of diseases characterised by abnormally 
increased cell division.  This collection of diagnoses is currently 
implicated in 28% of our deaths in the United Kingdom(1), and a greater 
proportion in Scotland, despite a wide variety of successful treatments. 
Accurate diagnosis of cancer is fundamental to choosing treatment.  
In almost all cases and in many different ways, clinical imaging 
contributes to cancer diagnosis.  Diagnosis of cancer is multifaceted.  
Currently organ of origin, histological type, and extent of disease are the 
cardinal elements.  Clinical imaging is usually critical to defining the 
first and third of these. 
Measuring the extent of a cancer in a patient is called ‘staging’ and 
clinical imaging always plays a role here.  Staging is considered in two 
parts: the size and extent of the primary tumour, then the extent of 
secondary disease that is distant (or metastatic) from this. 
Disease stage informs treatment options.  A limited extent of disease 
is the rationale for radical treatment, for example surgical resection.  
Conversely when disease is widespread, or cannot safely be uprooted, a 
patient is unlikely to benefit from a therapy that targets only part of it.  
(Metastatic lesions are sometimes more dangerous that the primary 
tumour.)  Therefore accuracy in staging is crucial.  Recurrence-rates 
after radical therapy must in part be due to under-staging cancers in 
patients who might have been better treated systemically.  This is a 
significant loss on many accounts and improvements in the accuracy of 
clinical imaging could improve treatment of patients with cancer.  
Therein lies the motive for this work. 
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Describing possible manifestations of cancer in clinical imaging 
exceeds the scope of this introduction.  However, a sketch of the current 
importance and variety of imaging in the diagnosis and treatment of 
cancer will be attempted under the sections: 1.1.1 to 1.1.4 below.  A 
brief systematic description of the clinical imaging techniques will 
follow in 1.2. 
1.1.1 Initial Detection 
There are three possible pretexts to a diagnosis of cancer: symptomatic 
presentation, incidental detection, and screening detection.  Cancers may 
present because of metastatic disease but still within these categories. 
1.1.1.1 Symptomatic Presentation 
Examples of imaging to investigate symptoms that may portend cancer 
are chest radiography following chronic cough, kidney ultrasound-scan 
following atraumatic sterile haematuria, and brain computed-tomography 
(CT) following seizure. 
1.1.1.2 Incidental Detection 
Incidental detection is the diagnosis of a tumour during investigation for 
an unrelated complaint, or scientific study.  Examples are the diagnosis 
of lung cancer during a CT coronary angiogram for exertional chest-
pain, or a glioma detected on a scan during a population-study of brain 
sizes.  In the ensuing reorientation, doctors sometimes call these 
diagnoses incidentalomas(2).  This type of diagnosis is becoming more 
common, and in addition to spawning new vocabulary it is opening new 
areas of practice in medicine, ethics and law(3, 4). 
1.1.1.3 Screening Detection 
The screening of asymptomatic patients for malignant diseases is no less 
controversial(5, 6) and an important source of cancer diagnoses.  
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Currently in Scotland we have a National Health Service breast-cancer 
screening programme based on mammography(7), and CT screening for 
colon cancer is available commercially to people over 45 years old(8). 
1.1.2 Staging - Detecting Metastases 
This is arguably the most important next step in diagnosing a cancer(9).  
The presence of metastases dramatically alters prognosis and treatment 
in most cases, diagnostic inaccuracy likewise.  Metastases are broadly 
divided into two types: those in regional lymphatics, and distant 
metastases.  To search for the latter, the field of view must include at 
least the whole trunk and this limits ability to resolve sub-centimetre 
lesions.  There are a variety of effective but imperfect techniques 
available so debate remains open about the best way to look for distant 
disease in even the most common(1) tumours: lung(10), colon(11), 
breast(12) and prostate(13). 
Whole body staging is initially carried out by contrast enhanced CT 
scan of the patient’s chest, abdomen and pelvis.  Often this supplies 
enough information for clinical decision making.  In the event of 
apparently limited disease, there are various additions such as CT of the 
brain or a radionuclide bone-scan for tumours with high-risk of 
metastases to these sites.  The use of 18FDG PET/CT is of increasing 
importance and it is now often used to check the staging of some cancers 
before radical therapy. It has become routine in our local practice before 
resecting lung(14) cancers for example. 
In many situations, the use of 18FDG PET/CT remains debatable and 
other techniques like whole-body diffusion-weighted MRI are being 
tested in some centres(15). 
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1.1.3 Staging - The Primary Tumour 
The aim of staging the primary tumour is to define the limits of the 
disease with respect to the local anatomy.  This will determine whether 
removal or localised radiotherapy are possible, and enable operative 
planning.  If a tumour is excised, pathological examination of the 
resection specimen can provide a definitive report of the local stage. 
Pre-operatively and pragmatically, clinical imaging is normally used.  
Sometimes initial staging at surgery (direct inspection of the tumour in 
situ) does occur, either by design or necessity.  An example of the latter 
is emergency resection of a gastric tumour to control bleeding.  
Otherwise, when a tumour is discovered to be unresectable during or 
after attempted removal, this represents a failure of pre-operative 
imaging. 
An example of a recent preoperative staging paradigm that has 
facilitated better treatment planning is MRI for rectal tumours(16).  The 
improved MR imaging of the rectum and surrounding fat-planes, 
coinciding with the recent surgical technique of total mesorectal 
excision, has refined treatment of this common disease. 
Limitations in imaging resolution mean that there is often reasonable 
doubt about tumour stage before attempting radical treatment.  Agendas 
are complex around pre-operative decision-making and when imaging 
findings are inconclusive, there is a tendency to down-stage. This 
justifies an attempt at cure and gives the patient this ‘benefit’ of the 
doubt (17).  Whilst pragmatic this is also suboptimal, witnessed by the 
dreadful recurrence rates after attempted radical treatment of some 
cancers (18).  An important consideration is that attempted radical 
treatment of patients who then develop recurrence (a proportion of 
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whom presumably had undiagnosed locally advanced or metastatic 
disease) delays and compromises their entry to appropriate systemic 
therapy and clinical trials. Accurate upstaging, which might be provided 
by better imaging resolution, would be difficult truth for patient and 
carer alike, but it would benefit the patient, the health-care disburser and 
research into systemic therapies. 
1.1.4 Monitoring Therapy 
Modern oncology increasingly uses feedback from clinical imaging in 
treatment evaluation, with both established and experimental treatments.  
Criteria for the dynamic radiological assessment of cancer are well 
standardised(19).  The essence (with heed to oversimplification) is that 
response assessment is carried out with contrast enhanced CT-scanning, 
and results are categorised as: Complete Response, Partial Response, 
Stable disease or Progressive disease, based on changes in lesion size.  It 
is rare to be able to categorise so neatly, and a variety of caveats, and 
even different scoring systems are sometimes required(20). 
The field of research in ‘response assessment’ is exceptionally 
dynamic, with application of many experimental imaging techniques. In 
many cases the patients under study are also on therapy that is still 
experimental.  Being able to image specific changes in metabolic activity 
would be of particular relevance to this rapidly expanding area of 
radiological practice.  Useful reviews of the topic have been published 
by Aboagye in 2010 (21) and Nishino et al. in 2014 (22). 
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1.2 Current Techniques, their Roles and Limitations 
This is a brief review of current clinical imaging modalities, including 
some example contrast agents and tracers. 
1.2.1 Radiographs 
In clinical imaging, a radiograph is a two dimensional image formed by 
the passage of x-rays through a body-part.  Differential absorption of an 
x-ray beam by different tissues, results in a spatial representation of x-
ray attenuation on a flat sensor.  Until recently this would be 
photographic film.  Silver-halide photographic techniques are almost 
entirely replaced by other detection media including semiconductor 
sensor arrays. 
In practical terms, the interpretation of radiographs is complex and 
often unreliable.  They are restricted in their ability to discern different 
soft-tissues and interpretation relies on the boundaries between tissues of 
different density in only four categories: Bone, Water (non adipose soft-
tissues), Fat (adipose tissue), and Gas (e.g. lung, or bowel lumen) 
1.2.1.1 Radiographic Contrast Agents 
Radiographic contrast agents are given to alter the radiodensity of a 
structure and aid interpretation. 
Radiodense contrast agents are based on the x-ray absorption of the 
elements iodine (in solutions of organoiodide compounds) or barium (in 
suspension of barium sulphate).  Liquids can be used to delineate 
structures into which they are introduced, or that iodinated solutes 
transfer to.  Examples are intra-arterial injection of iohexol to highlight 
arterial anatomy, enema of barium sulphate to visualise the colon and 
rectum, and intravenous injection of iohexol followed by delayed 
radiographs to show renal filtration and urine flow. 
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Air or carbon dioxide are frequently used as radiolucent (or negative) 
contrast agents. 
1.2.1.2 Role in Clinical Imaging of Cancer 
Although radiographs do have a role in the initial detection of cancer, 
they have been superseded by computed tomography and other 
techniques for staging and response assessment(19). 
1.2.2 Computed Tomography 
A Computed Tomogram is an image that represents a 2D cross-section 
of the object, in terms of x-ray attenuation.  In clinical imaging, a CT 
scan is a set of such cross sectional images at regular positions along the 
patient or body part.  The image is formed by computation using a series 
of projections through a slice from different angles(23).  The slice, (of 
defined thickness) is divided into discrete regular volumes or voxels.  
The calculated x-ray attenuation of each is shown as the greyscale value 
in a pixel.  By convention, the attenuation value is mapped to pixel 
brightness. 
 
FIGURE 1. Principles of Computed Tomography 
A: Arrangement of a patient in a rotating scanner gantry.  B: Projection of 
voxel data into a tomogram. 
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Although the spatial resolution is not as great, CT is better able than 
radiography to resolve differences in attenuation(24), allowing 
subdivision of the crude categories available with radiographs.  In the 
example of a brain CT, the crude radiographic category of ‘water 
density’ can be resolved into: simple fluid (cerebrospinal fluid), lipid-
rich soft tissue (white matter) and non lipid-rich soft tissue (grey matter). 
Modern CT scanners can acquire data from an entire human in a few 
seconds.  Subsequent computation and display of images based on 
contiguous millimetre-cubed voxels is available a few seconds after that.  
It remains normal practice to view the images of axial sections, but 
because the data is continuous in three dimensions, the plane of 
projection can usefully be varied. 
1.2.2.1 Contrast Agents for Computed Tomography 
Contrast agents for CT are similar to those for radiography, described in 
1.2.1.1.  Increase in the attenuation of a structure by contrast is called 
enhancement.  The ability of CT to accurately measure attenuation 
means that enhancement can be quantified.   
Orally given contrast is frequently used to demonstrate the lumen of 
the proximal gut, and rectally administered contrast or gas (negative 
contrast) can aid in assessment of the distal parts. 
The primary form of contrast enhancement used for CT is a solution 
of iodinated small-molecule drugs, injected intravenously. This can be 
visualised in the various vascular compartments within a few seconds.  
Most organs show transient parenchymal enhancement.  Extravasation of 
contrast from the capillaries of diseased tissue can cause a persistent 
enhancement.  The timing of the CT data acquisition in relation to 
contrast injection is referred to as the ‘phase’. 
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It is possible to make a rapid series of measurements, and thus 
enhancement can be sampled at different time points, assessing dynamic 
contrast enhancement (DCE). This is an experimental technique for 
assessing tumours(25).  Each measurement incurs a dose of radiation and 
this may result in a considerable accumulation. With restricted scan 
volume and in the context of malignant disease, this may be justifiable. 
Experimental gold nanoparticles are being developed as targeted 
contrast agents in murine xenograft models(26, 27), but in current 
practice CT contrast is essentially untargeted. 
1.2.2.2 Role in Clinical Imaging of Cancer 
Intravenous-contrast enhanced CT scanning is the current workhorse of 
clinical imaging in cancer(19).  Other techniques have specialised roles, 
but CT is near-ubiquitously used to look for metastatic disease.  It is also 
often sufficient for local staging of primary tumours. 
1.2.3 Ultrasound 
Ultrasound imaging is another form of tomography, based on the 
differential reflection of pressure oscillations (>20kHz) by tissues.  It 
relies on physical contact of a transducer (performing emission and 
detection) with the imaged part.  It is also limited by beam attenuation in 
many scenarios.  As such, it is not practical to perform in a systematic, 
whole-body manner.  Current systems use human monitoring of probe 
position, and therefore deferred analysis of a study is limited. 
Despite these disadvantages ultrasound remains a significant 
modality in clinical imaging, with a number of specific strengths such as: 
speed, lack of ionising radiation, relatively cheap and portable 
instruments and Doppler-shift analysis of the returning waves.  The first 
two reasons mean that it is particularly good for dynamic imaging, 
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including the guidance of procedures.  Ultrasound beams can also be 
modified for localised drug activation(28) and heating for tumour 
ablation(29). 
1.2.3.1 Contrast Agents 
Non-targeted ultrasound contrast agents based on hyperechoic 
microbubble suspensions are available and can help in the 
characterisation of liver lesions by ultrasound(30) although this is 
seldom applied in local practice.  The experimental assessment of 
tumour therapeutic-response, using changes in dynamic contrast 
enhancement(31) takes advantage of ultrasound’s strengths and may 
prove to be widely useful. 
Experimental targeted-microbubbles have been tested in animal 
models(32). 
1.2.3.2 Role in Clinical Imaging of Cancer 
Localised imaging, for instance of a primary breast tumour and axillary 
nodes is useful(33).  Two other examples are endoluminal ultrasound 
assessment of early stage tumours in the rectum(16) and oesophagus(34).  
Liver ultrasound for detection of distant metastases is a recognised 
technique but is now out-dated(35). 
1.2.4 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is based on the return of radio-
frequency signals from organised atomic nuclei, when a patient is in a 
strong magnetic field.  The predominant nucleus used is hydrogen-1 or 
1H, a single proton.  By using variation in the magnetising field, the 
timing and phase of stimulating radiofrequency pulses, and the timing of 
signal acquisition, the returning signals can be spatially decoded.  
Because of the high density of 1H in tissues, and differences in the 
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magnetic relaxation behaviour of 1H when bound in water or in lipids, 
they form an excellent substrate for imaging soft-tissues in this manner. 
As there is no ionising radiation employed, MRI is believed to be non 
harmful.  Incompatibility of some implanted devices and difficulties 
arising with relatively long and noisy scan-times in a narrow, horizontal 
bore do limit use in some patients. 
1.2.4.1 Contrast Agents 
MRI contrast agents in current practice are based on chelated organic 
gadolinium (Gd3+) complexes.  These are paramagnetic and alter the 
behaviour of nearby 1H nuclei.  In the most part, they are used in a non-
targeted fashion after intravenous injection, as with CT.  Some 
complexes show particular biliary excretion that makes them useful in 
assessing the liver parenchyma in the half-hour following injection(36). 
1.2.4.2 Role in Clinical Imaging of Cancer 
MRI has many roles but generally these are in the local and regional 
staging of tumours.  A good example is assessment of rectal cancers, 
where there are a number of operative strategies to choose depending on 
precise location and stage(16).  MRI of the whole body is possible, and 
while it is currently not in general use to detect distant disease, this is 
advocated(15).  It is also being tested as a surrogate marker of tumour 
response, for a balanced review see Heijmen 2012(37). 
1.2.5 Single Photon Scintigraphy 
Gamma ray emitting radiotracers can be localised in the body on a 
centimetre scale by using a collimating camera.  Collimation is 
inherently inefficient.  However, with established reliable methods of 
production and combination of radioisotopes, this remains a useful 
technique.  Rotation of the camera (or multiple cameras) around the 
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patient allows the construction of a computed tomogram from a series of 
projections.  This is called Single Photon Emission Computed 
Tomography (SPECT).  An x-ray CT gantry can also be combined in a 
single installation to enable acquisition of x-ray attenuation data in the 
same session (SPECT/CT) so that the two data sets can be superimposed, 
enhancing interpretation. 
1.2.5.1 Tracers 
Many different radiotracers have been developed and validated for 
clinical practice.  The most useful isotope is technetium-99m which 
decays by gamma emission with a half-life of 6 hours.  It is generated 
over a favourable timescale from the beta decay of molybdenum-99.  
This process can be managed in a small hospital setting, with harvest of 
the radioactive pertechnetate in a saline solution.  However there are 
concerns about the supply of molybdenum-99 from specialised nuclear 
reactors over forthcoming years. 
Unmodified sodium pertechnetate can be used in thyroid imaging and 
to identify ectopic gastric mucosa.  More frequently, the technetium is 
combined with another compound or drug that confers specificity for a 
location or process in the body.  A common example, and one frequently 
used in the assessment of cancer patients, is the complex of radioactive 
technetium with medronic acid.  After intravenous injection, this binds 
preferentially to areas of active bone metabolism, and can thus identify 
bony metastases. 
1.2.5.2 Role in Clinical Imaging of Cancer 
The bone-scan is the most common example of scintigraphy in cancer 
imaging.  This technique has continuing relevance in the detection of 
bony metastases when staging breast(38) and prostate cancer(39). 
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1.2.6 Positron Emission Tomography 
 
FIGURE 2. Principles of Positron Emission Tomography 
A: An emitted positron causes an annihilation reaction with an electron.  This 
results in a diametric pair of photos, each specifically 511 keV.  B: Coincident 
detection of such a pair by the annular array locates the event on the chord 
between the detectors.  In addition, time resolution is now sufficient to estimate 
position on the chord. 
Positron emission tomography (PET) is another radionuclide imaging 
technique that uses isotopes decaying by positron emission, which 
indirectly produces paired gamma photons (as opposed to a single 
gamma photon from nuclear emission).  In the body, a radiated positron 
will normally travel about 1mm before an annihilation reaction with an 
electron.  This yields a pair of high-energy photons with effectively 
antiparallel trajectories.  Detection of many coincident-pairs of photons 
in the detector array allows computation of where in the ‘slice’ the 
radioactive decays are occurring i.e. positron emission tomography 
(PET).  This enables filtration of noise to be performed by co-incidence 
analysis, rather than collimation, improving signal to noise ratio.  Noise 
includes excitations from background radiation or out-of-plane decays.  
For a useful review of PET instrumentation, see Turkington 2001(40). 
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Improvements in the many technologies that underlie PET, 
particularly isotope production, radiochemistry, computers and the 
integration of PET instruments with x-ray computed tomography 
(PET/CT) have brought PET/CT to be a practical technique for staging 
of many solid tumours. 
Combined PET and MRI in a single apparatus has been available 
commercially for about four years and is being evaluated as a further 
technique(41). 
1.2.6.1 Tracers 
The most commonly used isotope for PET is fluorine-18 (18F), which can 
be generated in a cyclotron.  Such devices are becoming smaller and 
cheaper, with a mass of a few tons and convenient operational cycles.  
Fluorine-18 decays by positron emission with a half-life of 110 minutes.  
The relatively short half-life, particularly when combined with near-
patient production and radiochemistry, give a further signal-to-noise 
advantage.  Other positron emitting species such as oxygen-15, with a 
shorter half-life of 122 seconds can be used for greater temporal 
resolution (42), but that same instability restricts the radiopharmaceutical 
possibilities.  Species with a longer half-life, such as zirconium-89 (half-
life 3.3 days) offer more time for chemical incorporation and long 
pharmacodynamics (43), but have corresponding loss of signal intensity. 
1.2.6.2 Fluorine-18 Deoxy-Glucose 
The only agent for PET of tumours in clinical practice is 18F 2-
fluorodeoxy-glucose (18FDG), which was developed in the 1970s(44).  
This undergoes uptake into cells and phosphorylation as normal glucose 
does, but arrests there.  Increased glucose metabolism is a long-observed 
feature of neoplasia(45).  There are often limitations in interpretation due 
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to the non-specific nature of increased 18FDG uptake, and it is not always 
increased in cancers. 
1.2.6.3 Role in Clinical Imaging of Cancer 
18FDG PET/CT is now often used to confirm the early stage of some 
cancers before radical therapy. It is routine in our local practice before 
resecting lung(14) and oesophageal cancers for example.  Although it is 
unquestionably a useful technique for the detection of distant metastases, 
care must be taken that the poor resolution of local extent by this 
impressive modality does not override information from other more 
sensitive staging investigations(46). 
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1.3 Novel Tracers – Where are they? 
Despite some understanding of abnormal proteins that are important in 
cancer, and their useful therapeutic targeting, our ability to demonstrate 
these with clinical imaging is poor.  Currently, for accurate diagnosis, 
any tissue in question must be examined ex vivo for histology.  This can 
include immunohistochemistry and in situ hybridisation assays.  Genetic 
sequence analysis of ex vivo tissue is also gaining importance.  Tissue for 
these analyses is obtained by resection or biopsy. 
 
FIGURE 3. CT Guided Biopsy of a Pulmonary Hilar Mass 
The patient was prone and awake.  The metal biopsy needle tip is seen entering 
the mass.  Proximity of the needle to the aorta and a left pulmonary artery 
evokes some of the risk to the patient inherent in this diagnostic technique. 
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Biopsy is an invasive procedure and obtains a limited sample.  Figure 3 
is provided to illustrate this and shows how CT can be used to guide 
needle placement, when retrieving tissue from a tumour adjacent to the 
great-vessels in the posterior mediastinum.  Cancers are often 
heterogeneous in terms of genetics, protein expression and treatment 
response, even within one patient’s disease(47).  It is thus a potential 
source of error to infer that a limited sample is representative, and some 
of the most aggressive tumours yield only necrotic debris that defies 
interpretation.  Non-invasive imaging that could highlight particular 
features of cancer might offer significant advantages: 
1. Characterise specific abnormalities that guide therapy 
• Reduce need for biopsy 
• Assess heterogeneity 
2. Increase sensitivity and specificity of tumour detection 
• More accurate staging and assessment of treatment response 
• Improve animal experimental systems 
Although the tracers in current practice are long established, there is no 
lack of activity or investment to develop others.  Some strategies are 
outlined with examples below: 
1.3.1 Affinity Targeting 
1.3.1.1 Cell Membrane Targeting 
Plasma membrane receptor targeted imaging has been used successfully 
in cancer staging since 1989(48) when somatostatin analogues were used 
to target carcinoid metastases.  This drug has been updated to use a 
positron emitter for PET/CT(49).  However, this is an unusual and rare 
cancer, not least because it tends to remain well differentiated. 
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More recently, and of greater impact, a number of plasma-membrane 
proteins have become successful targets for therapeutic antibodies(50) in 
common cancers.  This illustrates that despite heterogeneity, these 
aggressive cancers have an abnormal population of cell-surface proteins 
that can be usefully targeted.  Demonstrating the presence of these 
targets with imaging would help inform treatment decisions. 
Human Epidermal growth factor Receptor 2 (HER2) overexpression 
is oncogenic and targeted by the therapeutic monoclonal antibody 
trastuzumab(51).  Labelling the therapeutic antibody for use as an 
imaging agent links the imaging to potential therapy.  However, the long 
serum pharmacokinetics of an antibody (that serve its primary purpose 
well) hinder use as an imaging agent.  Despite this, potentially useful 
imaging of HER2 receptors can be achieved in patents with metastatic 
breast cancer(52) with this approach.  The kinetics of imaging an 
antibody mean that in this study, the best information was obtained at 4-
5 days after injection.  Imaging at such a long interval reduces the signal 
intensity that can be retrieved, and means that a great proportion of the 
dose of radioactivity is not useful.  It also requires a longer half-life label 
and zirconium-89 was used in this case. 
One approach to adapting the kinetics of antibodies for better imaging 
agents is to reduce the size of the protein, but preserve the antigen 
binding domain and affinity.  Smaller synthetic affibodies (58 amino 
acids or approximately 6kDa) have been successfully labelled and thus 
used to image HER2 receptors in metastatic breast cancer(53). There is 
ongoing preclinical research to optimise binding and labelling 
strategies(54). 
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Outwith oncology, and much of it predating PET/CT, there is a 
background of experience in using neurotransmitter analogues as PET 
tracers to image postsynaptic receptor populations in the brain(55).  This 
was an early use of PET and has been an important component of drug 
development including binding and competition studies.  For review, see 
Fowler et al.  1999 (56). 
1.3.1.2 Intracellular Targeting 
The Epidermal Growth Factor Receptor (EGFR), known also as Human 
Epidermal growth factor Receptor 1 (HER1) is another current 
therapeutic target.  It can sometimes be successfully targeted with 
cetuximab(57) (another monoclonal antibody drug) and also by 
inhibitors of its intracellular tyrosine kinase domain such as 
gefitinib(58).  Imaging in a patient with non small-cell lung cancer has 
been achieved with a labelled analogous small-molecule kinase 
inhibitor(59). 
1.3.1.3 Stromal Targeting 
Aside from ‘tumour cells’, other components of cancer may be potential 
targets for imaging.  With increasing understanding of the reliance of 
many cancers on a facilitating inflammatory response, connective tissue 
elements and neovasculature, it is clear that these are not only rational 
targets for therapy and imaging(60) but also potentially unifying (i.e. a 
common feature of various cancers).  A current example is the detection 
of osseous metastases by using the associated osteoblastic response to 
focus uptake of technetium-99m labelled medronic acid, detected by 
scintigraphy and commonly called a ‘bone scan’ (see also 1.2.5). 
Alpha-V, Beta-3 integrins are expressed in new blood vessels(61) and 
are the archetypal integrin(62), typified by affinity for an RGD peptide 
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motif found (not exclusively) in fibronectin(63).  There are recent reports 
of human imaging of Alpha-V, Beta-3 integrin expression using positron 
emitting drugs, targeted by RGD peptides(64, 65).  These are yet to 
prove more useful than established methods, and it should be noted that 
the imaging of neovasculature is already quite well achieved because it is 
permeable to untargeted contrast agents (such as iohexol or Gd3+ 
chelates) with patterns of dynamic and late phase enhancement that are 
well observed. 
1.3.2 Metabolic Uptake and Incorporation 
Irreversible uptake of a tracer into cells provides an excellent rationale 
for developing a signal.  Affinity based strategies will be inherently 
limited by the density of target expression, and the clearance of unbound 
tracer.  When considering cell-surface markers, the cell surface is 
already only a small proportion of available volume, thus limiting 
possible density.  In contrast, the uptake and terminating phosphorylation 
of 18FDG concentrates the tracer in the cytosol of active cells.  Once 
phosphorylated, it will neither proceed in metabolism, nor diffuse out.  
Also the blood pool of tracer is quickly eliminated by uptake (normal 
and pathological) or renal loss (it is not recovered from glomerular 
filtrate as effectively as glucose).  A number of different approaches are 
thus being tried to label small molecule metabolites as cancer biomarkers 
(which might have more specificity than glucose) such as a labelled 
glucosamine derivative to assess glycogenesis(66). 
The nucleoside analogue 3-Deoxy 3-Fluoro-Thymidine can be 
labelled with 18F(67), which links the radiotracer to DNA synthesis and 
thus tracer accumulation is putatively a surrogate marker of mitosis.  
This tracer has been used in clinical trials and can yield useful 
information in some settings.  A recent report from the Netherlands 
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describes the early use of FLT PET during treatment of head-and-neck 
squamous carcinomas, suggesting that the technique might be applicable 
for early response assessment and thus steering therapy(68). However a 
recent study comparing it with 18FDG in assessment of non small-cell 
lung cancer treatment response(69) found it to be less effective.  
Accumulation of the thymidine analogue in normal tissues including 
liver can limit studies but separation of signal in hepatic metastases from 
that in normal liver has been achieved by quantification and kinetic 
analysis(70).   
Metabolic stress in human cancer tissue can be imaged using hypoxia 
and pH.  Hypoxia in living cells can be effectively imaged by using the 
radiotracer 18F-fluoromisonidazole (among others(15)) The tracer is 
metabolically trapped by reduction inside hypoxic cells.  Tissue pH has 
also been successfully measured using distinct MRI signals from 
hyperpolarised carbon-13 in carbon dioxide and bicarbonate, following 
injection of hyperpolarised carbon-13 bicarbonate solution(71).  The 
complex and expensive practicalities of these techniques have thus far 
limited their application to a research setting. 
Positron-emitting radiolabelled choline has been used experimentally 
in the imaging of prostate cancer for over fifteen years(72, 73).  Its utility 
appears to be limited by rapid degradation of the choline analogues used 
as tracers.  New understanding of this metabolism, and its mitigation by 
a deuterium substitution, may help to rejuvenate the use of choline 
analogues as PET tracers (74). 
1.3.3 Enzymatic Activation 
Particularly, but not specifically, in the context of fluorescent imaging, 
there are a number of pre-clinical probes that can be activated by an 
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enzyme.  For a fluorescent probe or reporter, the mechanism of action 
either involves separation of a fluorophore from a quenching moiety(75, 
76), or an activating modification to a fluorophore(77). 
 
FIGURE 4. A Quenched Pair of Fluorophores are Revealed Following Separation 
A: The constrained proximity of the fluorophores means that quenching occurs 
by Förster resonant energy transfer between them.  B: Enzymatic division of 
the substrate releases the fluorophores, dequenching, or revealing their 
fluorescence. 
A potential problem with this approach is that activated probe may not 
remain localised.  Attempts to surmount this by designing activated 
fragments to be cell penetrating (whereas the inactive whole is not) have 
been tried (78, 79), and these are discussed further in 7.3. 
Activatable paramagnetic contrast agents for MRI are also in 
development and undergoing preclinical testing(80).  In this example, the 
paramagnetism of the contrast agent is amplified on polymerisation 
catalysed by myeloperoxidase. 
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1.4 Combinatorial Libraries and Affinity Selection 
Heteropolymers like DNA and proteins incorporate different sub-units in 
a sequence, like beads on a string.  In both of those cases, the polymers 
have a conserved, linear central structure and diverse side chains.  
Combinatorial libraries are collections of heteropolymers that share 
similar central structure but different sequence combinations. 
 
FIGURE 5. Selection and Amplification of an Aptamer Library 
Rounds of selection (including counter-selection) and amplification derive a 
pool of nucleic acid aptamers with specific affinity for a target.  In this case 
using adherent cells in tissue culture.  Reproduced with permission from 
Cerchia and de Franciscis 2010(81). 
It is possible to design such a library for easy amplification in the 
laboratory, for example by PCR.  Serial rounds of affinity-selection and 
amplification can reduce the library diversity to elements with affinity to 
the target(82).  The successful elements can then be sequenced and 
analysed (reviewed by Cerchia and de Franciscis in 2010(81)).   
Molecular Targeting for Clinical Cancer Imaging 
Introduction 25 
A successful sequence in such an experiment may only be a ‘lead 
compound’ requiring modification to optimise properties and enable 
translation.  For instance nucleic acid sequences may benefit from 
substitution with modified bases to increase nuclease resistance(83). 
1.4.1 Phage Display Peptides 
Combinatorial peptide libraries can be displayed(84) on the capsid of 
virions (bacteriophage), which can be amplified in host bacterial co-
culture.  This has been an important approach to drug development in the 
last quarter-century, with successful expression of libraries of antibody 
variable regions on bacteriophages(85) leading to some very successful 
drugs(86). 
Two peptide binders discovered using phage display have recently 
shown promise for in vivo fluorescent imaging.  The peptide 
QPIHPNNM demonstrates specificity for colonic dysplasia following 
local application performed endoscopically(87).  The peptide 
SHSNTQTLAKAPEHTGC was used to highlight murine peripheral 
nerves following systemic administration(88).  For review of phage 
display for molecular imaging of cancer see Deutscher 2010(89). 
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FIGURE 6. Selection and Elution of a Phage Display Peptide Library 
The virions express a variety of peptides on their capsids.  Viral particles are 
selected from this library on the basis of affinity with the presented target.  
Here the peptide sequence is expressed in the pIII coat proteins of an M13 
bacteriophage, giving pentavalent expression at one end.  Reproduced with 
permission from New England BioLabs(90). 
For this project we have used a commercially available 12-residue 
peptide library.  Starting diversity in this library is approximately 109 
elements(90) and hits are normally apparent after three or four rounds of 
selection and amplification. 
1.4.2 Nucleic Acid Aptamers 
Nucleic acid aptamers are short nucleotide sequences that adopt stable 
secondary structures due to complementary base pairing.  These 
configurations can result in particular properties such as specific affinity 
or catalysis, as seen in nature with ribozymes(91, 92). 
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FIGURE 7. Crystallographic Structure of an Aptamer Binding Cyanocobalamin 
A 35-base RNA polymer can form a stable tertiary structure with high affinity 
binding to another molecule.  A: 3D model of an aptamer in complex with 
vitamin B12, structure derived using x-ray crystallography.  B: Sequence 
scheme showing putative hydrogen bonds between bases that contribute to the 
structure.  Strands forming a triplex are coloured dark blue (strand 1; 
nucleotides 7–11), cyan (strand 2; nucleotides 15–22) and yellow (strand 3; 
nucleotides 22–30).  Strands forming a duplex are coloured green (nucleotides 
12–14) and magenta (nucleotides 31–33).  Overhanging bases on the 5' and 3' 
ends are grey.  Reproduced with permission from Sussman et al.  2000(93). 
Combinatorial libraries of random sequences can be formed using solid-
phase synthesis.  Inclusion of conserved priming sites on either side of a 
variable region allows library amplification by PCR.  Transcription into 
RNA, or strand separation using biotin and alkaline denaturation, can be 
used to return the library to single strands(81, 94). 
It is thus easy to handle libraries with huge diversity.  In a 40 base 
random sequence, the possibilities number 440 = 1.2 x1024.  This is 
greater than the Avogadro constant and would require about 20kg of 
anhydrous material to include a single copy of each possibility (and this 
makes no allowance for priming sites).  As such, this level of diversity is 
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impractical, and working libraries will only contain a proportion of this 
possible ‘sequence space’.  The library employed in this work used a 40 
base variable region, and two 22-base conserved priming flanks in a 
single stranded DNA molecule.  The approximate formula mass is 
25.8kg and using the yield from 1ml PCR amplification, experiments 
were performed with an amplified library containing copies of an 
estimated 1013 elements. 
Mutagenic amplification has been suggested as a concept that might 
add useful diversity during rounds, in the initial report(82) of an 
experiment to isolate a specific, avid sequence from a nucleic acid 
library.  Successful aptamer experiments have been reported using 
RNA(82), DNA (95, 96) and nucleic acids with base modifications(83).  
The translational potential of aptamers in drug development has been 
demonstrated by Pegaptanib(97), an approved drug for the treatment of 
neovascular age related macular degeneration.  Twenty-two years on, 
Larry Gold continues to write eloquently about aptamers(82, 98) 
remaining enthusiastic about their commercialisation, and reporting a 
number of interesting modifications. 
Aptamers have also shown some promise in preclinical cancer 
imaging (99) where favourable phamacokinetics and specific tumor 
targetting (using an aptamer to Tenascin-C) were reported.  However 
personal communication with the first author revealed that this aptamer 
and its application had been abandoned following non-replication of 
these results.  Another report of similar work to image xenograft tumours 
in mice, this time targeting MUC-1, detailed difficulties with off-target 
binding that obscured any specific signal(100).  For clear review of 
aptamers see Bunka and Stockley 2006(101), and for focus on specific 
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imaging considerations see Gambhir 2006(102) and Hong et al. 
2011(103). 
1.4.3 Selection Strategies 
A number of different target presentation strategies have been reported 
for both phage peptide and aptamer selection experiments. 
1.4.3.1 Selections with Purified Protein 
The earliest targets used for selection were purified proteins.  The first 
report of panning a phage library used a purified antibody, reported in 
1990(104). In the same year the first RNA library selection was 
performed using affinity to a purified viral DNA polymerase(82). 
It might be argued that this is the simplest and best strategy to 
identify binders to a target, and indeed, for agents to be applied in vitro 
this might be true.  SOMAlogic, who report sophisticated aptamer 
techniques (e.g. incorporation of hydrophobic modified nucleobases) use 
purified proteins for selection(105) but currently their main direction is 
the development of in vitro protein detection in fluid samples.  The only 
licensed aptamer drug was produced using a purified recombinant 
protein(97, 106).  However, monoclonal antibody drugs targeting the 
same protein are more successful(107). 
Performing affinity selection in the absence of competing targets will 
not make any selection for specificity. This may spell difficulties in the 
translation of successful sequences to more complex systems.  As 
libraries have been improved in terms of diversity and handling, there 
are also reports of successful selections using targets presented in more 
complex systems - discussed below. 
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1.4.3.2 Whole-Cell and in vivo Selections 
Target presentation using whole cells has been used to isolate both 
peptides(108) and aptamers(109) for further study.  Many such reports, 
including these two, are not cited in papers translating the findings into 
more complex systems, even though they are a few years old. 
There are also a number of reports detailing whole animal selections of 
phage(110) and aptamer libraries(111).  A recent report from Roger 
Tsien’s group details a phage displayed peptide selected in vivo, from 
which the peptide has been used in vivo(88). 
1.4.4 Counter-selections 
Counter-selection is an important concept in identifying a library 
element with specificity for a target.  To remove non-specific binders, a 
counter-selection step can be performed, see Figure 5 above.  In 
choosing targets, it is also important to consider valid counter-selection 
targets, analogous to a negative control.  Ideally these would include all 
the elements of the selecting reagent except the target, and things such as 
plastic containers and other elements of the target substrate should be 
considered. 
1.4.5 Sequencing Of Selected Libraries 
Sequencing of selected libraries can be carried out by integration into a 
bacterial vector, then dilution and colony selection to amplify clones, 
thus allowing Sanger sequencing of the DNA sequence. 
Modern sequencing technologies automate clonal selection and 
amplification without requiring a bacterial vector, and this has been 
applied with success to aptamer library sequencing(112).  Acquiring a 
great number of reads can give novel insights into library development 
during selection strategies(113).  Ion Torrent(114) offers a relatively 
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cheap next-generation platform whose sequencing scope, whilst 
currently less than a human genome, can theoretically read over one 
million sequencing reactions in a run costing a few hundreds of pounds. 
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1.5 Aims 
The work reviewed in this section is a daunting prospect.  Even with 
such impressive effort and ingenuity, the penetration to patient care has 
been limited.  The principal approach of this project was to identify a 
novel, putative cell-surface cancer marker.  This target would then be 
used to identify binders from combinatorial libraries of nucleic acid 
sequences and phage display peptides.  An extracellular protein domain 
was stipulated, so as to be available for targeting by non cell-permeable 
drugs.   
The approach was duplicated with another more-established tumour 
associated protein in an effort to find novel binders to that. 
An additional strand of work to investigate a target-activated 
fluorescent probe as a reporter of cancer-associated enzyme activity was 
also undertaken. 
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2.1 Materials 
2.1.1 DNA Techniques 
Agarose       Sigma Aldrich 
Metaphor Agarose      Lonza 
Ethidium Bromide      Sigma Aldrich 
Tris Base       Sigma Aldrich 
Boric Acid       Sigma Aldrich 
Ethylenediaminetetra-acetic (EDTA)   Sigma Aldrich 
Deionised water     ECRC central services 
Ultrapure DEPC treated water (10245203)  Fisher Scientific 
Hyperladder 1      Bioline 
DNA Polymerase mix (Pfu Ultra 600850)  Agilent 
DNA Polymerase mix (Paq 5000 600870)  Agilent 
DNA PCR primers (25nM synthesis, desalted, unless otherwise stated)
        Life Technologies 
TOPO blunt cloning vector kit (450245)  Life Technologies 
Miniprep and Maxiprep plasmid purification kits Qiagen 
Shrimp Alkaline Phosphatase (P9088)   Sigma Aldrich 
RNeasy minikit      Qiagen 
RNAlater       Ambion 
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Turbo DNA-free kit     Ambion 
Superscript 1st strand     Life Technologies 
SensiFAST SYBR Hi-ROX Kit    Bioline 
Restriction enzyme EcoR1   New England BioLabs 
Restriction enzyme BamH1   New England BioLabs 
15% TBE-Urea Gels EC6885    Life Technologies 
Veriti PCR thermocycler     Applied Biosystems 
Step One quantitative PCR thermocycler  Applied Biosystems 
Nanodrop 1000 spectrophotometer   Fisher Scientific 
Qiaquick gel extraction kit    Qiagen 
2.1.2 Bacterial Culture 
Universal Containers   Starlab 
Lysogeny Broth    ECRC central Services 
Lysogeny Broth Agar   Sigma Aldrich 
Kanamycin Agar (imMedia)  Life Technologies 
Ampicillin Agar (imMedia)  Life Technologies 
Tetracycline     Sigma Aldrich 
Zero Blunt TOPO cloning kit (K280020) Life Technologies 
2.1.3 Cell Culture 
Dulbecco’s Modified Eagle Medium  Life Technologies 
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RPMI 1640 medium    Life Technologies 
Fetal Bovine Serum    Life Technologies 
200mM L-glutamine    Life Technologies 
2.5% trypsin solution    Life Technologies 
Phosphate Buffered Saline   ECRC central services 
Phosphate Buffered Saline + 1mM EDTA ECRC central services 
G418 (Neomycin)      Sigma Aldrich 
Hygromycin B     Merck Millipore 
Cell Culture flasks and dishes, various Techno Plastic Products 
Cell Scrapers     Techno Plastic Products 
Amaxa Nucleofector     Lonza 
Amaxa Nucleofection solutions and disposables Lonza 
2.1.4 Protein Techniques 
2.1.4.1 Western Blotting 
Tween 20     Sigma Aldrich 
Triton-X     Sigma Aldrich 
ß-Mercapto Ethanol   Sigma Aldrich 
Bromophenol blue    Sigma Aldrich 
Glycerol     Sigma Aldrich 
Sodium Dodecyl Sulphate  Sigma Aldrich 
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Egtazic Acid (EGTA)   Sigma Aldrich 
Proteinase inhibitor cocktail (05892970001)  Roche 
Refrigerated Microcentrifuge (5424R)   Eppendorf 
Pierce BCA protein assay kit    Fisher 
Biophotometer      Eppendorf 
Polyacrylamide Gels (456-8083)   Biorad 
Running Buffer (161-0732)    Biorad 
Transfer Kits (170-4159)     Biorad 
Protein Standards (161-0376)    Biorad 
Electrophoresis tanks (165-8004)   Biorad 
Transfer Machine (170-4155)    Biorad 
Bovine Serum Albumin     Sigma Aldrich 
Dried Milk Powder     Waitrose 
HRP Anti-mouse #7076    Cell Signaling Technology 
HRP Anti-rabbit #7074    Cell Signaling Technology 
ECL substrate solution (170-5060)   Biorad 
Camera (170-8280)     Biorad 
MP FastPrep24 Tissue Homogeniser   MP Biomedicals 
MP FastPrep lysing matrix tubes A   MP Biomedicals 
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2.1.4.2 Immunofluorescence 
PIPES (P6757)      Sigma 
Formaldehyde (37% in water BPE531)  Fisher 
19mm Circular Cover Slip (MNJ-550-020X) Fisher 
Methanol (494437)     Sigma 
488nm fluoro-labelled Anti-mouse (A-11029) Life Technologies 
594nm fluoro-labelled Anti-rabbit (A-11012) Life Technologies 
Microscopy mounting medium with DAPI  Vector Labs 
FV1000 confocal microscope    Olympus 
2.1.4.3 Immunoprecipitation 
Anti-mouse-IgG Agarose beads (A6531)  Sigma Aldrich 
2.1.4.4 Immunohistochemistry 
Xylene       Sigma Aldrich 
Ethanol       Sigma Aldrich 
Sodium Citrate      Sigma Aldrich 
Citric Acid       Sigma Aldrich 
Hydrogen Peroxide     Sigma Aldrich 
Serum Free Block Solution    Dako 
Antibody Diluent      Dako 
EnVision Anti Rabbit secondary   Dako 
HRP-Anti Goat Secondary    Dako 
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Diaminobenzidine (DAB) reagent   Dako 
Haematoxylin      Sigma Aldrich 
Sodium Bicarbonate     Sigma Aldrich 
Magnesium Sulphate     Sigma Aldrich 
DPX Mountant for histology (06522)   Sigma Aldrich 
HRP-Anti Rabbit Secondary (sc2963)   Santa Cruz Biotech 
HRP-Anti Goat Secondary (sc2961)   Santa Cruz Biotech 
Tyramide Signal Amplification kit   Perkin Elmer 
2.1.4.5 Flow Cytometry 
FACSAria II      Becton Dickinson 
2.1.4.6 Zymography 
Novex Gelatin Zymogram Gels (10% Tris-Gly) Life Technologies 
Novex Tris-Glycine SDS Sample Buffer (2X) Life Technologies 
Novex Tris-Glycine SDS Running Buffer (10X) Life Technologies 
Novex Zymogram Renaturing Buffer (10X)  Life Technologies 
Novex Zymogram Developing Buffer (10X)  Life Technologies 
Colloidal Blue Stain B2025     Sigma Aldrich 
mouse MMP-2 (PF118)     Merck Millipore 
2.1.4.7 Antibodies 
anti ß-actin (A5441) (mouse)   Sigma Aldrich 
anti HA tag  (6E2) (mouse)   Cell Signaling Technology 
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anti LRRC15 (custom) (rabbit)   Genscript 
anti CD31 (ab28364) (rabbit)   Abcam 
anti Aquaporin-2 (C-17) (goat)   Santa Cruz Biotech 
anti Folate receptor-a (MOv18) (mouse) Enzo Life Sciences 
Mouse IgG1 isotype control  (G3A1)  Cell Signaling Technology 
647nm-fluoro anti HA tag  (6E2) (mouse) Cell Signaling Technology 
555nm-fluoro control  (G3A1) [mouse} Cell Signaling Technology 
anti MMP-2 (K-20) (goat)   Santa Cruz Biotech 
anti MMP-3 (ab53015) (rabbit)   Abcam 
anti MMP-9 (AB19016) (rabbit)  Merck Millipore 
anti MMP-13 (ab39012) (rabbit)  Abcam 
2.1.5 Phage Display 
PhageDisplay-12 library (E8110S)  New England Biolabs 
E. coli K12 ER2738    New England Biolabs 
IPTG / X-GAL  (B3928)    Sigma Aldrich 
QIAprep M13 DNA kit (27704)  Qiagen 
Sodium bicarbonate S6297   Sigma Aldrich 
Sodium carbonate S7795    Sigma Aldrich 
Alexa 488 labelled Streptavidin S-11223 Life Technologies 
800nm fluoro Streptavidin 926-32230  Licor Biosciences 
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Biotinylated Peptides    JPT peptides 
800nm fluoro Anti-rabbit 926-32211  Licor Biosciences 
96 Well Optical Bottom Plates 165305 Fisher 
2.1.6 Aptamer Reagents 
Aptamer library     Integrated DNA technologies 
Dulbecco’s phosphate buffered saline  Life Technologies 
Magnesium Chloride    Sigma Aldrich 
Glucose      Sigma Aldrich 
Yeast tRNA (83853)    Sigma Aldrich 
PCR primers, with 5' modifications  Life Technologies 
Other PCR primers    Life Technologies 
TOPO TA cloning kit (K4575J10)  Life Technologies 
Streptavidin sepharose (17-5113-01)  GE Health Sciences 
200mM NaOH (5318-500 )   Fisher 
Sephadex Desalting columns (17-0853-01) GE Health Sciences 
4x 72k DNA oligo Arrays   Roche Nimblegen 
Hybridisation System 4    Roche Nimblegen 
MS 200 array scanner    Roche Nimblegen 
2.1.7 MMP-9 Probe Fluorometry 
Brij 35 Detergent (85117)   Fisher 
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DMEM, no phenol red, (31053-028)  Life Technologies 
Ilomastat (CC1010)    Merck Millipore 
rh MMP-2 (SE237)    Enzo Life Sciences 
rh MMP-9 (SE360)     Enzo Life Sciences 
rh MMP-13 (SE246)    Enzo Life Sciences 
Victor 3 fluorescent plate reader  Perkin Elmer 
2.2 Suppliers 
Abcam  330 Cambridge Science Park  CB4 0FL 
Agilent  610 Wharfedale Road   RG41 5TP 
Ambion  see Life Technologies 
Applied Biosystems see Life Technologies 
Becton Dickinson  The Danby Building  OX4 4DQ 
Bio-Rad Laboratories Bio-Rad House   HP2 7DX 
Bioline Reagents Ltd. The Edge Business Centre NW2 6EW  
Cell Signaling Technology 3 Trask Lane Danvers
 MA01923  USA 
Dako  Cambridge House     CB7 4EX 
Enzo Life Sciences Palatine House    EX2 8NL 
Eppendorf AG  Barkhausenweg 1  22339 
 Hamburg Germany 
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Fisher Scientific  Bishop Meadow Road   LE11 5RG 
GE Healthcare Life Sciences  Amersham Place   HP7 9NA 
Genscript   860 Centennial Ave.  Piscataway 
 NJ08854  USA 
Integrated DNA technologies Woodside House   G3 7QF 
JPT Peptide Technologies GmbH   Volmerstrasse 5 (UTZ) 
 12489 Berlin Germany 
Li-cor Biosciences  Saint Johns Innovation Centre  CB4 0WS 
Life Technologies Ltd 3 Fountain Drive   PA4 9RF 
Lonza  Muenchensteinerstrasse 38  CH-4002
 Basel  Switzerland  
Merck-Millipore Boulevard Industrial Park,   NG9 2JR 
MP Biomedicals Santa Ana California   USA 
New England Biolabs 75-77 Knowl Piece   SG4 0TY 
Olympus Corporation KeyMed House   SS2 5QH 
PerkinElmer   Saxon Way Bar Hill  CB23 8SL 
Qiagen   Skelton House    M15 6SH 
Roche NimbleGen, Inc  504 South Rosa Road  Madison
 WI 53719  USA 
Santa Cruz Biotech  10410 Finnell Street Dallas 
 TX 5220  USA 
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Sigma Aldrich  The Old Brickyard   SP8 4XT 
Starlab   Unit 4 Tanners Drive  MK14 5NA 
Techno Plastic Products AG Fabrikstr. 17  D-79771
 Klettgau Switzerland  
Vector Labs   3 Accent Park   PE2 6XS 
Waitrose   Doncastle Road   RG12 8YA 
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2.3 Solutions 
Where stated, pH ajdustments were carried out using dropwise additon 
of 1M hydrochloric acid, or 1M sodium hydroxide solution as required. 
2.3.1 TBE buffer 
10.9g Tris Base, 
5.5g Boric Acid 
0.93g EDTA, 
in 1 litre deionised water. 
2.3.2 RIPA buffer 
‘Radio-Immunoprecipitation Assay’ buffer was used for some cell lysis 
and protein anlaysis experiments. The name relates to earlier use by 
other parties, coined in the 1960s. 
50mM Tris, pH7.4, 
150mM NaCl, 
1% Triton X100, 
0.50% Sodium-deoxycholate 
0.10% Sodium Dodecyl Sulphate 
5mM EGTA 
Shortly before use for cell lysis, proteinase inhibitors were added, 
according to manufacturers instructions (Roche), 1 tablet to 10mls of 
buffer. 
2.3.3 Tris buffered saline (TBS) 
2.42g Tris base 
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8.00g NaCl 
in 1litre of deionised water 
pH adjusted to 7.4 
2.3.4 Tris Buffered Saline + Tween (TBST) 
as above with 0.05% Tween-20 





trace bromophenol blue 
in deionised water 
2.3.6 Tissue Lysis Buffer 
This buffer was used to resuspend disrupted tissue pieces, for sonication 
and subsequent analysis of protein content, as in Almholt et al. 
2008(115). 
TBS, supplemented with: 
10 mmol/L CaCl  
1% Triton-X-100 
pH adjusted to 7.6 
2.3.7 Immunofluoresence Fixative 
1ml  Formaldehyde (37% in water) 
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1ml 100mM EGTA pH 8.0 
4ml 250mM PIPES ph 6.8 
10µl 1M MgCl2 
20µl Triton X-100 
3.97ml Deionised Water 
2.3.8 Immunofluoresence Wash Buffer 
100ml  TBS 
100µl  Triton X-100 
2.3.9 Immunofluoresence Block Buffer 
100ml  TBS 
100µl  Triton X-100 
2g  BSA 
2.3.10 Citrate Antigen Retrieval Buffer 
0.1M citric acid (21g dissolved in 1 litre distilled water) 
0.1M sodium citrate (29.4g dissolved in 1 litre distilled water) 
 
Combine 18ml 0.1M citric acid to 82ml sodium citrate, 
make up to 1 litre with deionised water, 
adjust pH to pH 6.0. 
2.3.11 ‘Scots Tap Water’ 
for haematoxylin counterstaining in immunohistochemistry. 
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3.5g Sodium Bicarbonate  
20g Magnesium Sulphate 
in 1 litre deionised water 
2.3.12 Bicarbonate antibody coating buffer 
for passive adsorption of antibodies to polystyrene plates for 
immunosorbent assays 
3.03 g Sodium Bicarbonate 
6.00 g Sodium Carbonate 
in 1 litre deionised water  
adjust pH to 9.6 
2.3.13 Aptamer Wash Buffer 
Details of this and the following buffer were taken from Sefah et al. 
2010 (94). 
0.45% glucose 
50mM Magnesium Chloride 
in Dulbecco’s phosphate buffered saline (Life Technologies) 
2.3.14 Aptamer Selection Buffer 
This was based the above wash buffer, with additional: 
0.01% yeast tRNA 
0.10% bovine serum albumin 
2.3.15 MMP-9 probe buffer 
This modified TBS was used for experiments with the MMP-9 probe 
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150mM NaCl 
50mM Tris  
10mM CaCl2 
0.05% Brij 35, 
adjust to pH7.5,  and filter sterilize 
2.4 Oncomine 
2.4.1 Search Parameters 
Oncomine is an online database of gene-expression data, based on 
measured mRNA levels in samples of tumor and normal tissue from 
human patients(116).  The database can be searched for genes 
upregulated in tumor compared to normal tissue and searches can be 
narrowed by tumor and histological subtypes.   
The database was accessed via the web-page 
http://www.oncomine.org/  on 14th Feb 2012. 
The analysis type ‘Cancer vs Normal Analysis’ was specified. 
The cancer type ‘Breast Cancer’ was specified(117). 
2.4.2 Output 
Relevant data sets were selected, excluding benign histologies and 
including only studies of mRNA expression level.  The “Compare” 
function was used to generate a graphic table (on which Figure 16 is 
based), ordered by the median overexpression rank.  Summary 
information from Oncomine, and literature searches for the genes in the 
table were reviewed to see if the overexpressed genes encoded potential 
plasma membrane proteins. 
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2.5 DNA Techniques 
2.5.1 FOLR1 DNA Amplification by PCR 
The FOLR1 gene open reading frame was obtained in a cloning vector in 
E.coli culture (IMAGE 100005374, Source Bioscience UK Ltd, 
Nottingham, UK). The culture was amplified, and the plasmid extracted 
by Miniprep (Qiagen) as detailed in the manufacturers’ protocol. 
The purified DNA plasmid was used as a template for a polymerase 
chain reaction (PCR). The primers were designed to extend the gene 
with a C-terminal myc tag according to the Roche epitope tagging 
handbook (Avialable online and accessed in March 2011). The primers 
were also designed to extend the product with EcoR1 restriction sites 
(EcoR1 sites in blue, myc tag in orange. C-terminal myc tag is the 
reverse-complement, on the reverse primer) 





20ng of template plasmid was used, along with 1µg of each primer in a 
50µl reaction, using 25µL of DNA polymerase mix (Agilent Pfu Ultra). 
The thermocycler settings were: 95˚C for 5 mins, 95˚C for 2 mins, 56˚C 
for 2mins, 72˚C for 2mins, return to step-2 29 times, 72˚C for 3 mins, 
4˚C hold. 
The PCR product was analysed by electrophoresis in a 1% agarose 
gel. The clean band, observed at the expected gel position for an 816 
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base-pair product, was excised and the DNA extracted using a Qiaquick 
Gel purification kit (Qiagen) according to manufacturers instructions. 
2.5.2 FOLR1 cloning into a mammalian expression vector 
Purified PCR product was then incorporated into a pre-prepared 
vector for cloning (zero blunt TOPO, Life Technologies) according to 
manufacturers instructions. Cloning was performed using the chemically 
competent E. coli from the same kit and analysis on Kanamycin agar 
plates (imMedia, Life technologies). Colonies were picked and amplified 
by overnight incubation, then plasmid DNA purified by Miniprep 
(Qiagen) and digested with EcoR1 (New England Biolabs) according to 
the suppliers’ instructions. Samples of the digest were run on a 1% 
agarose gel to identify those with the 816bp insert, and a larger scale 
digest and gel purification was performed with a successful clone. 
The destination mammalian expression vector used was pWZL Hygro 
(from Dr B Serrels).  This was prepared by digestion using EcoR1, as 
above and then with shrimp alkaline phosphatase (Sigma) according to 
the suppliers’ protocols prior to Qiaquick PCR purification (Qiagen).  
Ligation into the vector was performed using a ‘Rapid DNA ligation kit’ 
(Roche), according to manufacturer instructions (20 µl reaction).  The 
reaction product was used to transform chemically competent E. coli 
(from the TOPO cloning kit, Life Technologies). Culture on ampicillin 
selective plates (imMedia, Life Technologies) was used to identify 
positive colonies.  Multiple clones were picked, amplified and plasmid 
DNA extracted by Miniprep (Qiagen). As the cassette had symmetrical 
EcoR1 digestion sites, 2 orientations were possible and samples of the 
plasmids were digested with BamH1 to deduce orientation (New 
England Biolabs). The enzyme was predicted to cut once in the vector 
and once asymmetrically in the FOLR1 gene.  Electrophoresis of these 
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digestion products in agarose gel showed which clones had the insert 
correctly orientated (Figure 48). A clone containing the correctly 
orientated insert was further amplified for a Maxiprep plasmid extraction 
(Qiagen), the product of which was used for the transfection of cancer 
cell lines (described in 2.6.2 below).  The construct was also sequenced 
at this stage, in sections using the following primer sequences, by the 
institute sequencing service. 
Forward 1: GCATTTCATCCAGGACACCT 
Forward 2: GAGGACAAGTTGCATGAGCA 
Forward 3: GAGGGAGTGGCCGCTG 
Reverse 1: GGTGTAGGAGGTGCGACAAT 
Reverse 2: GCAGGTGTCCTGGATGAAAT 
Reverse 3: CAGGCATTCTTCCTCC 
Sequencing data was chelated manually, and matched with the desired 
sequence using an online Clustal W (118) server available at 
http://www.genome.jp/tools/clustalw/. 
2.5.3 Reverse Transcription of mRNA 
mRNA was isolated from cells in culture or from tissue by lysis in the 
buffers from the RNeasy kit according to manufacturers instructions 
(Qiagen).  Tissue samples were sometimes preserved for later analysis in 
RNAlater (Ambion) according to manufacturer’s protocols.   
Potentially contaminating DNA was removed from samples using the 
Turbo DNA-free kit (Ambion) according to manufacturers instructions. 
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cDNA libraries were prepared using a reverse transcription reaction 
kit (Superscript 1st strand, Life Technologies) using the random hexamer 
primers, according to manufacturer’s instructions. Total cDNA 
concentration was measured using a Nanodrop spectrophotometer. 
2.5.4 Polymerase Chain Reaction detection of cDNA 
Gene transcription was detected by PCR amplifications of two types 
using the cDNA libraries as template.  
Primarily, normal PCR reactions followed by gel electrophoresis 
were employed.  A PCR premix (Paq5000, Agilent) was used along with 
a standardised quantity of cDNA template and a predefined number of 
thermal cycles. DNA polymers produced in the reaction were analysed 
by electrophoresis in agarose gel and detected in the gel using the 
fluorescence of intercalated ethidium bromide, constituent in the gel. 
Following the demonstration of efficient PCRs with simple products, 
real-time quantitative PCR reactions were also used, providing 
fluorescence readout of polymerisation, from the contents of the reaction 
tube after each reaction cycle.  The SensiFAST SYBR Hi-ROX Kit from 
Bioline was used according to manufacturer instructions, in an Applied 
Biosystems Step One instrument, using the default reaction parameters. 
Gene RNA sequences were accessed in the NCBI Nucleotide data set 
(database references are given below and begin NM_ ).  Primers were 
designed using the linked online Primer 3 resource (119) to generate 
suitable amplicons. 
2.5.4.1 Positive Control Genes for PCR Reactions 
Human Beta-2-Microglobulin (B2M) mRNA NM_004048.2 
B2M F CTCACGTCATCCAGCAGAGA 
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B2M R TCTTTTTCAGTGGGGGTGAA 
Product length 198 
Murine Glyceraldehyde-3-Phosphate Dehydrogenase (Gapdh) mRNA 
NM_008084.2. 
Gapdh F  GCGAGACCCCACTAACATCA 
Gapdh R  GAGTTGGGATAGGGCCTCTCTT 
Product length 832 
2.5.4.2 Detection of LRRC15 
Human Leucine-Rich Repeat Containing 15 (LRRC15) mRNA 
NM_130830.4  (transcript variant 2, additional 5’ region, not included in 
amplicon) 
LRRC15 F AGGGACGGACACTGTACCTG 
LRRC15 R GTCTTCCACAGGGCTGGTTA 
Product length 208 
An additional set, with amplicon bridging the HA tag for specific 
detection of tagged construct expression. 
LRRC15 HA F  TAACCAGCCCTGTGGAAGAC 
LRRC15 HA R  CGTAATCTGGAACATCGTATGG 
Product length 246 
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2.5.4.3 Detection of FOLR1 and FOLR1myc 
Synthetic construct clone IMAGE:100005374; FLH189297.01X; 
RZPDo839D0874D folate receptor 1 (adult) (FOLR1) gene, encodes 
complete protein. GenBank: DQ892744.2 
FOLR1 F GCATTTCATCCAGGACACCT 
FOLR1 R GGTGTAGGAGGTGCGACAAT 
Product Size 160 
An additional set, with amplicon bridging the myc tag for specific 
detection of tagged construct expression. 
FOLR1myc F ACACCCACTGTTCTGTGCAA 
FOLR1myc R CAGAAATAAGTTTTTGTTCGCTGA 
Product Size 241 
2.5.4.4 Detection of murine Mmps 
Matrix metalloproteinase 2 (Mmp2) mRNA NM_008610.2. 
Mmp-2 F ACCCTAGGGGATGCTTGGAT 
Mmp-2 R ACGAGCGAAGGGCATACAAA 
Product length 285 
Matrix metalloproteinase 3 (Mmp3) mRNA NM_010809.1. 
Mmp-3 F GGAGGCAGCAGAGAACCTAC 
Mmp-3 R GACTGTTCCAGGCCCATCAA 
Product length 595 
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Matrix metalloproteinase 9 (Mmp9) mRNA NM_013599.2. 
Mmp-9 F GGGTCTAGGCCCAGAGGTAA 
Mmp-9 R TAACGCCCAGTAGAGAGCCT 
Product length 958 
Matrix metalloproteinase 13 (Mmp13), mRNA NM_008607.2. 
Mmp-13 F GACAGTGGAGGTGGCCTTAC 
Mmp-13 R GGTCTCAAAAGGGCGACTGA 
Product length 411. 
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2.6 Cell Culture 
2.6.1 Tissue Culture Techniques 
MCF7 human breast carcinoma cells, SKOV3 human ovarian carcinoma 
cells and A549 human lung carcinoma cells were obtained from other 
researchers within the Edinburgh Cancer Research UK Centre at the 
MRC IGMM at the University of Edinburgh.  MCF7 cells were cultured 
in DMEM (Invitrogen, Paisley, UK) supplemented with 10% foetal 
bovine serum and 2 mM L-glutamine (Invitrogen, Paisley, UK).  SKOV3 
and A549 cells were cultured in RPMI (Invitrogen, Paisley, UK) with 
similar supplements. 
Cell lines were cultured adherent to polystyrene flasks and dishes, 
incubated at 37˚C with 5% carbon dioxide. As the cell culture 
approached confluence, they were dissociated by short incubation with 
0.25% trypsin in Phosphate Buffered Saline plus 1mM EDTA. When the 
cells were seen to dissociate, they were re-suspended and diluted by 
addition of culture medium to the suspension, before reseeding new 
vessels. 
2.6.2 Protein Expression In Human Cancer Cells 
Transfections were carried out using the Amaxa nucleofector 
transfection system (Lonza) with solution V, 1e6 cells, and the cell-
specific electroporation program as detailed in the manufacturer’s 
protocols.  Transfected cells were allowed to recover for 24 hours in 
normal culture conditions before applying antibiotic selection. 
2.6.2.1 Haemagluttinin (HA) Tagged LRRC15 in 
Human Breast-Cancer Cells 
A pCDNA3 mammalian expression vector containing a C-terminal HA 
tagged LRRC15 construct was a kind gift from Kevin Ryan(120).  The 
construct also carries a resistance gene for the aminoglycoside antibiotic 
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G418, enabling selection for stable incorporation of the plasmid.  
Transfected MCF7 cells were selected and maintained in media 
containing 1.0mg/ml G418, which was demonstrated to be toxic to 
control cells in less than 7 days. 
The recombinant protein was detected by Western blot using an 
antibody against the HA tag, and localised at the plasma membrane 
using immunofluorescence, see Figure 15 below.  These transfected cells 
are hereafter denoted MCF-7 LRRC15_HA. 
2.6.2.2 myc Tagged FOLR1 in Human Lung 
Carcinoma Cells 
FOLR1_myc in pWZL Hygro transfected cells were grown in media 
containing 0.25mg/ml of Hygromycin B.  This was demonstrated to be 
toxic to control cells in less than 7 days. 
2.6.3 Lysis of Cultured Cells 
Lysates of cultured cells were made in RIPA buffer (described above) 
supplemented with a proteinase inhibitor cocktail.  Plates for lysis were 
washed twice with ice-cold PBS, with care taken to aspirate as much of 
the PBS as possible, and keeping the plates on ice. (Sometimes plates at 
this stage were snap frozen by placing on dry ice, before transfer to a  
minus 70˚C freezer for storage, 2 weeks maximum). 400µl of the lysis 
buffer was applied to a 90mm dish, or 800µl to a 150mm dish, and these 
were incubated for 15 minutes on ice, before scraping and collection. 
The lysates were then centrifuged at 16.2k times g for 15 minutes, at 
4˚C.  Supernatant was transferred to a fresh tube and the pellet discarded. 
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2.7 Protein Techniques 
2.7.1 Lysis of Tissue Pieces for Protein Analysis 
To extract proteins from tissue for analysis, samples from culled mice 
were placed immediately into ice-cold PBS. All handling and subsequent 
dissection was carried out in ice-cold PBS.  Samples for storage were 
transferred to ice-cold DMEM with 10% DMSO, snap frozen in dry ice, 
and stored at -70˚C. Prior to use, they were thawed on ice and washed in 
ice-cold PBS. 
For mechanical lysis, tissue pieces were placed in a tube containing 
an aliquotted lysing matrix of mineral flakes and a ceramic sphere (MP 
Biomedicals, lysing matrix A).  The tubes were agitated in an MP 
Biomedicals FastPrep24 machine at speed 6.0 for 20 seconds, followed 
by a 5-minute pause with the samples on ice, then a further agitation on 
the same program.  After this mechanical lysis, the samples were 
immediately suspended in a lysis buffer (2.3.6), using 5µl per milligram 
of tissue.  After mixing by inversion, the samples were then incubated on 
ice for 20 minutes, before transfer to a microcentrifuge for clearing by 
centrifugation (12 000g for 30 minutes, 4˚C) and transfer of the 
supernatant to a new tube. 
2.7.2 Protein Quantification by BCA Assay 
A BCA assay kit (Pierce - Fisher) was used according to the supplied 
instructions.  Diluted samples of the cell lysates were incubated with the 
freshly prepared BCA solution at 65˚C for 45 minutes, before an optical 
absorption measurement was taken at 592nm (Eppendorf 
Biophotometer).  For each set of measurements, a blank and a set of 
standard solutions was prepared and measured. Test values were 
calculated by interpolation with the standard results.  The standards and 
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samples were diluted into the BCA reagents, with working 
concentrations for the reaction up to 20µl/mL. 
2.7.3 Western Blotting 
Protein loading was standardised using the assayed protein 
concentration, with samples being diluted using RIPA buffer. The 
protein samples were then diluted using a ‘2x’ sample buffer (2.3.5 
above), to the standard loading volume for a gel.  After dilution and 
mixing in the electrophoresis buffer (sample buffer) the samples were 
denatured by heating to 95˚C for 5 minutes.  The samples were then re-
gathered by brief centrifugation before loading into a protein 
electrophoresis gel.  Protein standards (or ladder) were prepared in a 
similar way. 
Biorad Mini-PROTEAN TGX Stainfree 4-15% gels were used, with a 
20µl well capacity.  They were used in Biorad electrophoresis tanks and 
buffers, according to the supplier’s instructions.  After electrophoresis, 
transfer to nitrocellulose membranes was carried out using the Biorad 
Transblot Turbo system.  Protein loading was assessed using the Biorad 
Stainfree system, and by probing membranes for a common protein such 
as beta-actin. 
For Western blotting, membranes were blocked for one hour in TBST 
(2.3.4) supplemented with 3% Bovine Serum Albumin and 0.5% dried 
milk, for 1 hour, at room temperature, with rocking.  The same TBST  
with 3% BSA and 0.5% milk was used as a diluent for antibodies.  
Primary antibody incubations were carried out with an overnight 
incubation at 4˚C with rocking.  Primary antibodies were diluted 1:1000 
unless otherwise stated.  After primary incubation, blots were washed in 
TBST: 3 washes, each for 10 minutes with rocking, at room temperature.  
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Secondary antibody incubations with one of the HRP-linked secondary 
antibodies detailed above used a dilution of 1:4000, 60-minute 
incubation, at room temperature with rocking.  This was followed by a 
similar set of three 10-minute TBST washes.  Secondary antibody 
binding was observed by soaking the membrane in freshly constituted 
enhanced chemiluminescence (ECL) solution (Biorad), removing excess, 
and then by placing the blot in a computer controlled camera, with live 
monitoring of cumulative signal over 0.1 to 5 minutes (Biorad ImageLab 
software).  The protein molecular weight standards were detected using 
optical fluorescence imaging of their cyanine dye labels in the same 
camera, with the inbuilt illuminators and filter-sets (Biorad). 
2.7.4 Immunofluorescence 
Cells were cultured on 19mm glass cover-slips (Either in the bottom of 
12 well plate unit seeded with 5e4 cells, or free in Petri dish). When cells 
were ready for fixation and staining, they were washed in TBS, then 
immersed in a formalin fixation and permeabilisation solution (2.3.6) for 
10 minutes at room temperature, then immersed in methanol at -20˚C for 
2 minutes, then washed twice with wash buffer (2.3.8), before immersion 
in blocking buffer (2.3.9) for one hour at room temperature. This was a 
point where a pause for up to 1 week was sometimes taken, using storage 
at 4˚C). 
Cover slips were then transferred to a hydrophobic surface in a light tight 
box with humidification. Primary antibody staining was carried out for 1 
hour at room temperature. Antibodies were diluted in the block buffer at 
1:250, and applied 100µl per coverslip. 
Subsequently, 3 times 5 minutes in wash buffer, then secondary 
antibodies (detailed above), 1:200 in block, 45mins room temp, before 3 
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times 5 minutes immersion in wash buffer.  Coverslips were then 
aspirated to dryness, and mounted on a slide with a drop of mounting 
medium (Vectrasheild - Vector Labs), which contained a DAPI nuclear 
counterstain.  Slides were sealed with nail varnish, and stored at 4˚C 
until examination and image acquisition using an Olympus FV1000 
scanning laser confocal microscope and companion computer 
workstation. 
2.7.5 HA-tag Immunoprecipitation 
Using lysate containing 1mg of protein, volume standardised to 1ml with 
RIPA buffer, in a microcentrifuge tube. 6µl of primary antibody (Cell 
Signaling Cell Signaling Technology 6E2), or equivalent of isotype 
control, was added to samples before incubation at 4˚C overnight on 
roller.  After incubation, 20µl of anti-mouse IgG agarose beads were 
added prior to a further 1hr incubation at 4˚C.  The beads were pelleted 
using a 45 second spin in a microcentrifuge a full speed, and the 
supernatant was aspirated. Three times, the beads were washed in 400µl 
of RIPA buffer and vortexed, before being re-pelletted like this. After 
aspirating the third wash, the beads were taken forward into the panning 
experiments. Alternatively for quality control, they were analysed by gel 
electrophoresis (and Western blot) by re-suspension in 10µl of 
electrophoresis sample buffer and 10µl of RIPA buffer, prior to 
denaturation and gel loading as above. 
The reagent used for counter-selection in panning experiments was a 
similar immunoprecipitate from lysate of control MCF-7 cells, having no 
HA-tagged LRRC15. 
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2.7.6 Immunohistochemistry 
Tumour or normal-tissue fragments were fixed in formalin (4% 
formaldehyde in PBS) and embedded in paraffin wax for storage, before 
sections were cut onto glass slides.  Mounting in paraffin wax, and 
sectioning were performed by the central histology services in the 
institute, along with haematoxylin and eosin staining and mounting. 
Sections on glass slides were processed for immunohistochemistry as 
follows: 
2.7.6.1 Dewaxing, Rehydration and Antigen Retrieval 
Immersion in xylene 5 minutes, xylene 5 minutes, 99% ethanol 2 
minutes, 99% ethanol 2 minutes, 90% ethanol 2 minutes, 70% ethanol 2 
minutes, wash in tap water. 
During the above, 1 litre of citrate buffer (2.3.10) was placed in a 
plastic bowl, and microwaved until boiling.  The slides were placed in 
the hot buffer, and boiled in the microwave at 800W for 10 minutes.  
The slides were then allowed to cool in the antigen retrieval solution on 
the bench for 20 minutes before a wash in tap water. 
2.7.6.2 Blocking and Primary Antibody Binding 
Immersing the slides in a 3% hydrogen peroxide solution for 10 minutes 
treated endogenous peroxidase activity. Slides were then rinsed in tap 
water. 
Slides were transferred to a humidified box, and the sections were 
circled with a hydrophobic mark to contain reagents. 200µl of serum-free 
protein block solution (Dako) was applied to each slide, and incubation 
for 20 minutes at room temperature. Block solution was drained from 
slides prior to adding the antibody solution. Antibodies were prepared in 
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antibody diluent solution (Dako) and 200µl added to each slide for 
incubation overnight at 4°C.  
anti LRRC15 [rabbit]   1:1000 
anti MMP-2 (K-20) [goat]  1:400 
anti MMP-3 (ab53015) [rabbit] 1:800 
anti MMP-9 (AB19016) [rabbit] 1:800 
anti MMP-13 (ab39012) [rabbit] 1:800 
2.7.6.3 Secondary Antibody Binding, and Staining 
After primary antibody incubation, the slides were washed twice in TBS 
for 5 minutes on a mixer.  Excess TBS was drained, and Secondary 
reagents were added.  Rabbit EnVision was used for the LRRC15, 
MMP-3, 9 & 13 antibodies, or an anti goat secondary (Dako) 1:200 
dilution for the MMP-2 antibody.  200µl was added to each slide and 
incubated for 30 minutes at room temperature.  
Slides were then washed again in TBS for 5 minutes twice before 
adding the freshly constituted Diaminobenzidine chromogenic reagent 
(Dako) for 10 minutes. 
2.7.6.4 Counterstain, Dehydration and Mounting 
Slides were then rinsed in tap water before counter stain by brief 
immersion in haematoxylin, further tap water rinse, and immersion in 
‘Scott’s Tap Water’ until there was appreciable macroscopic blue 
staining. 
Sections were then washed in tap water before dehydration and 
mounting:  70% alcohol 1 minute, 90% alcohol 1 minute, 99% alcohol 1 
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minute, 99% alcohol 1 minute, xylene 1 minute, xylene 1 minute, mount 
using a drop of DPX mountant (Sigma).  Curing for approximately 60 
minutes at room temperature. 
2.7.7 Tissue Immunofluorescence 
For the triple-stained immunofluoresence in section 3.7, a different set of 
techniques were employed.  Help was gratefully received from the 
Queen's Medical Research Institute Shared University Research 
Facilities, who prepared and stained sections using the Perkin Elmer 
tyramide signal amplification system according to manufacturers 
protocols.  The antibody details are given below: 
CD31 antibody (ab28364), 1:200, with Cy3 amplification using 
Chicken anti-Rabbit Peroxidase. 
AQ2 antibody (C-17), 1:4000, with Cy5 amplification using Chicken 
anti-Goat Peroxidase. 
And LRRC15 antibody (genscript), 1:7500, with FITC amplification 
using Chicken anti-Rabbit Peroxidase. 
2.7.8 Flow Cytometry 
Fow cytometry was used in the detection of the alpha folate receptor 
(encoded by FOLR1) on the surface of intact cells using the MOV18 
antibody, a carboxyfluorescein labelled folate compound, and a quantum 
dot labelled folate compound. 
Different protocols were used for staining with MOV18 antibody, and 
for the folate targetted reagents. 
For antibody staining (Figure 50), the cells were trypsinised, and re-
suspended in media, to obtain a cell suspension.  In order to minimise the 
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theoretical effect of trypsin treatment on the presence of MOV18 
antigen, the cells were seeded one day before the experiment, to facilitate 
rapid re-suspension.  Cells were immuno-stained according to the 
protocol described in Brunton et al. 2001 (121).  A mouse IgG isotype 
antibody (G3A1) was used for negative control. 
To stain with folate targetted fluorescent reagents, cells were grown 
in test wells in a 12 well plate (area 3.6 cm2).  To maximise expression, 
and to minimise occupation of folate receptors, the cells were cultured in 
folate free medium for a minimum period of 6 days.  Cells were then 
washed in PBS, before the addition of 200µl of folate free medium. 
Staining with the carboxyfluorescein-folate compound (AL2-100, Dr 
Lilienkampf, Bradley Group) was achieved using a concentration of 
100nM, and a 4 hour incubation in culture conditions at 37˚C.  
Following this, the cells were trypsinised and re-suspended in PBS for 
flow cytometry.  Negative control preparation with preceeding addition 
of 500nM folic acid (10minutes before test compound) was used, as a 
saturating competetive agonist.  An unconjugated carboxyfluorescein 
compound was also used as a negative control. 
Preparation and controls for staining with folate targetted quantum 
dots was similar, but the quantum dot compounds (Dr Bernecker, 
Mareque Group, San Sebastien) were used at a concentration of 50nM. 
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FIGURE 8. Emission Spectrum of the Folate Conjugated Quantum Dots 
Intensity was measured using a 10 nm bandpass, at 5nm steps using the 
Olympus FV1000 confocal microscope, stimulating the specimen with a 405 
nm laser. Values have been normalised to the peak value which was observed 
at 645 nm. 
The flow cytometer (BD Biosciences FACSaria) was used according to 
manufacturers protocols.  Fluorophore stimulation laser and detection 
filters were: 
MOV18 antibody, detected with secondary Alexa 594 conjugated 
antibody,  561nm laser,  610nm / 20 bandpass filter (machine settings for 
PE-Texas Red). 
AL2-100, carboxyfluorescein conjugated folate, 488nm laser, 530nm 
/30 bandpass filter (machine settings for FITC) 
Quantum Dots, 488nm laser, 695nm /40 bandpass filter (machine 
settings for PerCP-Cy5.5).  Because the quantum dot experiments were 
unsuccessful, with effectively no signal detected on cells, a 75nM 
solution was examined as a positive control, demonstrating successful 
detection of the quantum dots by the set up (Figure 9). 
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FIGURE 9. Quantum Dot Fluoresence Detected Using the Flow Cytometer 
Using the machine settings for the PerCP-Cy5.5 fluorophore (488nm laser, 
695/40nm bandpass). The blue histogram represents a control PBS solution, the 
orange histogram is a 75nM solution of the Quantum Dots in PBS.  Quantum 
dots are successfully detected in a large proportion of the droplets. 
2.7.9 Zymography 
Zymography is a non-denaturing protein electrophoresis technique. After 
electrophoresis, the gel is developed to reveal proteinase activity in 
components of the sample, separated by gel migration. For a useful 
review see Snoek-van Beurden and Von dem Hoff 2005(122).  The 
zymogram displayed here was performed using lysates of murine tissue 
samples.  Sample preparation was described in 2.7.1.  A precast 10% 
Tris-Glycine gel was used, with incorporated gelatin (Life 
Technologies).  Samples were standardised by diluting with the tissue 
lysis buffer, and then diluted in a non-denaturing SDS electrophoresis 
sample buffer (Life Technologies) before immediate loading and 
electrophoresis.  Tank, running buffer and applied voltage as specified in 
the manufacturers instructions (125V, 90 minutes). 
After electrophoresis, the proteinases are reactivated by washing out 
the SDS, and the gel was incubated overnight at 37˚C using the 
accompanying reagents according to suppliers instructions (Life 
Technologies).  Subsequent development of the gel with a colloidal blue 
protein stain (Sigma) according to the suppliers protocol, stained the 
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remaining gelatin, with points of enzyme activity appearing as lucent 
areas.  The gels were imaged with the Biorad GelDoc camera using 
transmitted light from white light diffuser, and a 605nm /50 band pass 
filter. 
For controls on the gel, mouse pro-MMP-2 (Calbiochem) and Biorad 
Precission plus protein standards were used. (The latter were visualised 
with a combination of fluorescence before gel development, and a scant 
signal that seen following the colloidal blue stain). 
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2.8 Phage Display Peptide Techniques 
The bacteriophage peptide library, based on the M13 bacteriophage, was 
obtained from New England Biolabs. The bacteriophage genome had 
been modified to include expression of N-terminal 12mer random 
peptide sequences and a triple glycine spacer, in the sequence of the pIII 
coat protein(90). (And thus pentameric expression at one end of the 
bacteriophage filament). The M13 bacteriophage is a well-characterised 
inovirus having a single stranded DNA genome and ability to reproduce 
in E. coli among other bacteria.  The library was supplied with an 
optimised strain of E. coli, which was amplified and handled according 
to the given protocols. 
 
FIGURE 10. Bacteriophage Plaques in Cultures of Escherichia Coli 
The Peptide-displaying bacteriophage are also modified to include a beta-
galactosidase gene, meaning that in addition to causing a plaque in the lawn, a 
localised colouration occurs, because of X-gal digestion.  A- shows a densely 
seeded plate where the plaques are becoming confluent, therefore unsuitable 
for quantification.  B shows a slightly more sparse plate, but the plaques are 
less clear. Closer inspection (particularly around the edges) reveals that the 
bacterial lawn is grossly affected by near-confluent non-colourigenic plaques, 
due to contamination of the experiment by wild type bacteriophage. 
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2.8.1 Selection, Amplification and Quantification 
In phage panning for LRRC15, an immunoprecipitation of the target 
protein was used as a target. 
In preparation, the immunoprecipitation was performed with cell 
lysates containing 5mg of total protein. After the second wash in RIPA, 
the third wash of the beads was performed using the aptamer selection 
buffer, described by Sefah et al. 2010(94), (2.3.14). 
For phage selection, the agarose beads (which include complexed 
anti-mouse antibody, anti HA tag antibody, and bound proteins) were 
then re-suspended in the 400µl of aptamer selection buffer and a 100-
fold representation of the phage library, as suggested in the supplier’s 
instructions (estimated 1011 virions, library diversity estimated to be 
109).  The mixture was then incubated on a roller for 45 minutes.  After 
incubation, the beads were pelleted by centrifugation (12 000g, 30 
seconds) and the unbound phage suspension was aspirated.  The beads 
were washed 3 times by re-suspending in the aptamer wash buffer before 
pelleting as above.  Duration of incubations and washes was increased in 
stringency as the experiment progressed, detailed in Table 1.  
Incubations and washes were all carried out on a roller, and at room 
temperature. 
 Round 1 2 3 4 
Counter selection None 15 min 30 min 30 min 
Selection 45 min 45 min 45 min 15 min 
Wash (x3), each Short 15 min 15 min 15 min 
TABLE 1. Incubation and wash durations for LRRC15 phage selections 
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After the first round, counter selections were performed using an 
analogous immunoprecipitation from cells which had not been 
transfected with the HA tagged protein.  The library was incubated with 
the counter selection target as above, but following incubation and 
centrifugation, the supernatant was used to re-suspend the beads with the 
target, and the pelleted beads with counter-selected phage was discarded. 
After washing, bound phage were eluted from the target using 150µl 
of an acidic glycine buffer as described in the product manual.  (0 .2 M 
Glycine-HCl, pH 2 .2, 1 mg/ml BSA). After elution of phage, in the 
aspirated supernatant, the suspension was neutralised by adding 22.5µl 
of an alkaline TBS (1 M Tris-HCl, pH 9 .1). 
The eluted phage library was sampled for quantification, as described 
in the supplier’s instructions, to ensure that a useful proportion of the 
library phage were surviving (around 0.1%), to monitor for 
contamination (see Figure 10 above), and to enable sampling of 
individual plaques for sequencing.  The main fraction of the selected 
phage library was amplified by addition to a culture of the host bacteria, 
and then the amplified library was extracted from the broth, firstly in the 
supernatant, and then by precipitating phage particles with added poly 
ethylene glycol.  The amplified library was also quantified, to inform 
addition to the next round of an estimated 1011 virions. (All according to 
the suppliers instructions (90)) 
2.8.2 Cloning and Sequencing 
Clonal expansion of phage, all bearing a single peptide sequence, was 
performed by infecting a host bacterial culture with a sample from an 
isolated plaque on one of the titre plates.  DNA extraction from the 
resulting phage amplification was performed with the Qiagen M13 DNA 
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extraction kit according to supplied instructions.  The extracted DNA 
was sequenced by the local technical services department using the -96 
primer supplied with the phage library.  The sequence data was 
processed manually and translation to peptide sequences was performed 
with the online tool available at bioinformatics.org/sms/translate . 
-96 gIII sequencing primer: CCCTCATAGTTAGCGTAACG 
2.8.3 Ion Torrent Sequencing 
In addition a ‘next-generation’ sequencing method was used to identify 
sequences in the phage library.  Next generation sequencing techniques 
effectively automate the dilution and clonal expansion steps, which are 
necessary to sequence individual library elements.  Instead of these steps 
being performed macroscopically and manually in bacteria, the selection 
of individual library elements and their amplification is performed in 
vitro, with clones being separated by dilution onto a solid phase (e.g. 
beads or a 2 dimensional surface) before in situ amplification of the 
constrained template.  A number of different technologies and reagents 
for this are becoming well validated for the sequencing of genomic DNA 
libraries. The complexity of eukaryotic genomic libraries for which the 
techniques are designed is far in excess of the selected phage peptide 
libraries being sequenced here, giving useful redundancy for selection 
based on quality, and for frequency analysis of occurring elements. 
One such technology is Ion Torrent (114), which uses a bead 
emulsion PCR to isolate single library elements and amplify these an a 
bead surface. The beads can then be distributed across a semiconductor 
surface, which is segmented into wells, yielding <1 bead per well. The 
DNA sequence is then transduced electrochemically in a final staged 
PCR step.  Ion Torrent analysis was carried out in the genetics lab of the 
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Wellcome Trust Clinical Research Facility at the Western General 
Hospital. 
The variable region (detailed in the library handbook) was amplified 
directly from eluted phage libraries, using the primers detailed below. 
These were designed using an online Primer 3 engine (119) to generate 
an 87 base amplicon (designed to be within the 100-base sequencing 
reach of the Ion Torrent system employed.).  Details of the relevant part 
of the modified M13 genome were included in the literature with the 
phage display kit. 
PhD12 VR_L  5' CAATTCCTTTAGTGGTACCTTTCT 
PhD12 VR_R  5' CGGCCGAACCTCCAC 
The reaction was set up with 50µl of PCR mix (PfuUltra, Agilent), 10µl 
of the eluted phage, 1µM of each primer, and water to 100µl. 
Temperature steps were 95˚C for 2 minutes, 95˚C for 20 seconds, 52˚C 
for 20 seconds, 72˚C for 15 seconds, return to step 2 29 times, 72˚C for 3 
minutes, 4˚C hold. 
The primers were specific to the modified region of the M13 genome, 
and a test PCR using wild-type phage as a template did not yield an 
equivalent product. 
The 87bp, blunt-ended, PCR products were purified by 
electrophoresis in 3% agarose gel (Metaphor - Lonza), band excision, 
and gel extraction (Qiaquick - Qiagen), and were then passed to the 
sequencing lab for Ion Torrent library preparation (ligation of necessary 
priming and coding sequences, emulsion PCR, and sequencing).  Coding 
sequences were added to enable 8 libraries to be multiplexed in a single 
sequencing run. 
Molecular Targeting for Clinical Cancer Imaging 
Materials and Methods 77 
Despite significant investment of time to test a variety of priming 
sequences and reaction conditions, I was unable to achieve an extension 
PCR that could facilitate the amplification, coding and adaptor sequence 
addition in a single reaction. 
Sequencing data was returned in a format for genome assembly, 
rather than the analysis of element frequency. Post-processing was 
performed using Grep arguments in TextWrangler (Bare Bones 
Software, USA), a plain text word-processor with sophisticated text 
searching capability. Grep is the name of a system of text searching 
arguments, originating in Unix. 
Metadata were removed.  Experiments were then separated based on 
the coding sequence. Reverse-complement sequences (the adapter 
ligation reaction was not direction specific) were identified and 
separated.  Sequences were trimmed to the 36 bases coding the test 
peptide (data was effectively filtered for quality by requiring the correct 
sequence of 9 bases on each flank, and the correct number of bases in the 
variable region).  The reverse-complemented sequences were processed 
en-masse using an online server and returned to the library 
(www.bioinformatics.org/sms/rev_comp). 
Two example Grep arguments used in this handling of Ion Torrent 
data from FASTQ format are given below: 
Select metadata for removal: 
Find:  ^\+\r.*\r.* 
Replace:  nil 
Select and trim to just variable 12mer coding region: 
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Find:  ^.*TCTCACTCT(.[36])GGTGGAGGT.*$ 
Replace:  \1 
The 36 base sequences were translated using an online resource 
(bioinformatics.org/sms/translate), suppressing amber stop codons 
(TAG) with glutamate as in the host bacterial strain, and then analysed in 
Excel (Microsoft Corporation) to determine the frequency of repeated 
elements, as displayed inand Figure 37, and in Table 2 below, which 
shows the corroboration between frequent elements in the Ion Torrent 
sequencing and the sequencing of hand-picked colonies.  The most 
frequent 3 sequences in each round, and their proportions, are well 
conserved.  The pattern seen in the less frequent sequences is consistent 
with limited sampling achievable with manual selection of clones. 
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TABLE 2. Validation of Ion Torrent Sequencing 
Sequence identities are linked by arbitrary colours. 
2.8.4 Testing the Selected Peptide Sequences 
The two most successful sequences in round 4, SFKIPYHYDSGQ and 
VTLTTSTMTLNK were advanced for initial testing.  These were 
ordered as synthetic peptides, along with scrambled sequences of similar 
composition, from JPT Peptides, Germany.   
In the phage library, the peptide sequences are present at the 
unconstrained N-terminus of an external protein, with 3 glycine residues 
before the normal coat protein sequence.  The synthetic peptides 
Sequence Frequency Sequence Frequency
SFKIPYHYDSGQ 5 332 30.5% SFKIPYHYDSGQ 4 26.7%
YDKASVFRDGPL 3 456 19.8% YDKASVFRDGPL 3 20.0%
NAASTFHAPDRL 2 236 12.8% NAASTFHAPDRL 1 6.7%
TNVSPEPTRTHN 1 603 9.2%
TLLDYSLQPVAH 857 4.9% TLLDYSLQPVAH 1 6.7%
SNYHSIGREMHM 740 4.2%
DFQPNLSALGGF 714 4.1% DFQPNLSALGGF 1 6.7%
VLPTSSWQQGWQ 400 2.3%
VTLTTSTMTLNK 273 1.6% VTLTTSTMTLNK 1 6.7%
SPATAWLHNKWP 243 1.4%
others 1 605 9.2% others 4 26.7%
Unique Reads 207 1.2%
Total Reads 17 459 Total Reads 15
Sequence Frequency Sequence Frequency
SFKIPYHYDSGQ 5 376 30.8% SFKIPYHYDSGQ 3 20.0%
VTLTTSTMTLNK 5 128 29.4% VTLTTSTMTLNK 2 13.3%
TNVSPEPTRTHN 1 061 6.1% TNVSPEPTRTHN 1 6.7%
YDKASVFRDGPL 890 5.1%
SNYHSIGREMHM 484 2.8%
NAASTFHAPDRL 400 2.3% NAASTFHAPDRL 1 6.7%
VLPTSSWQQGWQ 130 0.7%
TLLDYSLQPVAH 106 0.6%
DFQPNLSALGGF 95 0.5% DFQPNLSALGGF 1 6.7%
TTTGMGLGMKWT 70 0.4%
others 491 2.8% others 1 6.7%
Unique Reads 122 0.9%
Total Reads 14 231 Total Reads 9
Round 4
Round 3
Ion Torrent of PCR amplicon Picking Colonies
Molecular Targeting for Clinical Cancer Imaging 
Materials and Methods 80 
included a C-terminal glycine, then a 4,7,10-trioxa-1,13-
tridecanediamine succinate (Ttds) linker, then a biotinylated lysine 
residue. Biotin was incorporated to allowed affinity capture or secondary 
fluorescence using streptavidin reagents. 
Seq1   SFKIPYHYDSGQ-G-Ttds-K-Biotin 
Seq1 scr  GKSQDIYHFYSP-G-Ttds-K-Biotin 
Seq2   VTLTTSTMTLNK-G-Ttds-K-Biotin 
Seq2 scr  TLTNVTSTLMKT-G-Ttds-K-Biotin 
2.8.4.1  Fluorescent Microscopy 
Fluorescent microscopy was performed, with cells prepared as for 
immunofluoresence, detailed in 2.7.4.  The peptides were added at 
20µM, using the immunofluorescence block as a diluent, along with the 
HA tag antibody as a counter stain.  Slides were also prepared without 
the counterstain antibody, to demonstrate that this did not affect peptide 
staining, and without any peptide, to provide a secondary only control.  
Scrambled peptide sequences were also included as negative controls. 
Secondary staining for the aptamers was performed using Alexa 
Fluor 488 labelled streptavidin, diluted 1:200 in IF wash buffer, as for 
the secondary antibodies in the immunofluoresence protocol above. 
2.8.4.2  Fluorescent Immunosorbent Assay 
Following failure of initial experiments to show co-staining at 
immunofluorescence, an experimental system was used that allowed 
protein presentation and peptide binding in buffers similar to those used 
in the selection steps. 
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FIGURE 11. Sandwich Immunosorbent Fluorescent Assay 
The stages of the assay are shown in sequence: passive adherence of the 
antibody to the test-plate at pH 9.4, Immunosorption of the target protein, 
binding of the test peptide and binding of the secondary fluorescent reagent. 
The HA tag antibody was adsorbed onto the optical plastic plates (Flat 
polystyrene optical bottom, black wall, Nunc 165305) 1:250 in pH 9.4 
sodium bicarbonate buffer, for 1 hr at 37˚C.  Positive controls were 
performed by binding the biotinylated peptides to the polystyrene using 
the same method, and also the dye labelled streptavidin. 
Washes with TBST, 2x brief wash. 
Bocking with 3% Bovine serum albumin in TBST, 30 mins at 37˚C 
Incubation with cell-lysates in RIPA, 4˚C.  Total-protein concentration 
of 0.1mg/ml was found to give the greatest signal in positive control 
experiments using antibody detection. 
Washes with Aptamer wash buffer, 2x brief wash. 
Test peptides incubated for 45 minutes at room temperature, in aptamer 
selection buffer. 100µM, 20µM or 4µM.  Antibody positive control 
using Genscript custom LRRC15 antibody, 1:250. 
Washes 3x15 mins, aptamer wash buffer. 
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Streptavidin incubation 1:500 in TBST, 30 mins room temp. (IRdye 
800nm labelled streptavidin, Licor biosciences).  (Irdye 800nm labelled 
anti rabbit for antibody positive control, 1:250) 
Washes - 4x TBST 
Water Wash + dry plate 
Reading on Licor Odyssey scanner at 800nm, Signal quantification by 
integrating fluorescence intensity over well area using Licor software. 
2.8.4.3 Peptide Arrays on Glass Slides 
To widen the scope of potential LRRC15 binding peptides and include 
more of the other frequent sequences in the selected libraries, a peptide 
array was used to test multiple potential binding interactions in a single 
set up.  All peptide sequences occuring at 0.1% or greater, in either of 
the selected libraries after 3rd and 4th rounds, were included (43 
peptides in total, listed below). 
ALGAEKQVFAHT	  	  	  	  HVPVFKSFNTES	  	  	  	  TNVSPEPTRTHN	  
ALWPPNLHAWVP	  	  	  	  NAASTFHAPDRL	  	  	  	  TPNAVLPTGRTH	  
AMPSLAITNDGP	  	  	  	  NISYAKQHSNTP	  	  	  	  TTTGMGLGMKWT	  
APKSPVERHNSP	  	  	  	  NSTDLLAVRAQW	  	  	  	  VGSNTDVLHAKL	  
APTAYNKNDWAL	  	  	  	  SFKIPYHYDSGQ	  	  	  	  VLPTSSWQQGWQ	  
DFQPNLSALGGF	  	  	  	  SFRFRIIMIGGQ	  	  	  	  VSGMTESQTPKY	  
DSNYATAVALKR	  	  	  	  SLEVTPMRSAGS	  	  	  	  VTLTTSTMTLNK	  
DSTSHPDAPSNI	  	  	  	  SLRFRNHYDSGQ	  	  	  	  WDNHSNILLNHT	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EPNNGDGSWRWL	  	  	  	  SNYHSIGREMHM	  	  	  	  WTHPHVLPSNYH	  
EPQTELLRVLNG	  	  	  	  SPATAWLHNKWP	  	  	  	  YDKASVFRDGPL	  
FAGTNSALLMVQ	  	  	  	  TGWHDLARPLHF	  	  	  	  YDKVFGFSAWPL	  
GATHATRSAMYA	  	  	  	  THMNQHASTNTA	  	  	  	  YQMKLQNQQGAP	  
GAVTLATTHLTP	  	  	  	  TLLDYSLQPVAH	  	  	  	  YTTRGTTEPFPL	  
GTQPQTVFMVTK	  	  	  	  TNDTMRHLAKMP	  	  	  	  	  
HGTDYPHVSSIH	  	  	  	  TNSVHELPANSL	  
The arrays were kindly supplied by Dr George Baillie of the University 
of Glasgow, along with the protocol given below to test for a binding 
interaction. Peptides had been synthesised with 3 glycine residues at the 
C-terminus, and spotted on glass slides. 
1. Wet slides in TBST  
2. Block slides in TBST containing 5% BSA for 1 hour at room 
temperature. 
3. Rinse slides in TBST 
4. Add protein diluted in TBST + 0.5% BSA, and incubate at 4˚C 
overnight.  (Cell-lysate in RIPA was used, diluted to a concentration of 
0.8mg /ml). 
5. Wash slides in TBST 3 x 10 min. 
6. Primary antibody diluted in TBST + 1%BSA, (anti HA tag, Cell 
Signaling Technology 6E2  1:1000) and incubate for 2 hours at room 
temperature. 
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7. Wash slides 3x5min TBST  
8. Secondary antibody (anti-mouse HRP, 1:1000) in TBST + 1% 
BSA, 1 hour at room temp. 
9. Wash slides in TBST 3 x 10 min. 
10. Add chemiluminescence reagents and image in camera as 
Western blot. 
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2.9 Nucleic Acid Aptamer Techniques 
We have used a library synthesised by Integrated DNA Technologies 





The regions highlighted in blue are reverse-complementary, stabilising a 
hairpin by base pairing between these.  The random sequence may 
contribute other self-interacting motifs or target binding. 
Amplification, sense-strand separation, aptamer preparation and 
storage were carried out according to the protocol of Sefa et al.2010 
(94).  PCR amplification was carried out using a 5’ biotin on the reverse 
primer. The dsDNA product was captured on streptavidin sepharose 
beads and the sense strand was eluted with 200mM NaOH solution. For 
all rounds of amplification in this work, the forward primer was 5’ 
labelled with an Alexa 488 fluorophore. Thus aptamers were selected in 
a labelled state, rather than planning a potentially disruptive modification 
after selection. 
2.9.1 Selection, Amplification and Quantification 
For the selection of aptamers to the alpha folate receptor, using whole 
cells, the selection strategy described by Sefah et al.2010 (94) was used. 
For the LRRC15 targeting, an analogous system using the previously 
described immunoprecipitation of HA tagged LRRC15 was used, with 
the buffers and amplification techniques from Sefa et al. 2010. 1mg of 
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total-protein in 1ml, was used as described above.  The final wash of the 
IP was performed with aptamer binding buffer, and the IP was then re-
suspended in 400µl total volume of binding buffer, containing 100nM 
aptamers. After the first round, a counter selection step was performed 
first (using an analogous immunoprecipitation setup using normal MCF-
7 cells as above). The library and the counter selection target were 
incubated for 15 minutes at room temperature on a roller. The beads 
were then pelleted by centrifugation and the supernatant was used to re-
suspend the IP to be used for selection. This was incubated for 15 
minutes at room temperature, and washed 3 times. 
In later rounds of selection, the buffer containing the aptamer library was 
also supplemented with up to 20% FBS. Survival of polynucleotides in 
the presence of serum nucleases is an important selection criterion for a 
putative in vivo reagent.  Initial rounds used short washes after the 
aptamer binding incubation. In the later rounds, when the library was 
displaying greater affinity, three 15-minute washes using 1500µl of wash 
buffer were performed.  
 Round 1 2-5 6-10 11-15 16-20 
Counter selection None 5 mins 5 mins 10 mins 20 mins 
FBS in selection  None None None 10% 20% 










TABLE 3. Incubation and wash conditions for the LRRC15 aptamer selections 
Twenty rounds were performed, with increasing stringency of counter 
selection, and washes, also the addition of FBS to the selection buffer in later 
rounds.  
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The pellet was then re-suspended in 400 µl deionised, micro filtered 
water, heated to 95˚C for 5 minutes, and then used as template for the 
first stage PCR amplification (1ml total volume using Paq5000 
mastermix [Agilent technologies, USA], 10 cycles). 
All aptamer PCRs were performed using the Paq5000 PCR mix, 1µM 
modified primers (forward primer with 5’ Alexa 488 dye, reverse with 5’ 
biotin), and using the cycle parameters: 95˚C 2mins,  95˚C 30 seconds, 
56˚C 30 seconds, 72˚C 30 seconds, return to step 2 n-1 times, 72˚C 3 
minutes. Where n is the number of cycles. 
2.9.1.1 Aptamer Amplification Quality Controls 
 
FIGURE 12. A Test 2nd-Stage Amplification PCR 
Using the first-stage PCR reaction as a template, a second stage reaction is set 
up and run for a variable number of cycles.  The desired product is 84bp, seen 
most prominently with 8 cycles in this example. However, with 8 and greater 
cycles, the emergence of unwanted products is also observed.  Negative control 
with no template for 10 cycles. 
Amplification was carried out in two stages as described by Sefah et 
al.2010. A small-scale test PCR (see Figure 12) informed the number of 
cycles for the main 1ml 2nd-stage PCR, which used the products of the 
first reaction as a template (10%). In the example shown (amplification 
of the LRRC15 8th selected pool on 15/8/2011), because of the 
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emergence of non-canonical products in 8 and greater cycles, 7 cycles 
was chosen for the main reaction. 
The PCR products were processed, handled and stored according to 
the methods described in Sefah et al.2010 (94). 
2.9.2 Cloning into TOPO TA Vector for Sequencing 
For sequencing of individual library elements, aptamer PCR product 
(using non-modified primers) were cloned into the TOPO TA vector 
(Life Technologies) and the products of this reaction were used to 
transform bacteria, for amplification on selective plates.  Individual 
colonies were selected and amplified in culture, and the plasmid DNA 
was extracted by Miniprep (Qiagen) for sequencing reactions with M13 
primers. 
2.9.3 Ion Torrent Sequencing 
For Ion Torrent sequencing, aptamer libraries were PCR amplified using 
extension primers to add the Ion Torrent adapter sequences (Life 
Technologies, adaptor sequences published online).  A four base code 
was also included in each of 4 primers, to code 4 different libraries. PCR 
amplicons were gel purified using the Qiaquick gel purification system 
(Qiagen). 
The components for the modular construction of the priming 
sequences is given for the left primers, using the Ion Torrent adapter A, 
one of 4 coding sequences, and then the left aptamer primer: 
Ion Torrent A  5’ CCATCTCATCCCTGCGTGTCTCCGACTCAG 
Codes:  1 CATG,  2 CTAG,  3 CAGT,  4 CTGA 
Aptamer Left 5’ CTACACGACGCTCTTCCGATCT  
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The components for the right primer were the Ion Torrent P adapter, and 
the then the right aptamer primer: 
Ion Torrent P  5’ CCTCTCTATGGGCAGTCGGTGAT 
Aptamer Right 5’ TGCTGAACCGCTCTTCCGATCT 
As above with Ion Torrent sequencing of the phage libraries, sequencing 
reactions performed by the Wellcome Trust Clinical Research Facility 
Genetics Core, and sequence data was processed as described above. 
2.9.4 Testing the Selected Aptamer Sequences 
The first sequencing from the selected libraries was the Ion Torrent 
sequencing of the 20th selected library, selected using the LRRC15 
immunoprecipitate.  This library contained a single dominant sequence, 
which was taken forward for further testing. Synthesis of the labelled 84-
base aptamer proved difficult, with low yield obtained despite two 
attempts at synthesis by Life Technologies. The limited availability 
restricted experimental approaches. 
As experiments progressed, other approaches were used rather than 
trying to optimise production of 84 base aptamers. Selected libraries 
were used rather than individual sequences, and aptamer sequences were 
synthesised on a microarray. 
2.9.4.1 Fluorescent Microscopy 
Due to limited availability of the aptamer, only initial experiments were 
possible.  These were carried out as described in the protocol in 2.7.4, 
using fixed and permeabilised cells.  Aptamers were applied at 10µM, 
for a 1-hour incubation at room temperature.  Immunofluorescence 
targeting the HA tag was used as a counterstain, along with DAPI in the 
mounting medium.  (Aptamers were applied along with the secondary 
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antibody).  Slides were also prepared without the HA tag 
counterstaining, in case this should interfere with the aptamer 
interaction.  A negative control using a scrambled aptamer sequence was 
also prepared. 
Aptamer: 




Alexa Fluor 488 5’ - CTACACGACGCTCTTCCGATCT - 
TACTCTATTATACTATATATCATACATATATATTATCTAT 
- AGATCGGAAGAGCGGTTCAGCA 
2.9.4.2 Fluorescent Immunosorbent Assay 
Similar methods to those described in 2.8.4.2 were used for testing 
aptamers. Selected libraries were tested, rather than individual 
sequences. The plate and immunosorption were prepared as above, with 
lysate of control MCF-7 cells for negative control. 
Labelled aptamer libraries were applied in the aptamer selection 
buffer, at a concentration of 100nM, and incubated for 1 hour at room 
temperature. 
5 short washes were performed using the aptamer wash buffer. The 
plate was dried and imaged to detect the 488nm fluorophore.  
Quantification was performed by integrating the signal from a manually 
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placed area within the well contours, and subtracting the background 
signal from control wells prepared with no aptamers. 
2.9.4.3  Microarray of ssDNA Sequences 
72000 sequence oligonucleotide microarrays were designed using the 
selected sequences from rounds 9 and 13.  After sequence selections, 
array layout and synthesis was performed by Nimblegen.  All sampled 
sequences from these libraries were included, along with the reverse 
complementary flanks, numbering 65 815.  In addition, all sequences 
occurring more than once in rounds 9 and 13 were duplicated, both with 
and without the reverse complementary ends, and as scrambled controls 
of each of these, adding a further 1440 sequences (360 sequences, in 
each of those 4 combinations), to a total of 67 255. Remaining spaces 
were filled with Nimblegen control sequences.  Arrays were duplicated 4 
times per slide, and each slide was supplied with an overlay, separating 
the arrays into different chambers. 
Protocol details are given below, but in essence: cell lysates 
containing the HA tagged target protein were prepared, and incubated 
with the aptamer microarray. Target protein detection was performed 
using a dye conjugated antibody to the HA tag and the microarrays were 
scanned using a Roche Nimblegen MS 200 array scanner. 
Cell lysates containing the target protein (or control) were prepared as 
described above in RIPA buffer.  For these experiments, the RIPA buffer 
was supplemented with 0.1% tRNA, as a block for non-specific 
oligonucleotide interactions.  When no specific protein binding was 
demonstrated in these experiments, the constitution of the cell lysate 
solutions was altered, with details given in Table 4 (Ch. 5) 
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The microarray slides were assembled and filled according to 
manufacturers protocols (Roche Nimblegen).  20 µl of cell lysate was 
applied to each array chamber, with care to load evenly and without 
bubbles.  This was 2.5 times the chamber capacity, and excess was 
mopped from the efferent pore of the chamber roof.  Slides were 
incubated for 6 hours at room temp in a Roche Nimblegen Hybridisation 
System 4 instrument, using mix mode B. 
The slide cover with its chambers was then removed, and the slide 
washed 3 times for 5 minutes in TBST, followed by blocking in TBST 
with 3% BSA and 0.1% tRNA for 30 minutes at room temperature. 
Antibody binding (in block buffer as above), anti HA tag 1 in 250, 
isotype control 1 in 1000. (6E2 647nm dye conjugate and G3A1 555nm 
dye conjugate, both from Cell Signaling Technology), 400µl to slide 
surface, under Para film, incubation overnight at 4˚C. 
3x 5min wash in TBST 
1 quick wash in deionised water. 
Slide spun in 50 ml Falcon tube at 1000G for 3 mins to remove water. 
Scanned using the MS 200 instrument (Roche Nimblegen) using the 
532nm and 635nm excitation lasers, and a 2µm resolution. 
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2.10 Fluorescent Reporter of Matrix Metalloproteinase 
9 Activity 
The Bradley group, based in the University of Edinburgh Chemistry 
department, have an active program developing enzyme-activated 
fluorescent reporters (123) for a number of enzymes, known to be 
important in inflammatory disease and cancer.  Termed ‘smart-probes’, 
these are designed for activation by a particular enzyme, based on the 
substrate specificity. The design of such probes was discussed in 1.3.3 . 
2.10.1 SVC-01-016 
The probe tested in the experiments reported here is called SVC-01-016.  
Exact details of the design are retained due to commercial and 
intellectual sensitivity.  In general terms, it corresponds to the paired-
fluorophore illustrated in Figure 4 above.  A short peptidomimetic linker, 
including a substrate sequence predicted to be cleaveable by MMP-9, 
constrains a non-identical fluorophore pair in a configuration that leads 
to quenching.  If the molecule is disrupted centrally, such as by 
enzymatic lysis of the peptoid, then the unconstrained 
carboxyfluorescein can be detected by fluorescence with 492nm 
excitation and 517nm emission maxima. 
Because of known overlap in enzyme substrate specification, the 
probe was expected to also be sensitive to MMP-2 and MMP-13.  The 
probe was stored in a DMSO solution at 12.9mM, at -20˚C and in the 
presence of hygroscopic beads.  Both the lysis reaction underlying 
activation, and the carboxyfluorescein fluorescence are understood to be 
pH sensitive, and so experiments were carried out in a modified tris-
buffered saline (2.3.15). 
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2.10.2 AMF-26 
An isomeric probe with a D amino acid substitution at the MMP-9 
cleavage site (the site shared with MMP-2 and MMP-13) was available 
as an experimental control.  Substitution of a non-natural amino acid at 
this point was designed to block activation of the probe by these MMPs, 
and was confirmed experimentally (Figure 58). 
2.10.3 Fluorometry 
The experiments reported in Chapter 6 were performed in 96 well plates, 
with wells having black sidewalls and translucent bottoms (Fisher) using 
a Victor 3 fluorescent plate reader (Perkin Elmer).  The wells contained a 
fluid volume of at least 75µl.  Serial measurements of fluorescence were 
acquired over time courses of approximately 1 hour.  The stage holding 
the plate, without lid, was maintained at 37˚C, and the measurement 
cycle included a 5s shake prior to acquisition.  The manufacturer’s 
fluorescein filter set and acquisition parameters were used, with 
excitation light into the well top and employing a one-second photometer 
count of emitted light collected below the wells. 
2.10.4 Murine Tissue and Tumour Samples 
Murine organs and breast tumour fragments were excised from freshly 
culled animals and placed in ice-cold PBS prior to dissection.  Dissection 
into 2mm cubes was performed in PBS, on ice, in sterile-filtered air, 
using sterile instruments.  With particular regard to the tumour 
fragments,  macroscopically fatty, necrotic or haemorrhagic parts were 
discarded. 
Aliquots for freezing were created with approximately ten pieces in 
ice-cold dye-free DMEM (Life Technologies) with 10% DMSO, in a 
cryovial.  These were kept on ice prior to transfer to -70˚C.  The 
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subsequent rate of cooling was attenuated by placing the cryovials in a 
rack, in a polystyrene box overnight prior to transfer to storage boxes. 
Aliquots were thawed for use on ice, before transfer to a 90mm petri 
dish for washing with PBS.  This was also performed on ice, along with 
any additional dissection to standardise fragments.  Fragments were then 
transferred to a 96-well plate on ice, with test wells preloaded with 75µl 
of MMP-9 probe buffer (2.3.15).  All the tissue fragments used in these 
experiments had been frozen and thawed in this manner. 
2.10.5 Plate Set-up 
Once the test-pieces of tissue were arrayed in the plate, all kept on ice, it 
was taken off ice, for the addition of the MMP inhibitor ilomastat,  
recombinant human MMP fragment positive controls, and finally the test 
probe.  These had each been prepared in the MMP-9 probe buffer to a 
standard loading volume of 3µl for accuracy and rapid addition with a 
multichannel pipette.  A bench timer was started as soon as all test 
reactions were set-up, to provide zero-point for the time-courses. 
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2.11 Transgenic Murine Models of Breast Cancer 
Murine breast tumour samples were taken from breast tumours arising in 
transgenic animals.  These models use conditional expression of 
oncogenes in the mammary epithelium, some also including conditional 
Cre recombinase to cause localised knockout of tumour suppressors by 
‘floxing’ (124).  These models use the promoter from the mouse 
mammary tumour virus (MMTV), a murine retrovirus, secreted in milk 
and causing lacteal transmission of breast tumour (125). The promoter is 
steroid responsive and thus active from puberty. Transgenic mouse 
models using recombinant MMTV promoter fused to oncogenes are well 
established (126). 
2.11.1 Polyoma Middle T Antigen Model 
Conditional expression of the polyoma-virus middle T antigen in 
mammary epithelium (under transcriptional control of the MMTV 
promoter) is known to cause widespread dysplasia and multifocal 
adenocarcinoma, and secondary pulmonary metastases (127).  This 
model has been used for a number of studies targeting Mmps and Mmp-
9 in particular (115, 128). 
2.11.2 NIC Model with Mono-Allelic Pten Knockout 
Also using the same murine mammary tumour virus promoter, the same 
group have later constructed a transgenic model incorporating genetic 
alterations more closely related to those seen in some human breast 
cancers(129).  This model employs conditional overexpression of an 
activated ErbB-2 (HER2 equivalent) analogue in the mammary 
epithelium, along with Cre recombinase.  By crossbreeding with strains 
containing a floxed Pten construct, strains with various conditional Pten 
genotypes were characterised (129).  The strain heterozygous for Pten 
(i.e. one wild-type and one floxed) was shown to have rapid 
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tumorigenesis in comparison with homozygous wild-type, and represents 
a genetic model based on important genetic events frequently seen in 
human breast cancer. 
2.11.3 Kindlin-1 knockout 
Others working in the Frame / Brunton group are studying the function 
of Kindlin-1 in the biology of breast cancer invasion and metastasis 
(130).  Among other approaches, they have modified the MMTV - 
Polyoma Middle T model to include conditional knockout of the 
Kindlin-1 gene along with the oncogene expression, using a Cre / lox 
recombination system, resulting in breast tumours with kindlin-1 
deletion.  The genetic construct is referred to as BC5. 
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3.1 Introduction 
Leucine-Rich Repeat Containing 15 (LRRC15), also known as Leucine-
rich repeat protein induced by ß-amyloid treatment (Lib)(131) was first 
described in rats due to mRNA upregulation in a model of Alzheimer’s 
disease, by Satoh et al. in 2002.  The number 15 refers to the quantity of 
repeated leucine-rich motifs. 
Leucine-rich repeat containing proteins are a recognised superfamily 
and the repeated motifs have been described as a hypothetical framework 
for protein-protein interactions(132). 
LRRC15 was chosen as a putative cancer biomarker because it is a 
trans-membrane protein, having an external domain available for 
targeting by macromolecules, and because of upregulation of the mRNA 
in human breast cancer, compared to normal breast tissue. 
3.1.1 LRRC15 is a Plasma-Membrane Glycoprotein 
To our knowledge, LRRC15 protein structure has not been determined 
experimentally.  Two in-silico predictions of LRRC15 domains were 
obtained.  The first was generated by an online server, using the amino 
acid sequence from the Consensus Coding DNA Sequence (CCDS) 
database(133), accessed via the National Centre for Biotechnology 
Information (NCBI) in Maryland, USA; see Figure 13 below.  The 
second was found in the UniProt(134) online database of protein 
information; see Figure 14 below. 
Both predictions concur in suggesting a type 1 transmembrane 
protein. They predict that the greater part, which contains the leucine-
rich repeat motifs, forms an extracellular domain that is not further 
characterised. 
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FIGURE 13. Predicted Structural Domains in the LRRC15 Protein 
Edited output(135) from a protein structure prediction server hosted by 
University College London(136), for the LRRC15 peptide sequence(137).  The 
sequence database, and the protein structure prediction were both accessed on 
6th February 2013. 
 
FIGURE 14. Predicted Structural Domains in the LRRC15 Protein (2) 
Edited report(138) from the UniProt database showing predicted protein 
domains; accessed on 6th February 2013. 
Reynolds et al. showed in 2003 that tagged recombinant LRRC15 was 
expressed in the plasma membrane(139).  We repeated this experiment 
using a similar overexpression construct in MCF-7 cells, a human breast 
cancer cell line(140).  In concordance with their report, plasma-
membrane expression of an 85kDa protein was observed.  The 
population of transfected cells were maintained and are hereafter denoted 
MCF-7 LRRC15_HA. 
Reynolds et al. also showed that glycosylation was partly responsible 
for the apparent molecular weight on electrophoresis, which is greater 
than the 64kDa predicted from the gene sequence alone (139). 
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FIGURE 15. Western Blot and Immunofluorescent Detection of Tagged LRRC15 
A: Western blot probed for the HA tag and actin control.  Lysates from control 
MCF-7 cells and MCF-7 cells following transfection with LRRC15_HA 
overexpression construct.  B: Confocal micrograph showing location of the HA 
tag by the same antibody (green), in a proportion of the MCF-7 LRRC15_HA 
cells.  Nuclear counterstain with DAPI (blue).  The HA tag antibody was 
detected with a fluorescent secondary antibody.  20µm scale bar. 
3.1.2 LRRC15 is the Most Upregulated Membrane Protein 
mRNA in Breast Cancer 
The online resource Oncomine was searched to find putative biomarkers 
for breast cancer. This is a database of nucleic-acid microarray data, and 
the platform can perform meta-analyses (116).  A meta-analysis of 
“Cancer vs. Normal” was performed, using data-sets comparing mRNA 
expression levels in breast tumour samples with normal breast tissue 
samples(117). 
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FIGURE 16. Oncomine Meta-analysis of Gene Transcription in Breast Cancer 
Oncomine chelates 25 human breast-cancer data sets to compare breast tumour 
tissue with normal breast tissue.  The meta-analysis orders genes using the 
median rank from the studies.  Not all genes are measured in all of the studies 
and studies with absent data are dark grey.  The heat-map gives additional 
information about relative expression in individual studies. Although a key was 
given with the table, the precise nature of the shading is obscure. It is salient to 
observe that LRRC15 has a complete data set, and that no blue shades to 
indicate down-regulation are present. 
The data for the Oncomine analysis in Figure 16 is drawn from a number 
of published studies(141-151).  The top three genes in this meta-analysis 
are not known as membrane proteins.  LRRC15 is thus reportedly the 
most overexpressed membrane protein mRNA in human breast cancer 
samples. 
Satoh et al. 2004 also specifically described LRRC15 mRNA 
upregulation in human breast cancer samples(152).  Their findings are 
not included in the Oncomine database. 
3.1.3 LRRC15 Transcription is Specifically Upregulated by an 
Oncogene, and Implicated in Invasion and Metastasis 
Reynolds et al. came to study LRRC15 after detecting specific 
transcriptional upregulation by an oncogenic fusion-protein(139).  They 
went on to show that HA tagged recombinant LRRC15, expressed in a 
human fibrosarcoma cell line, promoted their invasion in culture. 
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Satoh et al. 2005(153) also reports increased invasion of cultured 
cell-lines following transfection with a different recombinant LRRC15 
construct.  They also support this hypothesis with observations that the 
isolated protein has binding affinity for Matrigel, and fibronectin in 
particular. 
In human metastatic breast cancer, LRRC15 upregulation has been 
described in a subset of metastatic lesions (154).  Bone metastases show 
greater LRRC15 mRNA levels in comparison with brain metastases. 
3.1.4 Summary - LRRC15 is a Putative Cancer Biomarker 
Based on predicted structural domains and work using recombinant 
expression, LRRC15 is a cell-surface protein.  An increase in the mRNA 
encoding this protein is seen in human breast cancer biopsies in 
comparison with normal breast tissue, greater than that for any other 
membrane protein.  LRRC15 gene transcription is a specific target of an 
unusual oncogenic fusion protein, which dramatically upregulates its 
expression.  Experimental overexpression of recombinant LRRC15 
protein increases cultured cell invasion. In combination, these 
observations direct interest toward LRRC15 as a potential membrane-
located cancer biomarker. 
Studies to date have been based (in the most part) on mRNA and epitope 
tagged protein, with no papers describing commercially available 
antibodies. Satoh et al. 2005 present results using an antibody to 
LRRC15, but in personal communication the author explained that their 
research into the protein has finished, and that it had been difficult to 
raise a specific antibody. 
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3.1.5 Aims 
Validation of a novel antibody to LRRC15. 
Assess LRRC15 protein expression in human breast-cancer cell lines. 
Characterise expression of Lrrc15 in murine tissues and breast tumours. 
Assess LRRC15 protein expression in human breast-cancer biopsies. 
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3.2 A New Antibody Detects Recombinant LRRC15 
Eight ‘custom’ antibodies were commissioned, from two different 
companies.  They were all raised to short peptide motifs from the 
translated gene-sequence, selected by the manufacturers. These were 
tested in Western blot and immunofluorescence experiments using the 
MCF-7 LRRC15_HA cells, and control MCF-7 cells (see Figure 15 
above).  Detection of the HA tag on the recombinant protein was a 
positive control. 
3.2.1 Western Blot 
 
FIGURE 17. Screening of Six Test Antibodies Raised to Peptides in LRRC15 
Test antibodies are labelled A to F.  Positive control probing for the HA tag is 
shown on the left. Positive control for protein loading was by reprobing the 
blots for actin, shown below.  Negative control in each case is lysate from 
normal MCF-7 cells. A further negative control probing with only the 
secondary antibody is shown on the right. 
In Figure 17, all the sample antibodies except D show non-specific 
bands, and only D detects a band corresponding to the HA tag antibody 
in the positive control.  Only non-specific binding was observed with 
two further antibodies from another company, not shown. 
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A full-scale affinity purification of the successful antibody was 
supplied, along with a sample of the antigen peptide.  The sequence of 
this 14 residue peptide, and its position in the protein sequence is given 
in Figure 24.  Using the new batch of antibody, block and incubation 
conditions were optimised.  Inhibition of antibody binding by the antigen 
peptide was demonstrated, shown in Figure 18 below.  A discrete band is 
identified, specific to the cells transfected with the overexpression 
construct. 
 
FIGURE 18. Western Blot Detection of LRRC15_HA by a Novel Antibody 
Two blots were prepared and incubated with the novel antibody, one in the 
presence of the antigen peptide and the other with a control peptide.  Actin 
loading control. 
Because LRRC15 has been described as being upregulated in breast 
cancer, the lack of native LRRC15 detection in wild-type MCF-7 cell 
lysate was unexpected.  On the contrary, concerns were held that native 
protein expression would confound these experiments.  This is explored 
further in 3.3 below. 
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3.2.2  Immunofluorescence 
The antibody also successfully detected the recombinant over-expressed 
LRRC15_HA in immunofluorescence of fixed and permeabilised MCF-7 
cells. 
 
FIGURE 19. Immunofluorescence of LRRC15_HA Using a Novel Antibody 
Confocal micrographs of three areas in a culture of MCF-7 LRRC15_HA cells.  
Primary antibodies against LRRC15 (test) and the HA tag (positive control) 
were detected by fluorescently labelled secondary antibodies.  In the merged 
image on the right these are shown as red and green respectively, and the 
nuclear counterstain DAPI is blue.  Co-location of the red and green signals 
results in yellow.  40µm scale bar. 
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As in Figure 15 above, only a proportion of the transfected cell 
population express the HA tag.  (Some cells are seen in these images 
only by DAPI nuclear staining). There is very close co-location of the 
two antibody signals, which are both predominantly in the plasma 
membrane.  There is also some less-intense cytoplasmic / perinuclear 
staining noted.  This occurs with both antibodies, and is seen only in 
association with the stronger membrane signal. 
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3.3 Native LRRC15 Protein is Undetectable in Breast-
Cancer Cell Lines 
The lack of LRRC15 detection in the wild-type MCF-7 cells was 
surprising and concerning.  Because the protein was selected due to 
increased mRNA levels in breast-cancer samples, it was anticipated that 
MCF-7 cells would express the protein, and that this would be detected 
by the new antibody, targeting the native LRRC15 protein rather than the 
HA tag. 
3.3.1 Western Blot 
The next experiment aimed to quantify detection of LRRC15_HA by 
using low levels of total-protein loading, based on BCA assay of the cell 
lysates.  MCF-7 LRRC15_HA was added in decreasing quantities 
covering approximately 2.5 orders of magnitude.  A maximal quantity of 
the wild type MCF-7 lysate was also loaded. 
 
FIGURE 20. Western Blot to Assess Sensitivity of the New LRRC15 Antibody 
Lysate of MCF-7 LRRC15_HA cells was used, in range from 35 µg to 0.10 µg, 
35µg of MCF-7 lysate was used (mass of total protein).  Actin loading control.  
As signal from the actin antibody was not seen at the lower quantities, the more 
sensitive total-protein stain is also shown. 
Some detection of the tagged protein was observed down to protein 
loading 1/35th of that used for the wild-type MCF-7 cells.  LRRC15 
protein was detected at this level, though there is no appreciable signal 
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from the actin antibody.  However no native expression was detected in 
the wild type MCF-7 cells, suggesting that this occurs at a level lower 
than 1/35th of the over-expressed protein. 
Next the antibody was tested with different human breast-cancer cell 
lines using Western blot.  Eight cell lines were used, representing a 
variety of tumour histological types (140, 155-159). 
 
FIGURE 21. Non-Detection of LRRC15 Protein in Breast-Cancer Cell Lines 
Seven human, breast-cancer cell lines were tested for LRRC15 by Western blot 
using the antibody raised against the LRRC15 peptide.  Transfected MCF-7 
positive control.  Actin loading control. 
Figure 21 shows that native protein expression was not observed in these 
other cell lines either. 
3.3.2 mRNA Detection and Measurement 
To further explore this scenario, and remembering that the protein was 
brought to attention because of mRNA data, reverse transcription, 
followed by PCR (RT-PCR) was used to see if mRNA expression could 
be detected. 
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FIGURE 22. Detection of LRRC15 mRNA in Breast-Cancer Cell Lines 
Eight human, breast-cancer cell-lines were cultured before RNA extraction and 
reverse transcription to make cDNA.  These were PCR amplified using primers 
for a motif within the LRRC15 sequence.  PCR reaction products analysed by 
electrophoresis reveal a discrete amplicon of the expected size in some 
samples.  An amplicon from beta-2-microglobulin (B2M) was used as a 
positive control.  Negative controls were omission of template library from the 
reverse transcription, and from the PCR reaction. 
Figure 22 shows that LRRC15 mRNA was detected with this technique 
in most of the breast-cancer cell lines tested, including a relatively strong 
signal in MCF7 cells.  The quantitative difference between mRNA levels 
in MCF-7 and MCF-7 LRRC15_HA cells was explored using real-time 
detection of PCR products in similar reactions.  The MCF-10A cell line 
was also included in this experiment, which is a spontaneously 
immortalised human breast epithelial cell line, from benign breast 
disease(160).  Figure 23 shows good concordance between duplicate 
samples and good concordance between B2M levels in the different cell 
lines. 
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FIGURE 23. Quantification of LRRC15 mRNA in 3 Human Breast Cell-Lines 
MCF-10A is a human breast epithelial cell-line (red) 
MCF-7 is a human breast-cancer cell-line  (green) 
MCF-7 plus LRRC15_HA    (blue) 
cDNA was prepared from the three cell lines.  LRRC15 and Beta-2-
microglobulin motifs were amplified with PCR primers as for Figure 22.  The 
plot shows development of fluorescent signal corresponding to amplified DNA 
in duplicated samples.  Negative controls were PCR reactions omitting 
template and omitting primers. 
Using B2M signal to normalise the results, the estimated ratio of 
LRRC15 cDNA is: MCF-10A [1]: MCF-7 [64]: MCF-7 LRRC15_HA 
[3520].  This is a 55-fold increase after transfection with the over 
expression vector.  The relationship between transcription and translation 
is of course complex, but would be expected to amplify this difference.  
This result is in keeping with the non-detection of native LRRC15 
protein expression in MCF-7 cells. 
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3.4 The Peptide Antigen is also in the Predicted 
Murine Protein. 
 
FIGURE 24. Human LRRC15 Amino acid Sequence, and Murine Homologue 
The two amino acid sequences are aligned, and presented with the human 
LRRC15 sequence(137) above the murine homologue Lrrc15(161).  Amino 
acid identity is highlighted in black, and similarity in grey.  Amino acid 
similarity is based on the groups: GAVLI, FYW, CM, ST, KRH, DENQ.  The 
peptide antigen used to raise a successful antibody is highlighted in red.  The 
signal-peptide and the transmembrane domains are highlighted in green and 
blue respectively. 
Similarity of the human LRRC15 sequence and homologues in the 
murine and rat genomes has been described previously(139).  It is 
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repeated here to illustrate that the peptide antigen used to raise the 
successful rabbit antibody, comes from a well-conserved region.  (In this 
region, there is a single isoleucine to valine substitution only).  
Following the style of the consensus coding sequence project (133) the 
murine name uses lower case letters (Lrrc15). 
Because of this sequence similarity, the scope of antibody experiments to 
detect LRRC15 protein expression was extended to murine breast cancer 
models.  The working hypotheses being that LRRC15 protein expression 
was artefactually undetectable in cultured cells, or that the increase in 
mRNA recorded in Oncomine was due to expression in tumour stroma. 
A more concerning hypothesis was that a large ratiometric increase in 
mRNA levels could occur while absolute protein levels remain 
undetectable (because the starting level was so low).  The mRNA data 
sets in Oncomine are ratiometric.  Figure 23 shows a 64-fold greater 
level of mRNA in wild type MCF-7 cells compared to MCF-10A cells, 
though the protein remains undetected with the antibody in both cell 
lines. 
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3.5 The Antibody Detects a Protein of Similar Mass in 
Lysates of Murine Tissues and Breast Tumours 
Tissue lysates were made using samples of normal murine organs, and 
samples of breast tumours from four murine genetic models of breast 
cancer.  These were analysed by Western blots probed using the 
LRRC15 antibody. 
 
FIGURE 25. Western Blot of Murine Tissue Lysates, LRRC15 Antibody 
Lysate from MCF-7 LRRC15_HA cells was included as a positive control.  
Antibody specificity was tested by co-incubation with the antigen peptide.  
Protein loading demonstrated by gel staining. 
Figure 25 shows that a band of approximately 85kDa is observed in 
lysates of liver, and the four types of tumour tested, similar to that seen 
in the MCF-7 LRRC15_HA cell lysate, in support of the hypothesis that 
the protein is expressed at detectable levels in murine breast tumours.  
Protein loading (in the molecular-weight range of interest) is shown to be 
heterogeneous, despite standardising the samples using BCA assays. 
Two bands seen in the lysate of murine kidney, at approximately 110 and 
70 kDa, are of uncertain significance.  We know that the HA tagged 
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protein is glycosylated(139), and these may represent different 
glycosylation states. 
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3.6 Lrrc15 in Fixed Murine Tissue and Breast 
Tumours 
Detection of Lrrc15 in the murine tissue and tumour samples with 
Western blot was further characterised with immunohistochemistry, 
using sections of formalin fixed, paraffin embedded (FFPE) organs and 
tumours. 
 
FIGURE 26. LRRC15 Antibody Staining in FFPE Murine Liver 
A: Overview B: Detail 
Immunohistochemistry using the antibody to LRRC15, counterstained with 
haematoxylin.  Haematoxylin and eosin (H&E) staining of an adjacent section 
(right hand panels). 
In keeping with the low-intensity signal seen on the Western blot (Figure 
25), only weak staining was observed.  Minor staining was seen in the 
cytoplasm of cells around the portal triads. 
Molecular Targeting for Clinical Cancer Imaging 
Leucine-Rich Repeat Containing 15 118 
 
FIGURE 27. LRRC15 Antibody Staining in FFPE Murine Lung 
A: Overview B: Detail 
Immunohistochemistry using the antibody to LRRC15, counterstained with 
haematoxylin.  H&E staining of an adjacent section. 
No signal was seen in the lung lysate at Western blot, and only sparse 
staining was observed in immunohistochemistry.  Weak staining was 
seen on the luminal surface of the bronchial epithelium. 
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FIGURE 28. LRRC15 Antibody Staining in FFPE Murine Fat Pad 
A: Overview B: Detail 
Immunohistochemistry using the antibody to LRRC15, counterstained with 
haematoxylin.  H&E staining in an adjacent section. 
Fat pad staining in Figure 28 does not show any intense staining, in 
keeping with the lack of signal on Western blot.  Mild staining was seen 
in stromal cells around ducts. 
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FIGURE 29. LRRC15 Antibody Staining in FFPE Murine Breast Cancer 
A: Overview B: Detail  
Immunohistochemistry using the antibody to LRRC15, counterstained with 
haematoxylin.  H&E staining in another section of the same tumour.  The 
tumour is caused by conditional expression of the Polyoma-middle-T antigen 
in mammary epithelium. 
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FIGURE 30. LRRC15 Antibody Staining in FFPE Murine Breast Cancer 2 
A: Overview  B: Detail.   
Immunohistochemistry using the antibody to LRRC15, counterstained with 
haematoxylin.  H&E staining in another section.  Tumour aetiology as in 
Figure 29. 
Selected images from three PyMT antigen triggered tumours are shown.  
In figures Figure 29 and Figure 31, LRRC15 staining was located in the 
stroma around dysplastic ducts.  Figure 30 shows images of a higher-
grade tumour containing necrotic areas.  This tumour included some 
intense cell membrane staining of abnormal epithelial cells, particularly 
in areas adjacent to the central necrotic material. 
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FIGURE 31. LRRC15 Antibody Staining in FFPE Murine Breast Cancer 3 
A: Overview B: Detail Immunohistochemistry using the antibody to 
LRRC15, counterstained with haematoxylin.  H&E staining in another section.  
Tumour aetiology as in Figure 29. 
Figure 32 shows selected images of tumour from a different murine 
genetic model.  The staining in this example was densely located in the 
stroma forming a fibrous capsule around the tumour.  It was particularly 
prominent in areas where the tumour cells are invading into and through 
the capsule, although the tumour cells themselves did not stain. 
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FIGURE 32. LRRC15 Antibody Staining in FFPE Murine Breast Cancer 4 
A: Overview  B: Detail   (NIC Pten WGH 121 LM) 
Immunohistochemistry using the antibody to LRRC15, counterstained with 
haematoxylin.  H&E staining in another section.  This tumour was caused by 
conditional expression of an HER2 analogue, and heterozygous Pten loss. 
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3.7 Lrrc15 in Murine Kidney 
 
FIGURE 33. LRRC15 Antibody Staining in FFPE Murine Kidney 
A: Overview B: Cortical Detail C: Medullary Detail 
Immunohistochemistry using the antibody to LRRC15, counterstained with 
haematoxylin.  H&E staining in an adjacent section. 
Figure 33 shows the pattern of staining in murine kidney.  The antibody 
caused focal staining of a proportion of renal tubules in the cortex, and 
of discrete cells in the medulla.  Staining was located in the cytoplasm 
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and luminal membrane of tubular cells.  Some of these cells project an 
apex into the lumen of the tubules and this is where the densest staining 
is seen.  There is less prominent staining in selected tubules of the 
medulla. 
 
FIGURE 34. Location of Lrrc15 in murine Kidney - Triple stain 
Section of normal murine kidney was stained for LRRC15 (green), Aquaporin-
2 (blue) and CD31 (red) using three distinct fluorophores.  The separate 
scanning laser confocal micrographs, and an attenuated phase-contrast image 
are merged.  50µm scale bar. 
In a similar pattern, Figure 34 shows staining of distinct cells.  The 
tubules of a nephron are known to contain a variety of discrete cell 
types(162).  To help identify the type of cells that are staining for 
LRRC15, sections of the same kidney were co-stained with antibodies 
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for aquaporin-2 (expressed by principal cells of the cortical collecting 
ducts(163)), and cluster of differentiation-31  (CD31, expressed by 
vascular endothelium). 
Triple staining of the renal cortex showed that Lrrc15 positive cells 
occur in tubules where there is expression of aquaporin-2.  This 
identifies positive tubules as either ‘cortical collecting ducts’ or ‘cortical 
connecting tubules’.  The cells staining for Lrrc15 are in these tubules, 
but are aquaporin-2 negative.  Their distribution and appearance was 
compatible with intercalated cells, and the most intense staining is seen 
in the luminal apices.  The stain for CD31 highlights some of the 
vascular structures in the renal cortex, in particular, two glomeruli are 
seen in this image, and this staining is clearly separate from the Lrrc15 
positive cells. 
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3.8 LRRC15 is Detected in Biopsies of Human Breast 
Cancer 
After the successful staining of murine tissues, the antibody was tested 
with human breast-cancer samples. 
 
FIGURE 35. LRRC15 Immunohistochemistry in Human Breast-cancer samples 
Overview and details from four human breast tumours, selected from a tissue 
microarray. 
LRRC15 staining shows a combination of tumour cell and stromal 
staining, and is again particularly dense adjacent to areas of necrosis. 
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This preliminary experiment was performed with ‘off-cuts’ from a tissue 
microarray.  Perhaps because these slides were not freshly prepared, 
many samples became detached during staining, and correlation with 
other histological markers and outcome data has not yet been attempted. 
3.9 Conclusions 
A novel antibody, raised in a rabbit using the peptide sequence 
SLKELSPGIFGPMP (from the human LRRC15 gene sequence) 
corresponds well with detection of HA tag on a recombinant LRRC15 
protein, by both Western blot and immunofluorescence. 
Signal from native protein expression in human breast-cancer cell 
lines was expected to confound the experiment above.  However, the 
antibody did not detect native protein expression in a panel of human 
breast-cancer cell lines at Western blot.  LRRC15 mRNA, although 
detectable, was present at much lower levels in the wild type MCF-7 
cells than in the transfected MCF-7 LRRC15_HA cells. 
The LRRC15 sequence is well conserved between human and mouse 
(murine gene Lrrc15) and the antibody had been raised using a peptide 
from a conserved region.  Probing Western blots of murine tissue and 
tumour lysates with the antibody detected an antigen of similar size 
(85kDa) in murine liver and breast tumours.  Immunohistochemistry 
localises both stromal and tumour cell expression of Lrrc15 in the 
tumours.  Only weak staining was seen in liver, lung, and fat pad 
sections.  The increased detection in breast tumour samples, compared to 
normal fat pad, supports the hypothesis that Lrrc15 is involved in tumour 
progression. 
Preliminary antibody staining of LRRC15 in formalin fixed paraffin 
embedded human breast-cancer samples is also promising.  The 
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detection of protein expression in these tumours and in the murine 
tumours, validates selection of LRRC15 for study as a potential marker 
of neoplasia, although staining appears predominantly stromal.  
Restriction of LRRC15 protein expression to tumour stroma may explain 
the lack of protein detected in breast-cancer cell lines. 
The proposal of a stromal factor as a marker of neoplastic tissue has 
precedent.  The use of abnormal stroma to indirectly detect cancer 
underlies a number of current radiological techniques and was discussed 
in Chapter 1 (1.3.1.3).  Co-staining with other histological markers such 
as vimentin for myofibroblasts (164) or cluster of differentiation 68 for 
macrophages might further identify some of the cells expressing 
LRRC15.  It would also be interesting to correlate LRRC15 staining with 
clinical outcome data and other tumour factors such as HER2 and Ki 67 
staining. 
Western blot of murine kidney lysates showed two different bands, at 
110 and 70 kDa.  Immunostaining using the antibody in sections of fixed 
mouse kidney showed focal dense staining discrete cells in cortical 
connecting tubules and collecting ducts.  Expression is not seen on the 
principal cells (which express aquaporin-2), but is present on the luminal 
apices of a separate population of cells, which may be ‘intercalated 
cells’.  The significance of the different band-height in the kidney lysate 
requires clarification.  It is hypothesised that deglycosylation of proteins 
in the mouse kidney lysate, mouse tumour lysate, and MCF-7 
LRRC15_HA lysate would result in uniform band migration near 64 
kDa. 
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4.1 Introduction 
Based on the results reported in Chapter 3, we decided to take LRRC15 
forward as a potential cancer marker and use it as a target for affinity 
selection.  A commercially available phage display peptide library with 
12 residue peptides expressed on M13 bacteriophages(90) and an 
aptamer library with a 40 base variable region and two 22 base priming 
flanks from Integrated DNA Technologies were used as starting 
libraries. 
The aptamer library was amplified using primers with 5’ 
modifications to enable labelling and single strand separation as 
described by Sefah et al.(94).  Briefly, a 5’ biotin modification on the 
anti-sense primer allowed capture of double stranded DNA amplicons 
before alkaline elution of the sense strand.  A 5’ 488nm fluorophore was 
included on the primer for the sense strand to enable visualisation of the 
aptamer.  The fluorophore was included during selection to mitigate 
against subsequent labelling being deleterious. 
In choosing a target system for affinity selection, recombinant protein 
expression in bacteria and whole-cell selections were considered.  
Several attempts to express a recombinant LRRC15 fusion protein in 
bacteria were unsuccessful because the product persistently remained in 
the insoluble fraction on lysis.  Whole cell selection was discounted 
because background level of LRRC15 expression in cell lines was 
unknown at the time of decision.  Expression of HA tagged recombinant 
LRRC15 in MCF-7 cells (see 3.1.1) was established and provided a 
source of target material. 
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4.1.1 Aims 
Use MCF-7 LRRC15_HA expressed protein as target for the affinity-
selection of peptide and DNA sequences. 
Identification of consensus sequences and validation of binding 
interation with the target. 
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4.2 Recombinant Protein Expression in a Human Cell 
Line 
Effective expression of the target protein was achieved in MCF-7 cells 
and is reported in Chapter 3.  In order to simplify the target, and attach it 
to a substrate that could be used to partition the libraries by 
centrifugation, immunoprecipitation on agarose beads was employed.  
This is analogous to methods described by Sanna in 1995 and Gold in 
2010(105, 165). 
4.2.1 Immunoprecipitation of LRRC15_HA 
Two-stage antibody binding to agarose beads was used to extract the 
protein from lysate of MCF-7 LRRC15_HA cells.  The lysate was pre-
incubated with an anti-HA tag murine IgG.  Agarose beads with an 
incorporated anti-mouse-IgG were then added. After a second 
incubation, the beads were pelleted by centrifugation and then washed. 
 
FIGURE 36. Western Blot of LRRC15_HA Expression and Immunoprecipitation 
Lanes:  1.  Control MCF-7 lysate 
2.  MCF-7 LRRC15_HA lysate 
3.  HA tag immunoprecipitate from control MCF-7 lysate 
4.  HA tag immunoprecipitate from MCF-7 LRRC15_HA lysate 
5.  Isotype antibody control from MCF-7 LRRC15_HA lysate 
LRRC15_HA detected by probing for the HA tag. 
Figure 36 shows effective capture of LRRC15 by this method. The loss 
of the actin signal indicates that the target has been simplified to some 
extent.  The C-terminal HA tag epitope is over 30 amino acid residues 
away from the extracellular domain, thus it is hoped that antibody 
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binding here does not interrupt normal conformation, nor opportunities 
for the external domain to bind library elements. 
Although not necessary for library selection steps, immunopurified 
LRRC15_HA protein would have been a useful reagent for subsequent 
validation experiments.  Attempts to separate the captured protein from 
HA tag antibodies were made using excess epitope peptide, acid 
conditions and both in combination, but all had a very low yield 
(assessed by Western blot) when compared with either cell lysate or 
immunoprecipitate. 
At the time of screening putative antibodies to LRRC15 (Figure 17), 
their ability to immunoprecipitate the tagged protein from the lysate of 
MCF-7 LRRC15_HA cells was tested, but without success.   
4.2.2 A Control Immunoprecipitation for Counter-Selection 
Counter-selections (1.4.4) were performed with similar beads and HA 
tag antibody but with substitution of control MCF-7 lysate.  During 
rounds of selection, the counter-selection and selected libraries were 
estimated to ensure that reasonable proportions were retained in the 
relevant fractions (2.9.1). 
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4.3 Selection of Phage Display Peptides 
After four rounds of selection, the third and fourth round libraries were 
sequenced.  Sequencing was performed by two methods using both 
conventional sequencing (manual selection of clones from an appropriate 
plate in a dilution series) and Ion Torrent sequencing (2.8.2).  There was 
good correlation between the sequences returned from conventional 
sequencing and the next-generation sequencing.  The data presented in 
Figure 37 comes from the latter only.  A comparison of data from the 
two techniques was presented in Table 2 in 2.8.3 as a validation of the 
Ion Torrent sequencing method. 
4.3.1 Selected Libraries Contain Successful Sequences 
The results from sequencing (Figure 37) show clear dominance, in both 
rounds, of the peptide sequence SFKIPYHYDSGQ.  The nine top 
sequences from round 3 are preserved in round 4 (although re-arranged) 
implying maturation of the selection process. 
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FIGURE 37. Sequencing of LRRC15 Affinity Selected Peptide Libraries 
Top ten ranked sequences in libraries after rounds 3 and 4 of LRRC15_HA 
affinity selection.  Arbitrary colours link identical sequences in the different 
rounds.  Sequences outwith the top ten are uniformly light grey. 
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4.4 Testing Candidate Peptide Sequences 
Initial tests were carried out with the two leading peptides from round 4: 
SFKIPYHYDSGQ and VTLTTSTMTLNK. 
These were obtained commercially with a C-terminal G, a linker and 
a biotin residue to allow secondary labelling (hereafter LRRC15 peptide 
1 and LRRC15 peptide 2). 
4.4.1 Fluorescent Microscopy 
MCF-7 LRRC15_HA cells were cultured on glass coverslips, as for 
confocal fluorescent microscopy with antibody reagents.  Prior to 
staining, they were fixed and permeabilised.  The cells were costained 
with HA tag antibody (and labelled secondary) and also with DAPI.  
Test peptides were incubated overnight at 4˚C, 20µM in IF block buffer.  
After washing, secondary detection with a dye labelled streptavidin 
reagent was attempted. 
Figures 34 and 35 show that the peptides bind to cells independently 
of the LRRC15_HA expression, as detected by the HA tag antibody.  
The scrambled control peptides show a similar pattern.  They also bind 
all parts of the imaged cells, whereas LRRC15 expression is localised to 
the plasma membrane. 
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FIGURE 38. Confocal Fluorescent Microscopy, LRRC15 Peptide 1  
Confocal micrographs of MCF-7 LRRC15_HA cells.  Test peptides were 
detected with a dye labelled streptavidin, and the anti-HA tag antibody 
(positive control) was detected by a fluorescent-labelled secondary antibody.  
In the merged image on the right, these are shown as red and green 
respectively, and the nuclear counterstain DAPI is blue.  20µm scale bar. 
A: LRRC15 peptide 1, B: Scrambled control C: No peptide control. 
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FIGURE 39. Confocal Fluorescent Microscopy, LRRC15 Peptide 2 
See legend for figure 34. 
A: LRRC15 peptide 2 B: scrambled control. 
4.4.2 Sandwich Fluorescent Assay 
Following failure to demonstrate specific binding using fluorescence 
microscopy, concerns about the different method of target presentation 
were considered.  (The cells had been fixed with formaldehyde and 
permeabilised for the experiments in 4.4.1).  Rather than making further 
attempts to optimise an unproven binding interaction, the negative 
hypothesis, i.e. “there was no specific binding of the selected peptides to 
the selection system” was invoked.  Thus, rather than take forward the 
selected peptides into a more complex system, an assay to test binding in 
conditions similar to those used for selection was designed.  The 
LRRC15_HA protein was again immunosorbed using the HA tag 
antibody, and the test peptides were presented in buffers identical to 
those used for their selection.  An initial approach of putting agarose 
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beads through a flow cytometer encountered some difficulties and so the 
following experiments were performed in plastic plates.  A fluorescent 
secondary streptavidin reagent was used to detect bound peptide (Figure 
11). 
 
FIGURE 40. Plate-based Assay of LRRC15 Peptide 1 and 2 Binding 
LRRC15_HA or control lysate was immunosorbed to plate using the HA tag 
antibody.  Peptide binding was detected with a fluorescent streptavidin 
secondary reagent, as in Figure 11.  Positive controls were initial plate coating 
with peptide, initial plate coating with the fluorescent streptavidin and 
LRRC15 antibody detection.  Negative controls were omission of peptides 
(secondary only control) and use of the control MCF-7 lysate.  Left is the 
inverted fluorescent image of the plate.  On the right the mean and SE of two 
readings is presented graphically. 
Detectable peptide binding is identified, but as in the previous 
experiment, it is also present in the no-target controls.  Observed binding 
is thus non-specific.  Peptide was also presented at reduced 
concentrations, to test if a component of specific binding (perhaps 
overwhelmed at 100µM as used in Figure 40) might be revealed. 
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FIGURE 41. Plate-based Assay of Peptide Binding at Lower Concentrations 
This experiment is similar to that shown in Figure 40, but the test-peptide 
concentrations were decreased. 
Figure 41 shows that non-specific binding persists at lower 
concentrations.  In the same experiment, a similar pattern was seen with 
the scrambled control peptides, although this data has been omitted for 
clarity.  Signal levels from detection of peptide binding are very low, in 
comparison to positive controls using primary well coating with the 
peptide or labelled streptavidin. (These positive controls saturate the 
sensor at the settings used to generate the image in Figure 40, when 
maximal illumination and sensor-gain are employed.)  Therefore, further 
experiments to explore binding at nanomolar levels were not pursued. 
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4.4.3 Peptide Arrays on Glass Slides 
Following failure to demonstrate specific binding of the top two peptides 
with these approaches, a greater number of the selected sequences were 
considered.  All sequences occurring at 0.1% or greater in rounds 3 and 4 
were included, numbering 43.  These were printed on glass slides, with 
C-terminal GGG spacer and attachment similar to the configuration in 
the phage coat protein.  After rehydration, the slides were incubated with 
MCF-7 LRRC15_HA lysate.  The slides were then probed for bound 
LRRC15_HA using an anti-HA tag antibody, an HRP linked secondary 
antibody and a chemiluminescent substrate. 
 
FIGURE 42. Peptide Array Test of LRRC15_HA Binding 
43 peptides were arrayed in duplicate spots.  After incubating with lysate 
containing LRRC15_HA, immunodetection of bound protein was attempted 
using an HA tag antibody, followed by a peroxidase-linked secondary 
antibody.  Controls were included which omitted the target cell-lysate, and the 
primary antibody. 
Figure 38 presents an image of the chemiluminescent signal from the 
slides.  A similar pattern is seen on all three, including controls when 
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either target protein or the primary antibody were omitted.  This 
indicates that a direct interaction of the peptides with the anti-mouse-IgG 
secondary antibody is occurring. The peptide sequences are 
EPQTELLRVLNG, FAGTNSALLMVQ, and SLRFRNHYDSGQ. 
LRRC15 peptides 1 and 2 (section 4.4) are printed on the slide but do 
not cause a signal. 
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4.5 Selection of Nucleic Acid Aptamers 
Twenty rounds of aptamer affinity selection and amplification were 
performed.  In later rounds, stringency of washing was increased and 
serum was included during incubation as according to Sefah et al. 
2010(94). 
4.5.1 Selected Libraries Contain Successful Sequences 
Following 20 rounds of selection, the selected library was analysed using 
next-generation sequencing.  A dominant sequence (29% of sequences) 
was present. The putative aptamer was ordered as an 84 base DNA 
oligonucleotide with 5’ fluorophore modification for testing. 
In addition, to gain further insight into the library diversity in earlier 
rounds and the emergence of consensus, libraries from four earlier points 
in the selection were sequenced (selected libraries after rounds 5, 9, 13 
and 17).  After rounds 5 and 9, the libraries still exhibited great diversity, 
with 99.8% of the reads being unique in both cases.  The sequencing data 
following rounds 9, 13, 17 and 20 are presented in Figure 43. 
The sequences are shown in frequency tables, trimmed of the 
conserved priming regions.  Gradual and persistent emergence of the 
dominant sequence is demonstrated, along with conservation of many of 
the sequences occurring in the top of the table. 
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FIGURE 43. Sequencing of LRRC15 Affinity Selected Aptamer Libraries 
Top twelve ranked sequences in libraries after rounds 9, 13, 17 and 20 of 
LRRC15_HA affinity selection.  Arbitrary colours link identical sequences in 
the different rounds. 
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4.6 Testing Candidate Aptamer Sequences 
4.6.1 Fluorescent Microscopy 
 
FIGURE 44. Confocal Fluorescent Microscopy of Test Aptamer Binding to Cells 
Confocal micrographs of MCF-7 LRRC15_HA cells.  The test aptamer was 
detected using its 5’ fluorophore and LRRC15_HA (positive control) by using 
an anti-HA tag antibody and fluorescent-labelled secondary antibody.  In the 
merged image on the right, these are shown as red and green respectively.  The 
nuclear counterstain DAPI is blue.  20µm scale bar.  A: LRRC15 peptide 1, B: 
Scrambled control 
In parallel with the experiments described in 4.4.1, the first method used 
to test the candidate aptamer was by staining fixed cells.  A scrambled 
control aptamer was also used.  The test aptamer does not co-localise 
with the HA tag antibody.  Both the test and scrambled control 
sequences bind all of the cells, particularly their nuclei. 
These preliminary experiments were limited by difficulties in 
synthesis of the 5’-fluorophore labelled 84-nucleotide aptamer.  The 
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company commissioned to supply this were only able to supply a very 
small quantity; they supplied a complimentary second synthesis, which 
also had a very low yield. 
In addition, there was concern about possible PCR amplification 
artefact following later rounds of selection.  Thus, doubt was cast on the 
likely success an approach building on this single sequence (discussed 
further in section 4.6.4).  Therefore, as in section 4.4, experiments were 
designed to test binding of aptamers under conditions similar to those 
used for selection, and using the labelled aptamer libraries. 
4.6.2 Plate Based Testing of Selected Libraries 
A plate based assay with immunocapture of LRRC15_HA by adsorbed 
anti HA tag antibody was used (Figure 11 above).  This allowed re-
creation of selection conditions, and the selected libraries from five 
points through the selection process were tested.  The quantity of ssDNA 
aptamer library synthesis in a 1ml PCR, and a minimum well-loading 
volume of 50µl, limited test library concentrations to 100nM. 
Figure 45 shows the fluorescence image of the plate, and a graph of 
the image quantification.  Increasing affinity of the fluorescent aptamer 
libraries is seen, peaking at round 17.  However, in what is now a 
familiar theme, it is matched in the non-target control, and is therefore 
due to a non-specific interaction. 
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FIGURE 45. Binding of Selected Libraries to Immunosorbed LRRC15_HA 
The target protein was immunosorbed to the test well using anti HA tag 
antibody.  Fluorescently labelled aptamer libraries were presented, and after 
washing, aptamer binding was assessed by fluorescence intensity.  Negative 
controls were omission of aptamer library (used for background subtraction) 
and control MCF-7 lysate. 
4.6.3 Oligonucleotide Arrays on Glass Slides 
Following failure to demonstrate specific binding with the previous two 
approaches, and the difficulty in obtaining the 5’ labelled 84 base 
oligonucleotiedes, a further approach was tested.  Aptamer sequences 
were synthesised in DNA microarrays.  Nimblegen custom arrays with a 
library of 67 000 potential aptamer sequences were designed.  They 
included all sequences from the selected libraries after rounds 9 and 13 
with their reverse-complementing segments of the priming flanks.  
Sequences that were recurrent within these libraries were also included 
without the priming flanks, and were also used to generate scrambled 
controls. 
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The arrays were incubated with cell-lysates, washed and then 
incubated with labelled anti HA tag antibody (Alexa Fluor 647 
conjugated for detection in the 635 channel).  An isotype control 
antibody was also used, labelled for detection in the second scanner 
channel (Alexa flour 555 conjugated for detection in the 532 channel). 
 
FIGURE 46. DNA Microarray Test of LRRC15 Binding 
Detail from an image of a DNA microarray binding experiment (Slide 3, area 
2).  Each microarray area included over 67 000 test sequences, based on library 
sequencing following rounds 9 and 13.  Following incubation with cell lysates 
(buffer conditions in Table 4 below), target protein detection was attempted 
with a fluorophore labelled HA tag antibody.  Negative controls with 
scrambled and unrelated sequences on the array are included, and with an 
isotype control antibody.  Printed orientation features can be seen in the control 
channel. 
In all experiments, no intelligible pattern of antibody binding was 
detected in the test channel where the labelled HA tag antibody would 
have been seen.  Macroscopically, the slides showed a smeared 
adherence of the cell lysate solution, occurring in both the printed and 
unprinted areas that had been in contact.  This suggested that some 
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material in the cell lysate was non-specifically staining the slide, and 
therefore might obscure any specific interaction between LRRC15_HA 
and the successful aptamers.  Thus a subsequent attempt was made with 
more dilute lysates.  When this also failed in a similar manner, salt and 
detergent concentrations were increased, also without success.  The 
buffer conditions are described in the following table. 




 Lysate with target 
(2.5mg/ml) No SDS 
Control lysate 
(2.5mg/ml)  No SDS 
 









all lysate with target, 0.2mg/ml 








TABLE 4. Target and Buffer Conditions for DNA Microarray Experiments. 
Lysate with target was made from MCF-7 LRRC15_HA cells.  Control lysate 
was made with normal MCF-7 cells.  Total protein concentrations were 
standardised using BCA assay. 
Three slides were used, and each of these contained four copies of the 
array, allowing 12 experiments.  Even after increasing the salt and 
detergent concentration and reducing the total protein concentration, the 
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processed slides still had a uniform coating of material, both on and 
around the microarray, apparent on visual inspection. 
4.6.4 Late-Round Sequences Suggest Amplification Artefact 
Analysis of the base frequency in the aptamer sequencing reveals an 
increasing proportion of thymine and adenine in the later rounds.  A non-
proofreading DNA polymerase was used for these experiments.   
 
FIGURE 47. Base Composition in Aptamer Sequencing 
Frequency of bases in the variable region of sequenced aptamers in libraries 
affinity selected using LRRC15. 
It is reported that changes from cytosine/guanine to thymine/adenine are 
the most common misincorporations during PCR amplification(166).  
Whilst the observed change may reflect a genuine effect of the selections 
based on target affinity, an artefactual drift in the aptamer population due 
to compounding PCR inaccuracies is also hypothesised. 
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4.7 Conclusions 
Although consensus sequences were selected from the libraries by the 
technique employed here, they did not show any specific binding to the 
target in further testing.  This is despite testing in a variety of 
experimental techniques, including ones closely analogous to the 
selection system.  In this situation, it appears that the ‘winning’ 
sequences are not necessarily the most desirable elements.  Factors such 
as increased replication efficiency, or binding to parts of the selection 
other than the target, may artefactually favour success.  This is a 
recognised phenomenon in affinity selection experiments, but will be 
under-represented due to reporting bias.  It was reviewed by Vodnik et 
al. in 2011(167). 
Some insight into the nature of this failure is given by the fact that a 
number of the selected phage peptides had affinity for the rabbit anti-
mouse-IgG secondary antibody used to develop the peptide slides for 
imaging, shown in Figure 42.  Target presentation for peptide and 
aptamer selections used a rabbit anti-mouse-IgG antibody (on the 
agarose beads, to capture the anti-HA tag antibody).  This must have 
favoured success of these sequences, despite the counter-selection step 
containing the same antibody.  In defence of the counter-selection, no 
selected peptides showed affinity for the HA tag antibody. 
The stoichiometry of beads and antibodies was that recommended in 
immunoprecipitation protocols, and conserved between selection and 
counter-selection.  However, in the selection set-up, target binding may 
have reduced the efficiency of coupling between the primary and 
secondary antibodies.  (Incubation of lysate with primary antibody, then 
capture of the primary antibody by adding beads.)  This could result in a 
relative excess of anti mouse-IgG (secondary) antibody sites for phage 
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binding, because unbound HA tag antibody in the counter selections 
would bind more efficiently. 
Nonspecific adherence of oligonucleotides because of their multiple 
ionic charges is a potential problem with aptamer techniques.  We 
observed strong, non-specific nuclear staining with test aptamers, and 
this has been described previously by Gupta et al. in 2011(168), who 
suggest that preponderance of positively charged proteins in the nucleus 
(such as histones) is the cause.  Aptamers in aqueous solution are 
polyanionic.  In their work, they reduced this effect by both selecting and 
testing aptamers in the presence of dextran sulphate, to provide 
competition (or ‘block’) for non-specific binding based on electrostatic 
interactions. 
Sequencing of aptamers in late rounds of selection shows an 
increased proportion of adenine / thymine bases which are known to be 
preferentially misincorporated in PCR amplifications.  This suggests that 
an additional bias has also affected these experiments. 
Failure of both techniques to identify a binder for LRRC15 suggests 
that the selection system may have been at fault.  The stoichiometrics of 
the immunoprecipitation are not well understood, neither is denaturation 
that may be occurring in the preparation of immunoprecipitate (cell lysis 
in RIPA buffer is particularly concerning in this regard).  Although 
LRRC15 remains a target of interest, a future approach would benefit 
from improving selection reagents i.e. a purified protein fragment, or 
even identification and mimicking a physiological binding interaction. 
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5.1 Introduction 
The alpha folate receptor (gene FOLR1) was chosen for study because of 
protein over-expression in many breast and ovarian cancers, shown by 
immunohistochemistry(169, 170).  The receptor has already been 
recognised as an imaging and therapeutic target for ovarian cancer.  As 
such, there is some availability of reagents, such as folate probes under 
development in the Bradley group and the monoclonal antibody 
MOv18(171).  With established progress targeting the folate receptor 
being reported by other groups, it was chosen as a useful target to 
evaluate the peptide and aptamer affinity selection strategies, whereby 
these could be compared to the other more developed reagents. 
5.1.1 Alpha Folate Receptor is a Membrane Glycoprotein 
Alpha folate receptor cDNA isolation (from the KB human cancer cell 
line) and sequencing was reported in 1989(172, 173).  This allowed 
prediction of protein structure, identifying putative phosphorylation sites 
and a membrane-anchoring domain.  Its predominant membrane location 
and endocytotic cycling were described in 1990(174). 
In 1991 the alpha folate receptor was identified as the antigen 
targeted by the antibody MOv18(171), this antigen being expressed by 
many ovarian cancers and the SKOV3 human ovarian cancer cell 
line(175).  Deglycosylation experiments showed that much of the 
apparent molecular mass on electrophoresis was due to N-linked 
saccharides (173).  The peptide molecular mass predicted from the gene 
sequence is 30kDa, while the protein purified from KB cells had an 
apparent molecular mass between 44 and 50 kDa on electrophoresis 
(173). 
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5.1.2 The Protein is Upregulated in Many Cancers. 
By targeting with the cDNA sequence, the human gene was described in 
1997(176), and the name has latterly been standardised as FOLR1(177).  
Increased expression of folate binding proteins has been described in 
various types of human tumours(178-181), and has been associated with 
poor prognosis in breast and ovarian cancer(169, 170, 182). 
5.1.3 Targeting the Folate Receptor for Therapy and Imaging 
A humanised monoclonal antibody targeting the alpha folate receptor, 
Farletuzumab(183), has been evaluated as an adjunct in therapy for 
relapsing ovarian cancer(184), and a trial is ongoing in lung cancer(185). 
The folate receptor can be effectively targeted by drugs using folic 
acid (or derivatives) as a targeting moiety.  The receptor was recognised 
as a route for endocytosis of large molecules in 1991(186).  Recently, 
fluorescent folic-acid compounds have been used to improve 
visualisation of peritoneal metastases at laparoscopy for ovarian 
cancer(187). 
In 2013 there were favourable reports of a phase 2 trial of a folate-
vinblastine conjugate as an adjunct to treatment of platinum resistant 
ovarian cancer(188).  This trial also included folate receptor clinical 
imaging with a technetium labelled folate probe.  In a proportion of 
patients (from both the experimental and control groups), their disease 
was broadly classified according to the presence or absence of tracer 
activity in the measurable lesions.  Tumour response to the folate 
receptor targeted chemotherapy was associated with folate receptor 
expression measured in this manner.  The use of the imaging drug 
remains an experimental component of ongoing trials, not yet applicable 
outside this setting(189). 
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5.1.4 Aims 
Development of reagents for affinity selection using the folate receptor. 
Use of these regents to test experimental labelled folate compounds. 
Selection and sequencing of potential peptide and aptamer binders for 
the alpha folate receptor. 
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5.2 Epitope Tagged FOLR1 in an Expression Vector. 
To facilitate expression, handling and detection of alpha folate receptor 
protein, a recombinant gene, with a C-terminal epitope-tag sequence was 
created in a mammalian expression vector. 
5.2.1 PCR Amplification and Addition of a myc Tag 
 
FIGURE 48. Sequence Tagged FOLR1 in a Mammalian Expression Vector 
Agarose gel electrophoresis of FOLR1 DNA at stages of recombination.  A: 
PCR amplification of the open reading frame with primers adding a 3’ epitope 
tag sequence and flanking restriction enzyme sites.  B: The PCR product was 
incorporated into an intermediate bacterial vector.  Small-scale preparation and 
restriction enzyme digest demonstrated incorporation of the construct into one 
of clones shown.  C: The gene is inserted into a mammalian-cell expression 
vector at the restriction enzyme site in-frame with a promoter.  This vector also 
confers a prokaryotic antibiotic resistance to allow amplification of 
transformed bacteria.  Small-scale preparation and digestion with a different 
enzyme, (chosen to cut once in the vector and once in the insert) demonstrates 
correct orientation of the construct in three of these of clones. 
Briefly: (see also 2.5.1 and 2.5.2), the template gene from a cDNA 
library was purchased, and PCR amplified using primers to add a 3’ myc 
tag sequence and flanking restriction enzyme sites.  The epitope tag was 
added to the C-terminus of the protein to avoid involvement with the N-
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terminal signalling sequence. The N-teminal sequence is reported to 
direct protein location and port-transcriptional modification, and is 
cleaved(172).  The N-terminal extracellular receptor(173) part would 
also thus be unaltered and able to interact with library elements during 
selection. 
The cassette was transferred into a mammalian cell expression vector 
and sequenced to confirm accuracy.  The vector containing the myc 
tagged FOLR1 gene was transfected into A549 cells (a human lung-
cancer cell line), which are known to be folate receptor deficient(190, 
191).  The parent vector also includes a gene conferring resistance to 
hygromycin to transformed cells, allowing selection of those with 
successful incorporation. 
5.2.2 Recombinant Alpha Folate Receptor in A549 Cells 
Expression of the myc tagged construct in transfected A549 cells 
(hereafter A549 FOLR1_myc) was confirmed at both mRNA and protein 
levels.  The SKOV3 cell line was used as a positive control for alpha 
folate receptor expression(175, 192). 
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FIGURE 49. Recombinant FOLR1 Transcription and Expression 
A: Transcription of FOLR1.  Agarose gel electrophoresis of PCR from cDNA.  
The amplicon generated with a second set of primers includes part of the myc 
tag sequence (bottom panel).  B: Confocal Immunofluorescence of cells with 
anti folate receptor antibody then a fluorescent secondary antibody (green).  
DAPI nuclear counterstain (blue).  20µm scale bars.  SKOV3 cells as positive 
control.  Negative control with normal A549 cells.  Secondary only negative 
control was omitted in this experiment, but was performed with these reagents 
using flow cytometry.  See Figure 50. 
Reverse transcription of mRNA, followed by PCR, confirmed that 
mRNA for the alpha folate receptor is present in the SKOV3 cells and in 
the transfected cells, and that it was present with the myc tag sequence in 
the latter.  FOLR1 mRNA was not detected in the normal A549 cells 
(Figure 49 A). 
Immunodetection of alpha folate receptor in the cell membrane is 
demonstrated using both immunofluorescence confocal microscopy of 
fixed cells (Figure 49 B), and flow cytometry of trypsinised live cells in 
suspension (Figure 50).  These techniques detect the folate receptor in 
both SKOV3 cells (positive control) and in the A549 FOLR1_myc cells, 
but not in normal A549 cells. 
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The SKOV3 folate receptor signal measured at both 
immunofluorescence microscopy and immunofluorescence flow-
cytometry is less than that from the experimental positive A549 
FOLR1_myc cell line.  In both Figure 49 B and Figure 50, a proportion 
of the SKOV3 cells do not appear to show immunostaining for the folate 
receptor. 
 
FIGURE 50. Recombinant FOLR1 Expression by Flow Cytometry 
Brightness histograms of immunostained cells in suspension, using either the 
anti folate receptor antibody (blue) or an isotype control antibody (black).  
After washing, a fluorescent secondary antibody was applied.  Positive control 
with SKOV3 cells.  Negative controls with normal A549 cells, and duplicate 
sets using isotype control antibody.  These data are from a single run without 
replications, however similar experiments were run on several occasions and 
this result is representative. 
Western blot detection of the folate receptor using the MOv18 antibody 
was not successful, despite the use of non-reducing, non-denaturing 
sample preparation as recommended in information supplied with the 
antibody.  Neither could the myc tag on recombinant folate receptor be 
detected by Western blot or immunofluorescence.  Therefore failure to 
translate the myc tag sequence, or post translational loss of the myc tag 
is hypothesised. 
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5.3 A Carboxyfluorescein Labelled Folate Compound 
The Bradley group has produced a number of carboxyfluorescein linked 
folate compounds as agents for fluorescent imaging of folate receptors.  
One designated AL2-100, was tested with the A549 FOLR1_myc cell 
line to validate both the probe, and the recombinant alpha folate receptor 
expression.  The probe consisted of a carboxyfluorescein moiety, a short 
polyethylene glycol linker, and a folic acid moiety.  The compund had 
been developed following work reported by van Dam et al. in 2011 and 
the structural diagram was given in Figure 1 of that paper (187).  Testing 
was performed using flow cytometry (carboxyfluorescein fluorescence 
using 488nm stimulation and recording with a 512nm centred filter).  
With the A549 FOLR1_myc cell line as the experimental positive, the 
SKOV3 cells were replaced with KB cells as a positive control for 
endogenous expression.  KB cells are another human cancer cell line, 
with a confused provenance, now understood to be a HeLa 
contaminant(193-195).  This was the cell line used in the initial cloning 
of FOLR1 cDNA(172, 173).  An excess of unlabelled folic acid was 
used to block staining, by competitive inhibition. 
Figure 51 shows that the A549 FOLR1_myc cells are specifically 
stained by the folate linked carboxyfluorescein, in a manner similar to 
KB cells, and that this is blocked by excess unlabelled folic acid.  The 
lack of staining of normal A549 cells by this compound implies that the 
target is specifically the alpha folate receptor.  (While KB cells are well 
known to overexpress the alpha folate receptor, they may also express 
other folate binders or transporters.) 
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FIGURE 51. Flow Cytometry with Carboxyfluorescein Labelled Folate 
In each graph, six histograms are overlaid.  Three in grey are negative controls 
with unstained cells.  Three in green are the test conditions: A: 50nM 
carboxyfluorescein labelled folate (AL2-100).  B: 50nM carboxyfluorescein 
labelled folate with 5µM folic acid, C: carboxyfluorescein.  Negative controls 
are: untreated cells shown in grey, normal A549 cells, inhibition of staining by 
5µM folic acid and unconjugated carboxyfluorescein. 
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5.4 Quantum Dot Labelled Folate  
Quantum dots are nanometre scale semiconductors(196), which can have 
special fluorescence properties, with great potential for medical 
imaging(197). In particular they can exhibit a large Stokes shift.  Their 
successful use to harness Cerenkov radiation from positron emitting 
tracers (198) is a fascinating example. 
A collaborator, with previous experience of developing targeted 
quantum dot reagents (199), had developed a folate conjugated quantum 
dot for trial as an imaging agent and these were tested alongside the 
carboxyfluorescein labelled folate which was reported in section 5.3.  
These were supplied as a 300nM suspension of quntum dot micelles, 
estimated to have 40 - 80 folic acid residues bound to the surface of the 
targeted variety. 
Figure 52 shows that the quantum dots stain only a small proportion 
of cells, and that this occurs independently of folate receptor expression 
on the cells and independently of folate conjugation on the quantum 
dots.  (These bright cells make up the small tail to the right of the 
histogram peaks which otherwise overlay the control traces).  The 
images in Figure 53 are also in keeping with this.  A few bright foci are 
seen but most cells are unstained.  This pattern does not reflect that seen 
with the carboxyfluorescein labelled folate in the same cells, or folate 
receptor immunofluorescence in Figure 49.  The folate-linked quantum 
dots are seen to adhere to the cells non-specifically and non-uniformly. 
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FIGURE 52. Flow Cytometry with Folate Conjugated Quantum Dots 
In each graph, six histograms are overlaid.  Three in grey are negative controls 
with unstained cells.  Three in red shades are the test conditions: A: 30nM 
folate conjugated quantum dots, B: 30nM control quantum dots, C: 50nM 
carboxyfluorescein labelled folate (test traces in green).  Thus, positive controls 
are staining with the carboxyfluorescein labelled folate in KB and A549 
FOLR1_myc cells.  Negative controls are: untreated cells shown in grey, 
normal A549 cells and control quantum dots. 
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FIGURE 53. Live-cell Staining by a Folic Acid Quantum Dot Compound 
Fluorescence Microscopy of live KB cells after staining with the folate targeted 
fluorescent reagents.  Composite images with phase-contrast in greyscale and 
fluorescence overlaid in colour.  Images show cells after staining with either A: 
30nM folate quantum dot compound, or B: 50 nM carboxyfluorescein labelled 
folate (positive control). 
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5.5 Whole-Cell Selection of Aptamers and Peptides 
The A549 FOLR1_myc cells were developed as a reagent for the 
selection of peptide and aptamer binders from combinatorial libraries as 
discussed above.  Although the experiments in 5.2.2 show successful 
expression on the cell surface, because it was not possible to detect by 
Western blot the recombinant protein (neither with the myc tag or the 
main protein) it was decided to perform affinity selections using whole 
cells as described by Sefah et al. in 2010(94). 
As no detectable folate receptor expression is demonstrated on normal 
A549 cells in the experiments above, these are a cognate counter-
selection target. 
In considering other potential systems for affinity selection, 
successful immunoprecipitation using the myc tag would difficult to 
verify without Western blot.  In addition, following failure to 
demonstrate presence of the myc tag, it was also a dubious target.  
Immunoprecipitation using the MOv18 antibody would also be difficult 
to verify, and binding to the extracellular portion of the protein could 
confound selection by obscuring sites that might usefully bind the 
peptides or aptamers.  Expression of the recombinant alpha folate 
receptor as a fusion protein in bacteria was attempted, but was 
unsuccessful. 
5.5.1 Whole Cells in Tissue Culture for Selection 
Selections and counter-selections were performed using non-confluent, 
adherent cells on tissue culture plastic.  The A549 FOLR1_myc cells 
were maintained in media with hygromycin, but on passage into plates 
two days preceding selection, they were kept in standard tissue culture 
medium, which included a supplement of foetal bovine serum. 
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5.5.2 Consensus Sequences in Peptide Libraries 
 
FIGURE 54. Sequencing Of Whole-Cell Affinity Selected Peptide Libraries 
The twelve most-frequent sequences in each of three unrelated experiments 
using whole cell selection.  Arbitrary colours link identical sequences in the 
different rounds. 
Selection of phage peptides for affinity to folate receptor was being 
performed at the same time as two other experiments panning for 
peptides with different oesophageal cancer cell lines.  These other 
selections had been through four rounds, and so were considered ready 
for sequencing.  With an opportunity to multiplex the experiments into 
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the same sequencing run, the A549 FOLR1_myc selected libraries were 
sequenced early, at only the second round of selection. 
Figure 54 shows that the most frequent sequences returned in these 
three unrelated experiments fall into a similar pattern.  A single 
dominant sequence accounts for at least 75% in each library, and there is 
conservation of some other top-ranked sequences.  The fact that these 
varied experiments each returned a similar set of results was felt to 
indicate artefactual success of these sequences. 
5.5.3 Sequencing Aptamer Libraries 
Having observed both the misincorporation bias in late rounds of the 
LRRC15 aptamer selections (4.6.4), and the ability of the next-
generation sequencing technique to identify recurring sequences when 
they were only a few per cent within a very diverse library, it was also 
decided to sequence the early rounds of the aptamer selection. 
Although these libraries appear immature, with no sequence 
occurring as much as 0.40 per cent, they do show a consistent winning 
sequence, and conservation of some of the top ranked sequences. 
Selecting aptamers to take forward at this early stage of selection 
would be unprecedented, although the sequences reported here might be 
genuine binders.  Reasons for abandoning the work at this point are 
discussed in the following section. 
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FIGURE 55. Sequencing Of Whole-Cell FOLR1 Selected Aptamer Libraries 
The twelve most-frequent sequences after rounds 8, 10, 11 and 12 of selection.  
Arbitrary colours link identical sequences in the different rounds. 
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5.6 Conclusions 
5.6.1 Successful Targeting of the Receptor Using Folate 
Conjugates 
Although we have been able to demonstrate folate receptor specific 
staining with a folate-carboxyfluorescein conjugate, other groups have 
also made substantial progress with similar approaches for whole animal 
and clinical imaging. 
A high profile report in 2011(187), from an international 
collaboration, highlighted that abnormal folate receptor expression in 
metastatic human cancer is already amenable to targeting by small drug 
molecules, using a folate moiety for targeting.  They report ability to 
identify ovarian cancer metastases within the abdomen of a patient using 
a fluorescent folate conjugate.  Our work presented in 5.3 with 
carboxyfluorescein labelled folate uses a similar compound.  However, 
given that the work here relied on prolonged folate free culture, and we 
showed that adding 500nM folate provided saturating inhibition of the 
labelled agent, achieving such success in vivo (where serum folate is 
approximately 1µM) is impressive.  The lack of a non-targeted control in 
the experiments reported by van Dam et al. means that the role of 
passive extravasation could not be assessed. 
Some of the authors of that report also have interests in Endocyte 
(200).  This company has already made extensive efforts to develop 
clinical imaging of the folate receptor (201, 202).  These efforts include 
application of analogous technology in clinical trials of folate targeting 
drugs, reported in 2013 (188).  In addition, other groups have achieved 
preclinical success with folate-targeted PET tracers (203, 204).  
However, it is noted that the trial of vintafolide in relapsed ovarian 
cancer has been ‘stopped for futility’ in May 2014 (246) 
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5.6.2 Spurious Consensus in Phage Selection Experiments 
The consensus of phage sequences across three unrelated whole-cell 
selection experiments is suspicious of artefactual success.  This was 
discussed as a pitfall of experiments like this in section 4.7.  The failure 
of our recombinant alpha folate receptor to include expression of the 
myc tag, and failure of recombinant folate receptor expression from 
bacterial culture limited the availability of other approaches. 
As consensus sequences were conserved between selections using 
different cell lines, it is less likely to be due to a cell binding interaction, 
and is perhaps explained by another driver of artefactual success such as 
plastic binding or increased replication efficiency.  While the system 
employed for whole cell selection does have some record of success(94) 
in the selection of ssDNA aptamers, personal communication from a 
notable phage display expert(205) attested that “cell selections are very 
tricky”. 
5.6.3 Difficulty Advancing Aptamer Hits 
Work with the LRRC15 selected aptamer sequences exposed a number 
of practical problems including difficult synthesis of labelled 84 base 
polynucleotides for further testing, and requirement for positive controls 
in aptamer microarray experiments.  The failure to detect myc tag 
expression by the A549_FOLR1myc cells, and thus inability to 
immunoprecipitate the alpha folate receptor, or detect it on Western blot 
meant that there was also no reagent to take forward in any comparable 
experiments.  In combination with the good progress being made by 
other groups using folate conjugates for targeting, the rationale for 
developing aptamers for this purpose appeared smaller than the 
obstructions. 
Molecular Targeting for Clinical Cancer Imaging 
Matrix Metalloproteinase-9 Probe 173 
Chapter 6: Matrix Metalloproteinase-9 Probe 
6.1	   Introduction ............................................................................... 174	  
6.1.1	   Matrix Metalloproteinase-9 (MMP-9) ................................ 174	  
6.1.2	   Enzyme Activity can Activate an Imaging Agent .............. 175	  
6.1.3	   A Control Probe and an Enzyme Inhibitor ......................... 175	  
6.1.4	   Aims .................................................................................... 176	  
6.2	   Rapid Fluorescent Reporting of MMP Activity ........................ 177	  
6.2.1	   Probe Activation by Recombinant MMPs 2, 9 and 13 ....... 177	  
6.2.2	   Inhibition of the Reaction by Ilomastat .............................. 180	  
6.2.3	   Dextro Amino Acid Control Probe ..................................... 180	  
6.3	   Probe Response using Murine Tissue Fragments ..................... 181	  
6.3.1	   Probe Activation by a Selection of Murine Tissues ........... 181	  
6.3.2	   Probe Response to Breast Tumour vs. Fat Pad, Repeats .... 185	  
6.3.3	   Effect of Kindlin Deletion on Probe Activation ................. 189	  
6.3.4	   Tissue Fragments and Protein Standardisation ................... 192	  
6.4	   Variations in MMP-9 Positive Controls .................................... 194	  
6.5	   Mmp-2, 3, 9 and 13 in Murine Tissues ..................................... 196	  
6.5.1	   mRNA Expression .............................................................. 196	  
6.5.2	   Immunohistochemistry ....................................................... 197	  
6.5.3	   Mmp activity Detected by Zymography ............................. 210	  
6.6	   Conclusions ............................................................................... 213	  
6.6.1	   Off-Target Activation ......................................................... 213	  
6.6.2	   Probe Solubility and Dosing Accuracy .............................. 214	  
6.6.3	   Probe pH Sensitivity and Buffer Solutions ......................... 215	  
6.6.4	   Summary ............................................................................. 215	  
 
Molecular Targeting for Clinical Cancer Imaging 
Matrix Metalloproteinase-9 Probe 174 
6.1 Introduction 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent 
endopeptidases, involved in physiological and patho-physiological 
breakdown of extra-cellular matrix.  Such breakdown is an inherent part 
of tissue infiltration during inflammation and angiogenesis, remodelling 
and wound healing.  Inflammation, invasion and angiogenesis are all 
processes implicated in tumour spread and metastasis.  A number of 
clear reviews have been written about the potential of MMPs as 
therapeutic targets in cancer(206-208).  Although there were several 
trials of small molecule MMP inhibitors in cancer treatment during the 
early 21st century, these were unsuccessful.  A high profile failure at this 
stage occurred with the drug marimastat, precipitating the controversial 
collapse of British Biotech Ltd. 
In the meantime, knowledge of many different MMPs and other 
associated and analogous proteins has increased. MMPs remain a target 
of interest for other therapeutic approaches such as monoclonal 
antibodies(209). 
6.1.1 Matrix Metalloproteinase-9 (MMP-9) 
MMP-9 (or gelatinase B) is a collagenase that breaks down type IV and 
type V collagen.  Although expression and activation are variable in cell 
culture systems(210), protein expression is frequently seen in invasive 
tumour histology, and is a marker of poor prognosis in many human 
cancers(211, 212).  Stromal MMP-9 expression in human breast cancer 
samples is correlated with poor prognosis(213).  Experimental 
manipulation of a human breast cancer cell line links increased MMP-9 
expression with invasiveness(214).  It is thus of interest as an identifier 
of tumour tissue and a marker of disease biology. 
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As with other MMPs, MMP-9 is produced as a pro-enzyme, which is 
activated by proteolytic removal of an inhibitory domain(215).  As such, 
gene and protein expression measurements do not directly relate to 
MMP-9 activity.  MMP-9 activity can be demonstrated by gelatin 
zymography, which combines non-denaturing polyacrylamide-gel 
electrophoresis with cleavage of a gelatin substrate incorporated in the 
gel. 
A closely similar protein is also found in Mus Musculus and is here 
abbreviated as Mmp-9.  Other murine matrix metalloproteinases are also 
abbreviated in this fashion. 
6.1.2 Enzyme Activity can Activate an Imaging Agent 
The concept of imaging agent activation by enzymes (present to modify 
the extracellular matrix) was discussed in 1.3.3.  A number of MMP 
sensitive colorimetric reagents and in vivo imaging probes are available 
commercially, and the Bradley group are developing probes for real-time 
fluorescent imaging of enzyme activity in vivo.  In this work, a probe 
from the Bradley group, designed to be activated by MMP-9, was tested 
using excised fresh tissue from murine tumours and normal murine 
organs.  The probe has a structure analogous to that laid out in Figure 4, 
with a pair of quenched carboxyfluorescein fluorophores, dequenched on 
cleavage of the substrate peptide.  Due to the nature of the probe 
targeting for MMP-9 and known overlap of the enzyme substrates, it was 
anticipated that the probe would also be activated by MMP-2 and MMP-
13, and the murine equivalents of all three. 
6.1.3 A Control Probe and an Enzyme Inhibitor 
An isomeric control probe with a D amino acid substitution at the 
cleavage position in the peptide was also used.  This prevents MMP-9 
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endopeptidase susceptibility.  Both the test and control probes were 
uniformly used at 10 µM in these experiments. 
The multiple MMP inhibitor ilomastat (also known as GM6001 
(216)) was used to further analyse probe activation.  It is a broad 
spectrum MMP inhibitor and inhibits MMP-9 at nanomolar 
concentrations, along with many other MMPs(216).  In these 
experiments, it was uniformly used at 20 µM, significantly in excess of 
measured MMP inhibition constants, to provide complete MMP-9 and 
broad MMP blockade, and thus expose probe activation by other 
mechanisms.  Although a more specific MMP-9 inhibitor is 
available(217), this broad approach was still informative in these initial 
experiments. 
6.1.4 Aims 
To test use of the probe in identifying cancer, by comparing probe 
activation by murine breast tumour tissue with that by normal murine 
tissues. 
Correlate probe activation with other measures of Mmp expression 
and activity (mRNA detection, Western blot, Immunohistochemistry and 
Zymography). 
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6.2 Rapid Fluorescent Reporting of MMP Activity 
6.2.1 Probe Activation by Recombinant MMPs 2, 9 and 13 
Purified recombinant proteins based on the active sites of the human 
enzymes MMP-2, 9 and 13 were used to study probe activation and the 
inhibition of probe activation by ilomastat.  The recombinant active sites 
are designated rh MMP-2 etc. 
Figure 56 shows the fluorometry over time, in solutions containing 
the probe and recombinant human MMPs.  The fluorescence signal 
(released, or activated, by cleavage of the probe) was measured by 
photometric counts in a one second exposure (ct/s).  A background 
measurement for subtraction was made from a control solution without 
enzyme.  These control wells exhibited stable readings over the time 
course of the experiment, equivalent to 10 percent of the signal seen with 
30nM MMP-9 at15 minutes. 
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FIGURE 56. Probe Fluorescent Response using Recombinant Human MMPs (1) 
The catalytic domains of the human MMPs 2, 9 and 13 were added to different 
concentrations.  Negative controls were inhibition by ilomastat, and omission 
of enzyme, the latter was subtracted to give Corrected Fluorescence.  Means 
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Peak signal was similar with each enzyme at 30nM, but the kinetics of 
the enzymes are different, as shown by the different gradients.  With 
30nM addition of each enzyme, probe activation (gradient of the initial 
linear segment over 12 minutes) was MMP-13 > MMP-2 ≅ MMP-9.  
This is shown further in Figure 57, including the linear regression lines 
used to calculate the gradients.  The gradients (counts per second, per 
second are MMP-13  4960, MMP-2  1470 and MMP-9 1250) 
In Figure 56, the probe signal saturates at a similar level with all three 
enzymes at 30nM, but the rapid rise with MMP-13 achieves a slightly 
greater peak.  This also demonstrates a late phase decrease in 
fluorescence over time.  This may relate to photobleaching, or another 
deterioration in the fluorophore, and is presumed to be present when 
using the other enzymes, as all three converge on a similar value by 110 
minutes. 
 
FIGURE 57. Probe Fluorescent Response using 30nM rh MMPs 
This is the same data from Figure 56, but including only the 30 nM enzyme 
doses, and with focus on the initial 12 minutes, in order to allow comparison of 
the gradients in this linear phase. 
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6.2.2 Inhibition of the Reaction by ilomastat 
In Figure 56, the signal in wells containing probe, 30nM enzyme and 
20µM ilomastat is near zero with all three enzymes over the observed 
period.  This reflects parity with the background probe fluorescence and 
confirms the expected inhibition of these enzymes by 20µM ilomastat. 
6.2.3 Dextro Amino Acid Control Probe 
A limited amount of the control-probe, incorporating a D amino acid at 
the MMP cleavage site, was available.  Testing with rh MMP-9 showed 
a low signal only.  The corrected fluorescence with the control probe was 
1 percent of that with the test probe at 57 minutes, the final time points 
in Figure 58. 
 
FIGURE 58. D-Amino acid Control Probe with Recombinant Human MMP-9 
The test probe (black) is compared to the D amino acid control probe (green) 
using 30nM rh MMP-9.  Background fluorescence was measured by omitting 
the enzyme, the values subtracted to give the Corrected Fluorescence.  These 
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6.3 Probe Response using Murine Tissue Fragments 
To test the probe response with murine tissues, tissue pieces were cut 
manually into cubes of side 2mm, and incubated with the probe solution. 
6.3.1 Probe Activation by a Selection of Murine Tissues 
 
FIGURE 59. Fluorescent Response with Fragments of Murine Tissue 
Negative controls with addition of Ilomastat (red) and substitution of test-probe 
with the D amino acid control (green) are also plotted.  Background 
fluorescence with no added tissue was subtracted to give Corrected 
Fluorescence.  Mean and S.E. from three replicate tissue pieces are plotted. 
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FIGURE 60. Fluorescent Response with Fragments Of Murine Tissue (Continued) 
See Figure 59. 
In initial testing, a selection of tissue pieces was used, dissected from 
mammary fat pad, breast tumour, kidney, liver and lung.  Figure 59 and 
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Figure 60 shows that probe activation is different with different tissue 
types.  Contrary to results with pure hr MMPs, there is probe activation 
in the presence of ilomastat.  Very little activation of the D amino acid 
control probe is caused by the murine tissue samples.  Pieces of kidney 
elicit the greatest response of the tissues tested, significantly greater than 
tumour pieces.  This is of relevance in considering a probe that might be 
taken forward to systemic administration, because of the vascularity of 
the kidneys.  In humans, the kidneys are known to receive approximately 
20 percent of the resting cardiac output. Blood flowing through the 
kidneys passes through two capillary beds.  Thus for any drug, its 
interaction with the kidneys is an important consideration. 
 
FIGURE 61. Comparison Between Kidney, Tumour, and Fat pad Responses 
Repeat presentation of the data from these three tissues for comparison.  Linear 
regression analyses are also plotted. 
Figure 61 shows that within a few minutes, probe response to tumour 
pieces was significantly greater than to fat pad.  This is well illustrated 
by the graph, which shows no overlap of the standard error bars after 10 
minutes, and the p-value is 0.002 on static analysis of the data from the 
10-minute point.  The response to kidney was greater than both of these, 
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but also more variable.  There is some overlap of the standard error 
values with the tumour set until after 15 minutes.   
Probe response in the presence of ilomastat implies there are factors 
additional to MMPs -2, 9 or 13 contributing to activation.  These may be 
other enzymes present in the tissues causing ‘off-target’ activation of the 
probe, but another possible explanation was considered. 
 
FIGURE 62. Probe Activation by Lysates of Murine Kidney and Liver 
The soluble fraction of mechanical lysates of liver and kidney (20µg protein) 
were pre-incubated with either a DMSO control (black) or ilomastat (red) 
before addition of the fluorescent probe at time zero. 
It was suggested that different rates of action of the ilomastat, probe and 
activating factors might relate to their unquantified movement between 
the solid piece of tissue and the solution Using tissue lysates tested the 
hypothesis that probe activation in the presence of ilomastat might be 
due to pharmacokinetic complication with pieces of tissue.  Samples 
were mechanically liquidised, then clarified by centrifugation.  The 
supernatant was standardised to protein-concentration estimated by BCA 
assay.  Kidney and liver were the tissues chosen because they caused the 
largest probe response in the previous experiment, including a significant 
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proportion in the presence of ilomastat.  Unfortunately, supply of the D 
amino acid control probe had been exhausted by this stage. 
The probe response to kidney lysate is broadly similar in terms of 
magnitude, and the proportion remaining with ilomastat blockade, to that 
seen using pieces of kidney (shown in Figure 60).  As the reaction 
components are now all in solution, this proportion (44% with lysates 
and 24% with the tissue pieces at approximately 33 minutes) must be 
due to activation by an ezyme or process less sensitive to ilomastat than 
the hr MMPs presented in Figure 56. 
The lysate of liver shows a very different pattern.  The probe 
activation in the presence of ilomastat is similar in magnitude to that 
seen using pieces of liver, also in Figure 60.  However, there is now no 
difference between probe activation with or without ilomastat.  It 
therefore appears that the ilomastat-inhibited component of probe 
activation (presumably by MMPs) has been lost in the processes of tissue 
lysis and centrifugation. 
6.3.2 Probe Response to Breast Tumour vs. Fat Pad, Repeats 
The preliminary experiments reported in 6.3.1 showed an increase in 
fluorescent signal from probe when using breast tumour tissue, 
compared with that from normal mammary fat pad.  That experiment had 
used samples from the Polyoma middle-T antigen breast cancer model.  
The difference between breast tumour and normal fat pad was further 
explored using samples of breast tumours from three NIC Pten -/+ mice, 
and samples from the fat pads of three control mice.  The genetic breast-
cancer model is described in 2.11.2, and was chosen for further study 
because the manipulated Erb-B2 (murine analogue of HER2) 
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overexpression and Pten knockout lesions underlying tumours in these 
mice are a common pattern in human breast cancer. 
Three replicate wells of each of the three samples were used.  In order 
to display the heterogeneity between the samples, these are presented in 
the following figures as a mean and standard error for each sample, 
before the results are pooled for comparison between the entire sets of 
tumour and normal.  In addition, the whole experiment was repeated 
with equivalent samples, and this is presented in the subsequent figure.  
Samples had been prepared and frozen, and then aliquots were defrosted 
prior to each experiment. 
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FIGURE 63. Probe Activation by Fat Pad and Breast Tumour (1) 
Tumour samples from three mice and fat pad samples from three control mice.  
Three replicates of each sample.  The mean and linear regression of both sets 
(9 samples) is presented for comparison. 
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FIGURE 64. Probe Activation by Fat Pad and Breast Tumour (2) 
Repeat of the experiment presented in the previous figure. 
Greater probe activation is observed using breast tumour tissue than fat 
pad on both occasions (in addition to that reported in Figure 61).  The 
difference is clearly discernable before 10 minutes in both experiments.  
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At the final time point it is 2.5 times greater in the first experiment, and 
2.8 times greater in the second, with p-values less than 0.01 on t-test. 
There is a difference in the overall amplitude of the fluorescence 
signal between the experiments, and this did not correlate with the 
signals seen in a contemporary MMP-9 positive control (not shown).  
The MMP-9 positive control showed a greater signal in the second 
experiment, where the fat pad and tumour signals were lower.  
Variations in positive controls, implicating unreliability of probe loading 
or enzyme quality are presented and discussed in 6.4. 
6.3.3 Effect of Kindlin Deletion on Probe Activation 
Kindlin is a protein involved in integrin-mediated bidirectional 
signalling between the cytoskeleton and the environment, including 
extracellular matrix and other cells(218).  Data from other work in our 
lab shows that loss of kindlin-1 in mouse mammary tumour models is 
associated with a reduction in metastatic disease (the murine genetic 
model being studied is described in 2.11.3).  Observations in human 
breast cancer, reported by another group, positively correlate primary 
tumour kindlin-1 expression with metastatic disease (219).  An 
experiment to compare probe activation by different tumour types, 
measuring the effect of kindlin-1 deletion was performed.  It was 
hypothesised that tumour fragments from kindlin-1 deleted tumours 
would show a lower level of probe activation.  Control tumours are from 
mice incorporating the PyMT tumour model, but who did not have the 
BC5 construct (kindlin knock-out, see 2.11.3) at genotyping. 
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FIGURE 65. Activation by Tumour - Effect of Kindlin-1 Deletion (1) 
Tumours from six mice were sampled.  These were three control mice and 
three with kindlin knockout in the tumours.  Three replicates of each sample.  
The mean and linear regression of both sets (nine samples) is presented for 
comparison. 
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FIGURE 66. Activation by Tumour - Effect of Kindlin-1 Deletion (2) 
Repeat of the experiment presented in the previous figure. 
Although the first experiment shows that kindlin-1 deletion reduces the 
rate of probe activation, this is not borne out in the repeat experiment 
(Figure 65 and Figure 66 respectively).  Even in the first experiment, the 
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variation seen in replicates of a single sample exceeds the difference 
observed by averaging the entire sets. 
6.3.4 Tissue Fragments and Protein Standardisation 
In an effort to improve interpretation of this data, an estimate of total 
protein contained in the tissue pieces was sought.  After the probe 
fluorescence measurement series were completed, plates had been frozen 
for later analysis.  Well contents, including the tissue piece, were added 
to a fixed volume of buffer for mechanical lysis and BCA assay.  The 
resulting protein concentration was taken as a surrogate for the total 
protein in the sample. 
 
FIGURE 67. Rate of Fluorescence Increase against Total Protein 
Each tissue piece is represented, those from the first plate in red, and the 
second in blue.  A linear regression performed on the combined set is also 
plotted. 
The probe activation by each individual tissue piece was analysed by 
linear regression to obtain the rate of increase in fluorescence over the 35 
minutes time course.  (The rate of fluorescence increase was observed to 
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used, each having 18 tumour pieces.  Each piece was then plotted 
according to protein concentration, and rate of probe activation. 
Analysis of these 36 points shows that there is no relationship 
between the BCA assay value and the rate of probe activation (gradient = 
0).  In addition, there is a gross disparity between the BCA assay values 
for the two plates, which suggests a severe systematic error.  This is 
possibly due to a combination of variable efficiency in mechanical lysis 
and variable efficiency of centrifugal clarification.  The latter was 
particularly dubious because macroscopic particles from the lysing 
matrix meant that the pellets were not cohesive.  The fact that there is a 
significant, but unquantified amount of tissue material in the pellet 
further undermines rationale for this approach.  In an in vivo imaging 
scenario, assessment would depend on probe activity in a given volume 
of tissue, rather than probe activity per unit protein, so possible efforts to 
optimise the technique of protein quantification were not undertaken. 
Molecular Targeting for Clinical Cancer Imaging 
Matrix Metalloproteinase-9 Probe 194 
6.4 Variations in MMP-9 Positive Controls 
In each of the series of ten preceding experiments in this chapter, 30nM 
hr MMP-9 was included as a positive control.  The rate of fluorescence 
signal was variable in these. 
This had been noticed in earlier preliminary experiments, and the 
following steps had been taken to improve the reliability: storage of 
probe at -20˚C with desiccant, aliquoting and storage of rh MMP-9 at -
70˚C, use of Tris buffers with detergent for experiments and intermediate 
dilutions.  (The failure of preliminary experiments performed in a growth 
medium is discussed in 6.6.3). 
 
FIGURE 68. Rate of Fluorescence Increase in hr MMP-9 Controls against Date 
The rate of fluorescence increase, calculated by linear regression of the 
fluorescence recordings is plotted against the date of experiment (arbitrary zero 
for the first date in this series). 
Despite these measures, there is wide variation in the fluorescence signal 
from the probe, and a trend of deteriorating signal over time. 
To explain variability, the observation that the stock probe solution 
(in dimethyl sulfoxide) would partially precipitate on addition to aqueous 
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solutions is thought to be relevant, and this may explain a degree of 
unpredictable loading. 
Because the recombinant MMP-9 used as a positive control was taken 
out in aliquots, the reduction in signal over time is probably occurring 
because of deterioration in the probe stock. 
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6.5 Mmp-2, 3, 9 and 13 in Murine Tissues 
To better understand the mechanisms of probe activation in the murine 
tissues, other measures of Mmp gene transcription, protein expression 
and activity were applied.  Probe sensitivity had been demonstrated to 
human MMP-2, -9 and -13 and so these these were included for study.  
An antibody to MMP-3 was already in hand, so this was also included in 
the panel of analyses. 
6.5.1 mRNA Expression 
 
FIGURE 69. Mmp-2, 3, 9 and 13 mRNA Detection in Lysates of Murine Tissues 
Agarose gel electrophoresis of PCR amplicons from cDNA.  Primer sets were 
designed to generate specific amplicons from the selected murine Mmp genes.  
Positive control using the gene Gapdh.  Negative control was performed by 
omitting the enzyme from a reverse transcription reaction with liver RNA, thus 
generating no template. 
Mmp-2 gene transcription was identified in all the tested tissues.  Mmp-3 
and Mmp-13 were demonstrated in all the tissues except liver.  Mmp-9 
transcription was only seen in lung and fat pad (Figure 69). 
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All the tumour tissue samples contained Mmp-2, -3 and -13, but 
transcription of Mmp-9 was not identified. 
6.5.2 Immunohistochemistry 
Sections of murine kidney, liver, lung, spleen and fat pad were stained, 
in addition to archived sections of breast tumours from the murine 
genetic models of breast cancer.  Not all the tissues showed staining for 
each Mmp, but some examples of positive staining for each of the tested 
Mmps (2,3,9,13) are shown.  These examples of successful staining, and 
their correlation to the gene expression detected in mRNA, justified the 
examination of the tumour fragments.  Negative control experiments 
were performed using similar tissue sections, but omitting the primary 
antibodies. 
Mmp-2 and -3 were identified in the renal tubules, consistent with 
their expression at mRNA level (Figure 70).  Although they do not show 
identical staining, both are present to the greatest degree in the cortical 
collecting ducts (most internal cortical tubules) and in some of the 
medullary ducts.  Mmp-2 is present only in a few medullary tubules, and 
Mmp-3 is present in most of the medullary tubules. 
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FIGURE 70. Mmp-2 and 3 Immunohistochemistry Murine Kidney 
A. Mmp-2 B. Mmp-3 C. H&E 
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Mmp-9, the next of the examined Mmps was observed in the bronchial 
epithelium of murine lung sections (Figure 71).  This is consistent with 
the observed low level of Mmp-9 mRNA expression detected at qRT-
PCR.  Mmp-9 mRNA was also detected in the fat pad samples but fat 
pad immunohistochemistry for Mmp-9 appeared to be dominated by 
spurious background staining (not shown). 
 
FIGURE 71. Mmp-9 IHC in Murine Lung 
A. Mmp-9 B. H&E 
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FIGURE 72. Mmp-13 IHC in Murine Kidney 
A. Mmp-13 B. H&E 
Like Mmp-2 and -3, and in keeping with the mRNA results, Mmp-13 
staining was also seen in the kidney.  Again, it was most pronounced in 
the ducts of the inner cortex (Figure 72). 
Following this successful staining of control murine tissues, the 
technique was used to examine the presence of Mmp-2,  -3,  -9, and -13 
in tumour sections.  Two PyMT tumours and two NIC Pten -/+ tumours 
were stained for each of these Mmps on adjacent sections.  The images 
are collected by tumour sample to allow comparison between the 
different Mmp staining patterns, in correlation with haematoxylin and 
eosin staining.  Descriptions in the text are subsequently gathered 
according to the Mmp being examined. 
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FIGURE 73. Mmp-2 and 3 IHC in a PyMT Breast Tumour 
PyMT BC5 WGH 589 LM 
A. Mmp-2 B. Mmp-3 C. H&E 
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FIGURE 74. Mmp-9 and 13 IHC in a PyMT Breast Tumour 
PyMT BC5 WGH 589 LM 
A. Mmp-9 B. Mmp-13 C. H&E 
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FIGURE 75. Mmp-2 and 3 IHC in a Second PyMT Breast Tumour 
PyMT BC5 WGH 606 RL 
A. Mmp-2 B. Mmp-3 C. H&E 
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FIGURE 76. Mmp-9 and 13 IHC in a Second PyMT Breast Tumour 
PyMT BC5 WGH 606 RL 
A. Mmp-9 B. Mmp-13 C. H&E 
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FIGURE 77. Mmp-2 and 3 IHC in a NIC Pten -/+ Breast Tumour 
NIC Pten WGH 121 LM 
A. Mmp-2 B. Mmp-3 C. H&E 
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FIGURE 78. Mmp-9 and 13 IHC in a NIC Pten -/+ Breast Tumour 
NIC Pten WGH 121 LM 
A. Mmp-9 B. Mmp-13 C. H&E 
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FIGURE 79. Mmp-2 and 3 IHC in a Second NIC Pten -/+ Breast Tumour 
NIC Pten WGH 129 LL 
A. Mmp-2 B. Mmp-3 C. H&E 
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FIGURE 80. Mmp-9 and 13 IHC in a Second NIC Pten -/+ Breast Tumour 
NIC Pten WGH 129 LL 
A. Mmp-9 B. Mmp-13 C. H&E 
6.5.2.1 Mmp-2 Immunohistochemistry 
Mmp-2 staining is predominantly in fibrous tissues intercalated with 
tumour cells in these four examples (Figure 73, Figure 75, Figure 77, 
Figure 79).  Some staining is seen within the tumours, but this is mostly 
non-specific staining of necrotic debris.  The tumour cells themselves do 
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not appear positive for Mmp-2.  This pattern is seen in both the PyMT 
and NIC Pten -/+ tumours. 
6.5.2.2 Mmp-3 Immunohistochemistry 
The Mmp-3 staining is present in the areas of tumour cells (Figure 73, 
Figure 75, Figure 77, Figure 79).  It is greatest where these are adjacent 
to areas of stroma and near where disordered ducts or vessels can be 
identified.  Mmp-3 staining is also seen in the surrounding fibrous tissue 
or stroma.  This pattern is seen in both the PyMT and NIC Pten -/+ 
tumours. 
6.5.2.3 Mmp-9 Immunohistochemistry 
The Mmp-9 antibody shows widespread staining (Figure 74, Figure 76, 
Figure 78, Figure 80).  Recalling that Mmp-9 mRNA was not detected in 
the tumour tissue this discrepancy arouses suspicion of artefactual 
staining.  This suspicion is reinforced by the relative lack of Mmp-9 
activity demonstrated by gelatin zymography in section 6.5.3.  The 
staining is not consistently localised to any particular area on histology 
in either tumour type. 
6.5.2.4 Mmp-13 Immunohistochemistry 
Mmp-13 staining shows a similar pattern to that for Mmp-3, with 
staining seen in populations of tumour cells that are adjacent to other 
features such as stroma, ducts and vessels (Figure 74, Figure 76, Figure 
78, Figure 80) and the tumour stroma itself. 
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6.5.3 Mmp activity Detected by Zymography 
 
FIGURE 81. Proteinase Activity in Murine Tissue Lysates, by Gelatin Zymography 
The quantity of total protein loaded was 25µg for the lysates, except the kidney 
and spleen, which were 0.2µg and 5µg respectively.  Purified mouse Mmp-2 
control on the right.  A second duplicate gel was developed in the presence of 
ilomastat. 
Zymograms show breakdown of a gel-incorporated protein by enzymes 
in the lysates, separated by non-denaturing electrophoresis.  Following 
electrophoresis and removal of detergents, the gel is incubated, during 
which time the substrate can be degraded and lost from the gel.  After 
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incubation and fixation, the gel is then stained for the presence of 
protein, and areas of substrate breakdown are revealed as lucent bands.  
Gelatin zymography is best described for detecting Mmp-2 and Mmp-9 
activity (220).  Loading hr MMP-13 in the gels used for these 
experiments did not cause a band.  Mmp-2 activity is positively 
identified by running a sample of purified murine Mmp-2 in the right 
hand lane.  Corresponding Mmp-2 activity is seen in all samples and is 
blocked by ilomastat.  The presence of at least two bands is consistent 
with other people’s observations and to some extent explained by the 
understanding that Mmps and MMPs have partially active cleavable 
precursors (122). 
Only low levels are observed liver, concurrent with observations from 
mRNA amplification. It is also interesting to recall that all of the 
ilomastat-sensitive probe activation was lost when liver lysate was used 
instead of whole liver.  
On this gel, the kidney lysate was loaded at less than one-hundredth 
of the others in an effort to resolve the activity clumped at the top.  
Despite this dilution, significant unresolved activity remains there, and 
faint bands corresponding to Mmp-2 can still be seen. 
No positive control for Mmp-9 was available, but Mmp-9 is reported 
to run at about 90kDa, and from the mRNA data we might expect to see 
this in lung and fat pad.  Corresponding bands are seen and are inhibited 
by ilomastat.  Strong signal is also seen in spleen (particularly noting that 
this was run at one-fifth strength in order to resolve the bands), which is 
at odds with the mRNA data.  The PyMT tumour lysate also clearly 
shows a corresponding band and faint bands are suspected in the other 
tumour samples too. 
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Perhaps the most significant observation from these zymographs is 
the specific presence of bands at about 70kDa in the tumour tissue, 
which are unaffected by ilomastat.  In addition, there is poorly resolved, 
ilomastat-unaffected signal seen at the top of the lane containing kidney 
lysate.  Whilst ability to activate the probe may not be directly related to 
gelatin removal from these gels, it can be seen that there is proteinase 
activity in these tissue lysates that has not yet been characterised here.  
The discrepancy between liver tissue and liver-lysate is also salutary in 
this regard. 
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6.6 Conclusions 
The experimental probe reliably and rapidly produced a fluorescence 
signal when used with pieces of tissue in a buffer system at physiological 
pH and salt concentrations.  The time course to generate a signal was 
approximately ten minutes. 
The magnitude of probe signal was, on-average, greater using pieces 
of breast tumour than when using pieces of fat pad.  No difference was 
observed in probe activation between two tumour types that were 
different in respect of their experimental knockout of the Kindlin-1 gene. 
Strong probe activations were also seen when using other tissues, and 
there is evidence that this does not relate to Mmp-9 activity, or the 
activities of Mmp-2 or -13 either. 
Expression and activity of the Mmps is shown by other methods in 
normal murine tissues and tumour samples.  However, because the 
signals observed with both the fluorescent probe and the zymogram, 
appear to be caused in part by uncharacterised components in the tissues, 
this limits any interpretation linking Mmp expression to probe activation. 
6.6.1 Off-Target Activation 
By design, probe activation by Mmp-2, 9 and 13 is expected.  This was 
demonstrated using recombinant fragments of equivalent human 
enzymes.  These positive controls were substantially inhibited by 20µM 
ilomastat.  However, when using pieces or lysates of tissue with the 
probe, some activation was still observed in the presence of this broad 
spectrum Mmp blockade.  Additional complexity was revealed when 
using tissue lysates for gelatin zymography: unidentified bands (which 
occur in the presence of Mmp blockade), unresolved contributors to 
gelatin breakdown (at the top of the kidney lane, also ilomastat resistant) 
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and the relative lack of any active Mmp-2 or -9 on zymography of liver 
lysate, despite probe activation by pieces of whole liver. 
Probe activation by a factor in kidney would be a major confounder 
for any paradigm involving systemic administration.  The recently 
published work of van Duijnhoven et al. (79) shows that a probe 
designed using similar MMP specificity principles, and incorporating a 
cell-penetrating peptide to fix probe location after cleavage, was 
activated independently of the presence of tumour. Although the probe 
was seen to accumulate in the tumour, this was due to other non-specific 
factors.  Their panel of test proteinases included thrombin, plasmin and 
urokinase, to which their probe was resistant. They did not identify the 
factor responsible for activation in vivo. 
The problem of predicting off target activations is recognised to be 
difficult.  Two online proteinase queries using the sequence NH2-
PLGLAG from the work of Jiang et al. (78) and taken forward by van 
Duijnhoven did not reveal any likely candidates.  (These profiled only a 
few tens of enzymes.)  In addition, such analysis of off-target effects is 
difficult because it could be due to either or both of specific effects by 
another enzyme present in small amounts, or non-specific, low activity 
effects of an agent present in greater amounts. 
6.6.2 Probe Solubility and Dosing Accuracy 
Probe precipitation  in aqueous solutions and variability in signal from 
positive controls highlight a difficulty with probe application.  Reliable 
solubility in physiological conditions is necessary for accurate dosing. 
In retrospect, to demonstrate that dose accuracy was a factor here, 
completing experiments with an excess dose of one of the recombinant 
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enzymes, to elicit a saturated response, would have been a useful 
measurement. 
6.6.3 Probe pH Sensitivity and Buffer Solutions 
Some initial experiments, not shown here, were performed using a dye-
free culture medium as the solvent - Dulbecco’s Modified Eagle 
Medium.  Following prior equilibration in a 5 percent carbon dioxide 
atmosphere, the rate of probe activation was demonstrated to be 
dependent on the length of time the medium had been in room air.  This 
medium’s main buffer system is based on bicarbonate, and is therefore 
dependent on carbon dioxide concentration.  Carboxyfluorescein 
fluorescence is known to be pH dependent, and it has been used in the 
past as an intracellular pH indicator (221).  Although pH variation could 
be eliminated in these experiments by changing buffer system, variations 
in pH, which are a common feature of diseased tissue, are not so easily 
controlled.  A probe for use in diseased tissue would require both the 
fluorophore and the activating reaction to be pH independent over a 
pathophysiological range of  approximately 6.0 to 8.0 (222). 
6.6.4 Summary 
The experimental probe was successfully activated using pieces of 
fresh murine tissue.  However, there is confounding by uncharacterised 
off-target activation and unpredictable dose due to insolubility. 
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The scope of this chapter is to provide an overview of the field of drug 
targeting for cancer imaging.  It is limited to strategies employing 
exogenous agents, aligned with the work reported in this thesis.  It does 
not address techniques that might use intrinsic properties of abnormal 
tissue to identify abnormality, such as abnormal radiodensity or 
magnetic resonance signals.  A variety of techniques, including but not 
limited to those studied here, are discussed in the light of those findings. 
The potential of LRRC15 protein expression as a targetable tumor 
marker is discussed. 
7.1 Limits on Imaging with Exogenous Agents 
Pharmacokinetics is usually a complex topic for any drug.  In the context 
of a therapeutic agent, this is sometimes amenable to simplification when 
off-target binding does not have any significant side effect.  On the 
contrary, off-target binding can sometimes favourably affect a drug’s 
pharmacokinetic profile by stabilising variations inherent in intermittent 
dosing.  An extreme example is the persistently useful coumarin 
anticoagulant warfarin (of no relevance to imaging, but a well studied 
example from clinical practice).  After therapeutic oral administration of 
warfarin to a human, 97% of the drug in serum is inactively bound to 
albumin (223).  Only the unbound 3% is available for active 
pharmacology or excretion.  The large ‘reserve’ of albumin-bound drug 
can thus ‘buffer’ the concentration of the active, unbound fraction.  
Whilst this might have some advantages stabilising drug concentration 
for therapy, an attempt to use such a drug for anatomical location of its 
target would be overwhelmed by the off-target binding.  This 
exemplifies a persistent theme in attempts to develop new drugs, and 
particularly imaging agents. 
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Further explanation was given by Gold et al. in their 2012 paper 
(224), in which they coin the term ‘albumin problem’.  With a contrived 
example, they explain the difficulty of using a single binding interaction 
to localise or measure a protein within an organism.  They postulate a 
reagent having an exceptional 1pM dissociation constant for a target 
present at low levels, and 1mM dissociation constant for albumin.  
Despite the favourable binding interaction with the target, the reality of 
albumin in serum at 1 mM and target at 1 pM would mean that as much 
of the tracer would be bound to albumin as to the target, causing 
substantial background noise in any binding experiment. 
Off-target binding will always be detrimental to any agent used for 
diagnostic purposes, either localisation or quantification.  In a complex 
system, non-specific interactions with the background will still be 
detected, and produce a “noise”, which may overwhelm the signal from a 
very promising binding interaction, because the background is present in 
great excess. 
In molecular biology techniques such as Western blotting or 
immunofluorescence, the use of blocking and washing allow many 
proteins to be identified and localised using a single antibody interaction.  
‘Blocking’ includes the co-incubation of a removable excess of complex 
protein counter-target (such as a solution of bovine serum albumin, or 
milk) with the antibody and target.  The block provides competition for 
low-affinity interactions, but no competition for the target interaction.  
Washing refers to the performance of ‘unbinding’ steps, whereby the 
antibody is given time to go back into solution, and thus only avid 
binding will persist, favouring high affinity interactions over ‘non-
specific’ binding.  The understanding that demonstration of results with 
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these methods in simplified model systems requires painstaking 
optimisation of block and wash conditions is sobering. 
Reliable assessment of many serum biomarkers, for instance alpha-
feto protein, (a serum marker of hepatocellular carcinoma among other 
things) requires a pair of binding interactions, commonly by sandwich 
ELISA.  Initial antigen immobilisation simplifies the target for the 
second binder, and the requirement for two unrelated binding 
interactions  (unrelated, but connected because they are different 
epitopes on the target macromolecule) facilitates much greater 
specificity.  Many of the practicalities crucial to these methods, 
including the use of extracted samples, blocking and wash steps, are not 
available to an in vivo study.  In addition, the complexity of a whole 
organism will inevitably exceed that of its serum. 
Given the expense and frequent frustrations of developing novel 
drugs, computer prediction of off-target binding that might cause side 
effects is becoming an area of development (225).  The challenges facing 
a novel imaging agent are arguably greater than those facing a novel 
therapeutic agent, because inactive off-target binding is a fundamental 
problem.  Imaging drugs do however have a major advantage in that 
intravenous access is a trivial concern, (generally a single bolus dose to a 
patient in a healthcare facility) so the non-trivial complications of oral 
formulation, bioavailability, portability and stability can be ignored. 
However, targeting diseased tissues in a whole organism is dependent 
on additional pharmacokinetic processes.  The movement of 
macromolecular drugs between tissue compartments is complex even 
when they have good blood supply.  Diseased tissue (including abscesses 
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and cancer) may include areas of hypoxia, abnormal acidity and necrosis 
meaning that the behaviour of drugs can be unpredictable. 
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7.2 Affinity Targeting Tissues in vivo 
7.2.1 Antibodies 
Use of antibodies to image cancer and inform treatment has been 
reported for over 30 years (226), including recent reports employing 
humanised monoclonal antibodies, modern radionuclide methods and 
sophisticated scanner technology (52) (227). 
Antibodies are large proteins, not filtered by the kidneys.  
Immunoglobin G molecules are approximately 150kDa.  A long serum 
lifetime is consistent with their role in maintaining serum immunity and 
sensing disease.  Unmodified exogenous antibodies are know to have 
serum life-times in the order of days and this is highly dependent on the 
presence of target antigen (228).  The long serum-lifetime of antibodies 
limits their value as imaging agents, because there would be the 
persisting signal from the unbound fraction.  The most promising report, 
describes zirconium-89 labelling of trastuzumab, imaged with PET/CT, 
four days after administration (52).  The 78-hour half-life of the isotope 
means that 43 percent of the tracer will still be active after this interval.  
However, the longer half-life isotope also means a lower activity for a 
given quantity of tracer, decreasing available signal.  When a subject or 
patient can lie still, it may be possible to mitigate some of this by 
increasing the scan acquisition time.  Dijkers et al. do not directly report 
on scan acquisition times, but an approximate time of 80 minutes can be 
calculated, which is somewhat longer than current practice in FDG 
PET/CT cancer staging investigations which normally require about 20 
minutes in acquisition. 
An additional interesting finding in their report is the dose and dose-
history dependence of tracer excretion into the bowel.  They observe a 
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saturatable rapid phase of bowel excretion in trastuzumab naïve patients.  
This may be due to a circulating pool of HER2 antigen. 
7.2.2 Other Antibody Strategies 
The dependence of radioisotope techniques on emission from the tracer 
means that available signal decreases with time.  Emissions occurring 
after injection, but before imaging, are also undesirable in terms of 
radiation dose not harnessed for imaging (to the patient, and potentially 
also to environment and population if the patient is ambulant).  
Therefore there is much interest in working around this, in at least three 
broad approaches:  i) use of antibody fragments or small antibody 
analogues with rapid clearance, ii) secondary labelling of antibodies and 
iii) labelling methods for detection using an external energy source (e.g. 
magnetic resonance imaging). 
7.2.2.1 Antibody Fragments and Affibodies 
A number of successful reports of imaging experiments have been 
published.  The leading work again tends to target the HER2 
transmembrane protein.  In contrast to trastuzumab, a monoclonal 
antibody IgG produced my eukaryotic cells,  smaller proteins based on 
the antigen binding portions are used, produced using bacteria(54, 229) 
or chemical synthesis (53). 
The report by Baum et al. from 2010(53) describes successful 
imaging of HER2 positive metastases in a patient, including the 
identification of biopsy-proven lesions that were not appreciated on 18F-
FDG studies. 
The later reports of Wallberg et al. (229) and Trousil et al. (54) detail 
recombinant antibody proteins. The recombinant proteins include 
sequence tags that allow rapid labelling before administration.  The 
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favourable radiochemistry and in vivo kinetics allow imaging tumour 
xenografts with short half-life isotopes like carbon-11 (half-life 20 
minutes) and fluorine-18 (half-life 110 minutes). 
Tumour targeting by antigen-binding fragments of antibodies to other 
antigens is also reported (230).  In this case, tracer accumulation in 
Insulin-like Growth Factor-1 Receptor expressing xenografts is shown 
using a labelled pepsin digestion product, from a monoclonal antibody to 
the receptor. 
7.2.2.2 Secondary labelling 
Secondary labelling strategies have also been employed in antibody 
imaging techniques.  An example is the use of a radiolabelled 
streptavidin to rapidly demonstrate a biotinylated antibody (231).  In 
theory, such a strategy could favourably separate the antibody kinetics 
from those of the radiotracer.  In practice, endogenous biotin binding, 
biotinidases, and other complications may not be surmountable.  Other 
approaches utilising a ‘bi-specific antibody’ (a fusion protein 
incorporating two different antigen binding domains) have been reported 
more recently(232). 
7.2.2.3 Alternative labelling strategies 
Labelling with iron oxide particles to allow magnetic resonance 
imaging(233) means that longer kinetics is not inherently detrimental to 
detecting the label. 
Some dilution of optimism occurs in considering that the complex 
organisms in which we aspire to selectively locate abnormal tissue, 
already have sophisticated immune systems to identify and destroy 
abnormal tissue, using affinity based-identification of cell-surface and 
local-humoural factors (234).  Because clinically relevant cancer is that 
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which has developed in spite of the ability of the organism’s immune 
system, it has already proved some ability to escape from this form of 
recognition. 
7.2.3 Peptides 
Peptide tracers have held a small role in the imaging localisation (and 
radiotherapy) of some selected tumours, for instance labelled 
somatostatin (or analogues) for the imaging of carcinoid (48, 49).  A 
number of other peptides based on regulatory hormones are also being 
explored as a basis for imaging agents (235). 
Peptides have short and predictable plasma kinetics, demonstrated by 
a number and variety of peptide hormones employed in rapid endocrine 
control, some requiring quick off-responses by return to baseline levels.  
With multiple examples of very specific binding interactions, small 
peptides are thus an excellent class of drug for imaging agents.  
However, there are not many examples of novel peptide imaging agents 
in testing. 
18-fluorine labelled RGD peptide analogues are currently in clinical 
testing (64, 65) for the PET localisation of Alpha-V, Beta-3 integrin 
expression.  This was discussed previously in 1.3.1.3 and the peptide / 
target interaction has been characterised for 30 years (63). 
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FIGURE 82. Fluciclatide structural diagrams 
A:  The chemical structure of fluciclatide after labelling and removal of 
protective groups (236).  B:  A further two-dimensional structural diagram 
showing the cyclisation and hairpin presentation of the RGD peptide motif 
(237). 
The structure of fluciclatide, illustrated in Figure 82, includes many 
sophisticated elements such as side chains for pharmacokinetic 
optimisation and the coupling of a moiety containing the 18F radiolabel 
to the unlabelled precursor.  The radiochemistry also includes 
subsequent removal of protective groups (absent from the final 
structure).  In order to maintain relevance, drug production and quality 
control must all take place within the same-day time frame imposed by a 
110-minute radioisotope half-life. 
The fact that fluciclatide is in current multicentre clinical testing 
represents a novel height in terms of radiopharmacy, achieved in a 
climate of increasing regulation.  Whether imaging of Alpha-V, Beta-3 
integrin expression will generate clinically relevant information remains 
to be seen.  However, the system also includes many elements that might 
transfer to other peptide / target interactions. 
There are a number of exciting reports of preclinical affinity-targeted 
peptide discovery, one of the most promising being a 12-residue peptide 
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targeting peripheral nerves (myelin basic protein) reported by Tsien’s 
group (88). 
7.2.4 Aptamers 
Although pegaptinib was licensed for treatment of neovascular macular 
degeneration (97) by local injection, and a successful aptamer for 
thrombin was developed two decades ago (95), neither is currently in 
mainstream use. 
The facility for in-vitro amplification by PCR, and the possibility of 
immense library variability are attractive, but aptamers also have a few 
notable drawbacks in considering them as targeting drugs.  They are 
comparatively large molecules, with each monomer including a sugar 
ring and phosphate backbone  (a 40 nucleobase DNA polymer will have 
molecular weight around 13kDa).  The four-character ‘alphabet’ limits 
library diversity in short polymers, in contrast to the twenty-character 
alphabet of peptides.  Diversity can easily be expanded by extending the 
polymer, but this may be adding other properties.  Irrespective of 
specific attributes, nucleic acid polymers are strongly cationic due to the 
phosphodiester bonds in the central structure.  They also have many 
other non-ionising polar covalent bonds.  This makes them hydrophilic, 
and imbues them with non-specific electrostatic attraction to alkaline 
proteins, which are common, e.g. albumin.  In papers that report the 
affinity of unselected libraries and selected aptamers to target, there is 
sometimes a remarkably high affinity of the unselected libraries to the 
target (111).  As the unselected library contains millions of random 
sequences, specific aptamer interactions will not be present here to any 
significant degree, therefore the quoted 0.1µM Kd is presumably due to 
non-specific binding of nucleic acid polymers to the target, which might 
reasonably be expected to occur to non-target proteins too. 
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Serum nucleases also represent a significant hurdle to any aptamer 
drug expected to work in or via the bloodstream.  The most promising 
report of in vivo imaging with a labelled aptamer was in 2006 (99), but 
personal communication with one of the authors suggests that this was 
not replicable.  Many of the people who have published about progress 
with aptamers are currently with SOMAlogic.  SOMAlogic’s focus is 
now on extracorporeal testing, rather than in vivo imaging.  An effort to 
collaborate with SOMAlogic and test one of their HER2 targeting 
aptamers(168) was thwarted by incompatibility between the terms of my 
employment and their requirement for data ownership. 
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7.3 Target Activation 
Target activation of imaging-probes brings a different set of 
opportunities and pitfalls.  The use of biochemical modification to alter a 
compound’s interaction with electromagnetic radiation means that this is 
primarily an optical imaging technique.  Nuclear changes involved in 
radiolabeling and nuclear magnetic resonance, or the inner electron-shell 
disruptions of x-ray absorption are outwith the reach of chemistry, 
particularly in a biological setting.  However, secondary strategies to 
immobilise a probe at the site of activation, may enable accumulation of 
a radioactive probe, discussed below.  
For a recent lucid review on the characterisation and localisation of 
enzyme activity, including in vivo imaging applications see Vandooren 
et al. 2013 (238). 
7.3.1 Signal Amplification 
Perhaps the most exciting advantage of enzyme activated imaging agents 
is the potential for a single target molecule to activate many probe 
molecules, facilitating time dependent signal amplification. 
7.3.2 Unconstrained Active Probe 
However, the same process that provides the benefit above, limits use in 
studies of localisation.  Reacted substrate is released from the enzyme to 
diffuse away.  One approach to abrogate this process, pursued for a 
number of years by Tsien’s group (78, 239), has been to include in the 
probe a ‘cell-penetrating’ peptide sequence based on multiple basic 
residues (i.e. poly-arginine).  The ‘cell-penetrating’ peptide is part of the 
active fragment but its properties are masked in the precursor molecule.  
Lysis of the molecule by the specific target enzyme activates both the 
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imaging signal and the property of cell penetration.  Theoretically, 
intracellular accumulation would occur local to probe activation. 
However, this multistage process might be prone to complication at a 
number of points and work by another group has shown that although a 
probe like this can be shown to accumulate at sites of a xenograft 
tumour, this appears to be due to non-specific probe activation and 
pathological vascular permeability at the site of model tumour (79).  By 
implication, the agent will not exceed the abilities of a passive x-ray or 
MRI contrast agent, which is able to diffuse into the tumour stroma. 
7.3.3 Inactive Precursor Gives no Background Signal 
Vying for the most exciting advantage of a probe-activation strategy is 
non-interference by inactive probe.  This is in contrast to confounding by 
unbound active probe in an affinity-based strategy.  Many in vivo target 
detection strategies suffer from overwhelming noise, rather than a lack of 
detectable signal, and in some cases this is due to background signal 
from the imaging agent.  Signal from an imaging agent that is inactive on 
administration, but locally activated, might be detected without removal 
of the precursor. 
This does not however apply in the context of radiolabelled 
strategies.  For instance in a radiolabelled ‘cell-penetrating’ peptide 
system, inactive probe would have similar activity to the active one.  An 
offset phase would need to be observed prior to measuring any 
remaining activity, before deducing that it was related to probe cleavage. 
Inability of biochemistry to influence a compound’s interaction with 
penetrating electromagnetic radiation means that this advantage is 
restricted to optical techniques.  (In a philosophical digression, it is 
interesting to note that our vision is restricted to a narrow but chemically 
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relevant band of the electromagnetic spectrum, and to wonder whether 
this relates more to the relevance of biochemistry in our environment, or 
to the dependence of our optical apparatus on biochemistry). 
Optical clinical imaging techniques, because of their reliance on 
highly interactive (and thus non-penetrating) photons, have limited scope 
for whole body imaging.  If the site of interest has been predetermined, 
and can be reached, they offer many possibilities (240).  Quenched 
fluorescence activation by enzymatic cleavage is an elegant proposition, 
and with improving possibilities for fluorescent imaging during 
endoscopy and in surgical fields, optical techniques will remain relevant.  
There are many scenarios where local assessment of pathology by such 
methods is important.  However, when the question is:  “Is there disease 
elsewhere?”, then they will be more difficult to apply. 
7.3.4 Non-Specific Probe Activation 
Non-specific probe activation by other enzymes complicates 
interpretation of the experiments in Chapter 6 and is a problem 
recognised by other groups.  Subsequent work in the Bradley group has 
shown that the SVC-01-016 probe is also significantly cleaved by 
plasmin(personal communication), which might explain some of the 
non-specific probe activation and zymogram signal observed in the work 
in Chapter 6.  Van Duijnhoven et al. deduce that their smart probe is 
undergoing cleavage by an unidentified factor.  Their probe was not 
sensitive to plasmin on in vitro testing (79).  Strategies to minimise non-
specific activation are particularly difficult when the relevant enzymes 
are not identified. 
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7.3.5 Potential Enzyme Targets 
The work reported in Chapter 6, and that of others (79), has shown that 
there are a number of potential problems with this approach.  Problems 
of off target activation and the deranged chemistry in diseased tissue 
represent imposing barriers to the interpretation of whole-body imaging 
experiments.  Localised assays, i.e. targeted endoscopic assessments, are 
much more likely to provide a system where signal from smart-probes 
like these can be interpreted.  Some promising targets are discussed 
below: 
Matrix metalloproteinases, and specifically MMP-9 have been 
discussed as targets in 6.1.1.  A number of other groups are pursuing 
matrix metalloproteinase activated imaging agents, notably the Tsien 
group (239).  Perkin Elmer also sell a non-specific MMP-activated 
645nm fluorescent probe.  The latter was briefly tried alongside some of 
the experiments in chapter 6, but was unsuccessful.  No significant signal 
was observed using the recombinant MMP positive controls over the 1-
hour time courses.  The compound is sold for in vivo applications, with a 
recommendation to image at 6 to 72 hours. 
Lysyl Oxidase and its homologues (Lysyl Oxidase Like 1 to 4) are 
extracellular copper-dependent amine oxidases.  Their canonical role is 
in the oxidation of lysine residues in collagen and elastin for covalent 
cross-linking of the extracellular matrix.  Their inhibition and 
suppression are proving to be of considerable interest in cancer 
treatment(241, 242) in preclinical testing, and this enzyme may be a 
potential probe activator or immobiliser.  A fluorometric solution phase 
assay has been described, blockable by drugs and an antibody (243) 
(242).  Being able to quantify abnormal activity of these enzymes could 
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help in the assessment and understanding of inflammatory disease states, 
including cancer. 
 Neutrophil elastase is a serine protease with broad substrate activity.  
It is a key effector of innate immunity but also well known for its ability 
to digest extracellular matrix.  It has long been implicated in chronic 
lung injury such as emphysema and pulmonary fibrosis (244).  
Neutrophils, and their proteases are also implicated in the relationship 
between cancer and the host immune system (245) and therefore also of 
interest for cancer imaging.  Both Perkin-Elmer and the Bradley group 
have developed fluorescent probes activatable by neutrophil elastase.  
These may also prove to be important approaches in the assessment of 
cancer. 
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7.4 LRRC15 
I am unaware of any studies describing LRRC15 published since 
2011 and none of the groups previously working with LRRC15 has 
described a successful antibody.   
Paraphrasing section 3.1, LRRC15 was primarily recovered in the 
Oncomine search as an upregulated mRNA in breast cancer.  This 
correlates with an independent specific assessment of LRRC15 
expression by Satoh et al.(152).  Gene transcription has also been shown 
by Reynolds et al.(139) to be the specific target of an oncogenic fusion 
protein 
The work in Chapter 3 characterises a good antibody to this protein 
(both human and a murine homologue).  Whilst it offers no immediate 
prospect as a target for clinical imaging in cancer, the new antibody 




1. CancerResearchUK. Cancer Statistics Report: Cancer Mortality in 
the UK in 2010. 2013 
2. Grumbach MM, Biller BMK, Braunstein GD et al. Management 
of the clinically inapparent adrenal mass (“incidentaloma”). 
Annals of Internal Medicine. 2003;138:424-429. 
3. Booth TC, Jackson A, Wardlaw JM, Taylor SA, Waldman AD. 
Incidental findings found in "healthy" volunteers during imaging 
performed for research: current legal and ethical implications. Br J 
Radiol. 2010;83:456-465. 
4. Pinato DJ, Stavraka C, Tanner M et al. Clinical, ethical and 
financial implications of incidental imaging findings: experience 
from a phase I trial in healthy elderly volunteers. PLoS One. 
2012;7:e49814. 
5. Screening IUKPoBC. The benefits and harms of breast cancer 
screening: an independent review. Lancet. 2012;380:1778-1786. 
6. Gøtzsche PC, Jørgensen KJ. The benefits and harms of breast 
cancer screening. The Lancet. 2013;381:799. 
7. Colquhoun C, National Services Scotland. Breast Screening. 
www.nsd.scot.nhs.uk/  20/9/2013 
8. Bupa. Colon Health Check. www.bupa.co.uk/  20/9/2013 
9. Hicks RJ. Should positron emission tomography/computed 
tomography be the first rather than the last test performed in the 
assessment of cancer? Cancer Imaging. 2012;12:315-323. 
 
References 235 
10. Yi CA, Shin KM, Lee KS et al. Non-small cell lung cancer 
staging: efficacy comparison of integrated PET/CT versus 3.0-T 
whole-body MR imaging. Radiology. 2008;248:632-642. 
11. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. 
Primary colon cancer: ESMO Clinical Practice Guidelines for 
diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010;21 
Suppl 5:v70-7. 
12. Heusner TA, Kuemmel S, Koeninger A et al. Diagnostic value of 
diffusion-weighted magnetic resonance imaging (DWI) compared 
to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl 
Med Mol Imaging. 2010;37:1077-1086. 
13. Venkitaraman R, Cook GJ, Dearnaley DP et al. Does magnetic 
resonance imaging of the spine have a role in the staging of 
prostate cancer? Clin Oncol (R Coll Radiol). 2009;21:39-42. 
14. Crino L, Weder W, van Meerbeeck J, Felip E. Early stage and 
locally advanced (non-metastatic) non-small-cell lung cancer: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann Oncol. 2010;21 Suppl 5:v103-15. 
15. Padhani AR, Koh D-M, Collins DJ. Whole-body diffusion-
weighted MR imaging in cancer: current status and research 
directions. Radiology. 2011;261:700-718. 
16. Goh V, Halligan S, Bartram CI. Local radiological staging of 
rectal cancer. Clin Radiol. 2004;59:215-226. 
17. DiPerna CA, Wood DE. Surgical management of T3 and T4 lung 
cancer. Clinical cancer research. 2005;11:5038s-5044s. 
 
References 236 
18. Cancer Research UK. Pancreatic cancer survival statistics. 
http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/pancreas/survival/  11/06/2012 
19. Eisenhauer EA, Therasse P, Bogaerts J et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline 
(version 1.1). Eur J Cancer. 2009;45:228-247. 
20. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, 
Sandrasegaran K. Response criteria in oncologic imaging: review 
of traditional and new criteria. Radiographics. 2013;33:1323-
1341. 
21. Aboagye EO. The future of imaging: developing the tools for 
monitoring response to therapy in oncology: the 2009 Sir James 
MacKenzie Davidson Memorial lecture. Br J Radiol. 
2010;83:814-822. 
22. Nishino M, Hatabu H, Johnson BE, McLoud TC. State of the art: 
response assessment in lung cancer in the era of genomic 
medicine. Radiology. 2014;271:6-27. 
23. Radon J. On the determination of functions from their integral 
values along certain manifolds. Medical Imaging, IEEE 
Transactions on. 1917;5:170-176. 
24. Hounsfield GN. Computerized transverse axial scanning 
(tomography): Part 1. Description of system. British Journal of 
Radiology. 1973;46:1016-1022. 
25. Lind JS, Meijerink MR, Dingemans AM et al. Dynamic contrast-
enhanced CT in patients treated with sorafenib and erlotinib for 
 
References 237 
non-small cell lung cancer: a new method of monitoring 
treatment? Eur Radiol. 2010;20:2890-2898. 
26. Chanda N, Kattumuri V, Shukla R et al. Bombesin functionalized 
gold nanoparticles show in vitro and in vivo cancer receptor 
specificity. Proc Natl Acad Sci U S A. 2010;107:8760-8765. 
27. Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G. Folic acid-
modified dendrimer-entrapped gold nanoparticles as nanoprobes 
for targeted CT imaging of human lung adencarcinoma. 
Biomaterials. 2013;34:470-480. 
28. Mitragotri S. Healing sound: the use of ultrasound in drug delivery 
and other therapeutic applications. Nature Reviews Drug 
Discovery. 2005;4:255-260. 
29. Illing RO, Kennedy JE, Wu F et al. The safety and feasibility of 
extracorporeal high-intensity focused ultrasound (HIFU) for the 
treatment of liver and kidney tumours in a Western population. Br 
J Cancer. 2005;93:890-895. 
30. Hohmann J, Skrok J, Basilico R et al. Characterisation of focal 
liver lesions with unenhanced and contrast enhanced low MI real 
time ultrasound: on-site unblinded versus off-site blinded reading. 
Eur J Radiol. 2012;81:e317-24. 
31. Leen E, Averkiou M, Arditi M et al. Dynamic contrast enhanced 
ultrasound assessment of the vascular effects of novel therapeutics 
in early stage trials. Eur Radiol. 2012;22:1442-1450. 
 
References 238 
32. Ellegala DB, Leong-Poi H, Carpenter JE et al. Imaging tumor 
angiogenesis with contrast ultrasound and microbubbles targeted 
to alpha(v)beta3. Circulation. 2003;108:336-341. 
33. Johnson S, Brown S, Porter G et al. Staging primary breast cancer. 
Are there tumour pathological features that correlate with a false-
negative axillary ultrasound? Clin Radiol. 2011;66:497-499. 
34. Rampado S, Bocus P, Battaglia G, Ruol A, Portale G, Ancona E. 
Endoscopic ultrasound: accuracy in staging superficial carcinomas 
of the esophagus. Ann Thorac Surg. 2008;85:251-256. 
35. Mvere MZ, James JJ, Cornford EJ et al. Frequency and patterns of 
metastatic disease in locally advanced inflammatory and non-
inflammatory breast cancer. Clin Oncol (R Coll Radiol). 
2011;23:608-612. 
36. Huppertz A, Haraida S, Kraus A et al. Enhancement of focal liver 
lesions at gadoxetic acid-enhanced MR imaging: correlation with 
histopathologic findings and spiral CT--initial observations. 
Radiology. 2005;234:468-478. 
37. Heijmen L, Verstappen MC, Ter Voert EE et al. Tumour response 
prediction by diffusion-weighted MR imaging: ready for clinical 
use? Crit Rev Oncol Hematol. 2012;83:194-207. 
38. Costelloe CM, Rohren EM, Madewell JE et al. Imaging bone 
metastases in breast cancer: techniques and recommendations for 
diagnosis. The lancet oncology. 2009;10:606-614. 
39. Meirelles GS, Schoder H, Ravizzini GC et al. Prognostic value of 
baseline [18F] fluorodeoxyglucose positron emission tomography 
 
References 239 
and 99mTc-MDP bone scan in progressing metastatic prostate 
cancer. Clin Cancer Res. 2010;16:6093-6099. 
40. Turkington TG. Introduction to PET instrumentation. J Nucl Med 
Technol. 2001;29:4-11. 
41. Pichler BJ, Kolb A, Nagele T, Schlemmer HP. PET/MRI: paving 
the way for the next generation of clinical multimodality imaging 
applications. J Nucl Med. 2010;51:333-336. 
42. Heinonen I, Saltin B, Kemppainen J et al. Skeletal muscle blood 
flow and oxygen uptake at rest and during exercise in humans: a 
pet study with nitric oxide and cyclooxygenase inhibition. Am J 
Physiol Heart Circ Physiol. 2011;300:H1510-7. 
43. Dijkers EC, Kosterink JG, Rademaker AP et al. Development and 
characterization of clinical-grade 89Zr-trastuzumab for HER2/neu 
immunoPET imaging. J Nucl Med. 2009;50:974-981. 
44. Ido T, Wan C, Casella V et al. Labeled 2‐deoxy‐D‐glucose 
analogs. 18F‐labeled 2‐deoxy‐2‐fluoro‐D‐glucose, 2‐deoxy‐2‐
fluoro‐D‐mannose and 14C‐2‐deoxy‐2‐fluoro‐D‐glucose. Journal 
of Labelled Compounds and Radiopharmaceuticals. 1978;14:175-
183. 
45. Warburg O. On the origin of cancer cells. Science. 1956;123:309-
314. 
46. Fischer BM, Mortensen J, Hansen H et al. Multimodality approach 
to mediastinal staging in non-small cell lung cancer. Faults and 
benefits of PET-CT: a randomised trial. Thorax. 2011;66:294-300. 
 
References 240 
47. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour 
heterogeneity in the clinic. Nature. 2013;501:355-364. 
48. Krenning EP, Breeman WAP, Kooij PPM et al. Localisation of 
endocrine-related tumours with radioiodinated analogue of 
somatostatin. The Lancet. 1989;333:242-244. 
49. Gabriel M, Decristoforo C, Kendler D et al. 68Ga-DOTA-Tyr3-
octreotide PET in neuroendocrine tumors: comparison with 
somatostatin receptor scintigraphy and CT. Journal of Nuclear 
Medicine. 2007;48:508. 
50. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile 
platforms for cancer immunotherapy. Nat Rev Immunol. 
2010;10:317-327. 
51. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of 
trastuzumab as a single agent in first-line treatment of HER2-
overexpressing metastatic breast cancer. Journal of Clinical 
Oncology. 2002;20:719-726. 
52. Dijkers EC, Oude Munnink TH, Kosterink JG et al. 
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-
positive lesions in patients with metastatic breast cancer. Clin 
Pharmacol Ther. 2010;87:586-592. 
53. Baum RP, Prasad V, Muller D et al. Molecular imaging of HER2-
expressing malignant tumors in breast cancer patients using 




54. Trousil S, Hoppmann S, Nguyen QD et al. Positron Emission 
Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody 
for Detection of HER2 Expression and Pharmacodynamic 
Response to HER2-Modulating Therapies. Clin Cancer Res. 
2014;20:1632-1643. 
55. Comar D, Zarifian E, Verhas M et al. Brain distribution and 
kinetics of 11 C-chlorpromazine in schizophrenics: Positron 
emission tomography studies. Psychiatry Research. 1979;1:23-29. 
56. Fowler JS, Volkow ND, Wang GJ, Ding YS, Dewey SL. PET and 
drug research and development. J Nucl Med. 1999;40:1154-1163. 
57. Cunningham D, Humblet Y, Siena S et al. Cetuximab 
monotherapy and cetuximab plus irinotecan in irinotecan-
refractory metastatic colorectal cancer. New England Journal of 
Medicine. 2004;351:337-345. 
58. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional 
randomized phase II trial of gefitinib for previously treated 
patients with advanced non-small-cell lung cancer (The IDEAL 1 
Trial) [corrected]. J Clin Oncol. 2003;21:2237-2246. 
59. Liu N, Li M, Li X et al. PET-based biodistribution and radiation 
dosimetry of epidermal growth factor receptor-selective tracer 
11C-PD153035 in humans. J Nucl Med. 2009;50:303-308. 
60. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. 
Nat Rev Cancer. 2009;9:285-293. 
 
References 242 
61. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular 
integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-
571. 
62. Cheresh DA. Human endothelial cells synthesize and express an 
Arg-Gly-Asp-directed adhesion receptor involved in attachment to 
fibrinogen and von Willebrand factor. Proceedings of the National 
Academy of Sciences. 1987;84:6471-6475. 
63. Pierschbacher MD, Ruoslahti E. Cell attachment activity of 
fibronectin can be duplicated by small synthetic fragments of the 
molecule. Nature. 1984;309:30-33. 
64. Mittra ES, Goris ML, Iagaru AH et al. Pilot Pharmacokinetic and 
Dosimetric Studies of 18F-FPPRGD2: A PET 
Radiopharmaceutical Agent for Imaging αvβ3 Integrin Levels. 
Radiology. 2011;260:182-191. 
65. Tomasi G, Kenny L, Mauri F, Turkheimer F, Aboagye EO. 
Quantification of receptor-ligand binding with 
[(1)(8)F]fluciclatide in metastatic breast cancer patients. Eur J 
Nucl Med Mol Imaging. 2011;38:2186-2197. 
66. Witney TH, Carroll L, Alam IS et al. A novel radiotracer to image 
glycogen metabolism in tumors by positron emission tomography. 
Cancer Res. 2014;74:1319-1328. 
67. Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation 
in vivo with [F-18] FLT and positron emission tomography. 
Nature medicine. 1998;4:1334-1336. 
 
References 243 
68. Hoeben BA, Troost EG, Span PN et al. 18F-FLT PET during 
radiotherapy or chemoradiotherapy in head and neck squamous 
cell carcinoma is an early predictor of outcome. J Nucl Med. 
2013;54:532-540. 
69. Mileshkin L, Hicks RJ, Hughes BG et al. Changes in FDG- and 
FLT-PET Imaging in Patients with Non-Small Cell Lung Cancer 
Treated with Erlotinib. Clin Cancer Res. 2011 
70. Contractor K, Challapalli A, Tomasi G et al. Imaging of cellular 
proliferation in liver metastasis by [18F]fluorothymidine positron 
emission tomography: effect of therapy. Phys Med Biol. 
2012;57:3419-3433. 
71. Gallagher FA, Kettunen MI, Day SE et al. Magnetic resonance 
imaging of pH in vivo using hyperpolarized 13C-labelled 
bicarbonate. Nature. 2008;453:940-943. 
72. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using 
carbon-11-choline. Journal of nuclear medicine: official 
publication, Society of Nuclear Medicine. 1998;39:990-995. 
73. Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate 
cancer with PET/CT and radioactively labeled choline derivates. 
Urol Oncol. 2013;31:427-435. 
74. Challapalli A, Sharma R, Hallett WA et al. Biodistribution and 
radiation dosimetry of deuterium-substituted 18F-fluoromethyl-[1, 




75. Stryer L. Fluorescence energy transfer as a spectroscopic ruler. 
Annual review of biochemistry. 1978;47:819-846. 
76. Mook ORF, Overbeek CV, Ackema EG, Maldegem FV, Frederiks 
WM. In Situ Localization of Gelatinolytic Activity in the 
Extracellular Matrix of Metastases of Colon Cancer in Rat Liver 
Using Quenched Fluorogenic DQ-gelatin. Journal of 
Histochemistry & Cytochemistry. 2003;51:821-829. 
77. Palamakumbura AH, Trackman PC. A fluorometric assay for 
detection of lysyl oxidase enzyme activity in biological samples. 
Anal Biochem. 2002;300:245-251. 
78. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. 
Tumor imaging by means of proteolytic activation of cell-
penetrating peptides. Proceedings of the National Academy of 
Sciences of the United States of America. 2004;101:17867-17872. 
79. van Duijnhoven SM, Robillard MS, Nicolay K, Grull H. Tumor 
targeting of MMP-2/9 activatable cell-penetrating imaging probes 
is caused by tumor-independent activation. J Nucl Med. 
2011;52:279-286. 
80. Chen JW, Querol Sans M, Bogdanov AJ, Weissleder R. Imaging 
of myeloperoxidase in mice by using novel amplifiable 
paramagnetic substrates. Radiology. 2006;240:473-481. 
81. Cerchia L, de Franciscis V. Targeting cancer cells with nucleic 
acid aptamers. Trends Biotechnol. 2010;28:517-525. 
 
References 245 
82. Tuerk C, Gold L. Systematic evolution of ligands by exponential 
enrichment: RNA ligands to bacteriophage T4 DNA polymerase. 
Science. 1990;249:505-510. 
83. Green LS, Jellinek D, Bell C et al. Nuclease-resistant nucleic acid 
ligands to vascular permeability factor/vascular endothelial growth 
factor. Chem Biol. 1995;2:683-695. 
84. Smith GP. Filamentous fusion phage: novel expression vectors 
that display cloned antigens on the virion surface. Science. 
1985;228:1315-1317. 
85. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage 
antibodies: filamentous phage displaying antibody variable 
domains. 1990 
86. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully 
human anti-tumor necrosis factor alpha monoclonal antibody, for 
the treatment of rheumatoid arthritis in patients taking 
concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 
2003;48:35-45. 
87. Miller SJ, Joshi BP, Feng Y, Gaustad A, Fearon ER, Wang TD. In 
vivo fluorescence-based endoscopic detection of colon dysplasia 
in the mouse using a novel peptide probe. PLoS One. 
2011;6:e17384. 
88. Whitney MA, Crisp JL, Nguyen LT et al. Fluorescent peptides 




89. Deutscher SL. Phage display in molecular imaging and diagnosis 
of cancer. Chem Rev. 2010;110:3196-3211. 
90. Biolabs NE. Ph.D.TM Phage Display Libraries Instruction 
Manual. 2009 
91. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech 
TR. Self-splicing RNA: autoexcision and autocyclization of the 
ribosomal RNA intervening sequence of Tetrahymena. cell. 
1982;31:147-157. 
92. Guerrier-Takada C, Gardiner K, Marsh T, Pace N, Altman S. The 
RNA moiety of ribonuclease P is the catalytic subunit of the 
enzyme. Cell. 1983;35:849-857. 
93. Sussman D, Nix JC, Wilson C. The structural basis for molecular 
recognition by the vitamin B 12 RNA aptamer. Nat Struct Biol. 
2000;7:53-57. 
94. Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W. 
Development of DNA aptamers using Cell-SELEX. Nat Protoc. 
2010;5:1169-1185. 
95. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. 
Selection of single-stranded DNA molecules that bind and inhibit 
human thrombin. 1992 
96. Hicke BJ, Marion C, Chang YF et al. Tenascin-C aptamers are 




97. Gragoudas ES, Adamis AP, Cunningham ETJ, Feinsod M, Guyer 
DR. Pegaptanib for neovascular age-related macular degeneration. 
N Engl J Med. 2004;351:2805-2816. 
98. Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human 
proteomics at high scale with the SOMAscan proteomics platform. 
N Biotechnol. 2012;29:543-549. 
99. Hicke BJ, Stephens AW, Gould T et al. Tumor targeting by an 
aptamer. J Nucl Med. 2006;47:668-678. 
100. Pieve CD, Perkins AC, Missailidis S. Anti-MUC1 aptamers: 
radiolabelling with (99m)Tc and biodistribution in MCF-7 
tumour-bearing mice. Nucl Med Biol. 2009;36:703-710. 
101. Bunka DH, Stockley PG. Aptamers come of age - at last. Nat Rev 
Microbiol. 2006;4:588-596. 
102. Gambhir SS. Using radiolabeled DNA as an imaging agent to 
recognize protein targets. J Nucl Med. 2006;47:557-558. 
103. Hong H, Goel S, Zhang Y, Cai W. Molecular imaging with 
nucleic acid aptamers. Curr Med Chem. 2011;18:4195-4205. 
104. Scott JK, Smith GP. Searching for peptide ligands with an epitope 
library. Science. 1990;249:386-390. 
105. Gold L, Ayers D, Bertino J et al. Aptamer-based multiplexed 
proteomic technology for biomarker discovery. PLoS One. 
2010;5:e15004. 
106. Ruckman J, Green LS, Beeson J et al. 2'-Fluoropyrimidine RNA-
based aptamers to the 165-amino acid form of vascular endothelial 
 
References 248 
growth factor (VEGF165). Inhibition of receptor binding and 
VEGF-induced vascular permeability through interactions 
requiring the exon 7-encoded domain. J Biol Chem. 
1998;273:20556-20567. 
107. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related 
macular degeneration. The Lancet. 2012;379:1728-1738. 
108. Cao J, Zhao P, Miao XH, Zhao LJ, Xue LJ, Qi Zt Z. Phage display 
selection on whole cells yields a small peptide specific for HCV 
receptor human CD81. Cell Res. 2003;13:473-479. 
109. Shangguan D, Li Y, Tang Z et al. Aptamers evolved from live 
cells as effective molecular probes for cancer study. Proc Natl 
Acad Sci U S A. 2006;103:11838-11843. 
110. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage 
display peptide libraries. Nature. 1996;380:364-366. 
111. Mi J, Liu Y, Rabbani ZN et al. In vivo selection of tumor-
targeting RNA motifs. Nat Chem Biol. 2010;6:22-24. 
112. Fischer NO, Tok JB, Tarasow TM. Massively parallel 
interrogation of aptamer sequence, structure and function. PLoS 
One. 2008;3:e2720. 
113. Schutze T, Wilhelm B, Greiner N et al. Probing the SELEX 
process with next-generation sequencing. PLoS One. 
2011;6:e29604. 
114. Rothberg JM, Hinz W, Rearick TM et al. An integrated 




115. Almholt K, Juncker-Jensen A, Lærum OD et al. Metastasis is 
strongly reduced by the matrix metalloproteinase inhibitor 
Galardin in the MMTV-PymT transgenic breast cancer model. 
Molecular cancer therapeutics. 2008;7:2758-2767. 
116. Rhodes DR, Yu J, Shanker K et al. ONCOMINE: a cancer 
microarray database and integrated data-mining platform. 
Neoplasia. 2004;6:1-6. 
117. Oncomine. Breast Cancer, Cancer vs. Normal Analysis. 
https://www.oncomine.org/resource/login.html  18/7/2012 
118. Larkin MA, Blackshields G, Brown NP et al. Clustal W and 
Clustal X version 2.0. Bioinformatics. 2007;23:2947-2948. 
119. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, 
Leunissen JA. Primer3Plus, an enhanced web interface to Primer3. 
Nucleic Acids Res. 2007;35:W71-4. 
120. O'Prey J, Wilkinson S, Ryan KM. Tumor antigen LRRC15 
impedes adenoviral infection: implications for virus-based cancer 
therapy. J Virol. 2008;82:5933-5939. 
121. Brunton VG, Fincham VJ, McLean GW et al. The protrusive 
phase and full development of integrin-dependent adhesions in 
colon epithelial cells require FAK- and ERK-mediated actin spike 
formation: Deregulation in cancer cells. Neoplasia. 2001;3:215-
226. 
122. Snoek-van Beurden PA, Von den Hoff JW. Zymographic 
techniques for the analysis of matrix metalloproteinases and their 
inhibitors. Biotechniques. 2005;38:73-83. 
 
References 250 
123. Avlonitis N, Debunne M, Aslam T et al. Highly specific, multi-
branched fluorescent reporters for analysis of human neutrophil 
elastase. Org Biomol Chem. 2013;11:4414-4418. 
124. Lakso M, Sauer B, Mosinger B et al. Targeted oncogene 
activation by site-specific recombination in transgenic mice. 
Proceedings of the National Academy of Sciences. 1992;89:6232-
6236. 
125. Bittner JJ. THE MILK-INFLUENCE OF BREAST TUMORS IN 
MICE. Science. 1942;95:462-463. 
126. Murphy D. Transgenic animals and the study of cancer. Methods 
Mol Biol. 1993;18:23-36. 
127. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors 
by expression of polyomavirus middle T oncogene: a transgenic 
mouse model for metastatic disease. Mol Cell Biol. 1992;12:954-
961. 
128. Hallett MA, Teng B, Hasegawa H, Schwab LP, Seagroves TN, 
Pourmotabbed T. Anti-matrix metalloproteinase-9 DNAzyme 
decreases tumor growth in the MMTV-PyMT mouse model of 
breast cancer. Breast Cancer Res. 2013;15:R12. 
129. Schade B, Rao T, Dourdin N et al. PTEN deficiency in a luminal 
ErbB-2 mouse model results in dramatic acceleration of mammary 




130. Patel H, Zich J, Serrels B et al. Kindlin-1 regulates mitotic spindle 
formation by interacting with integrins and Plk-1. Nat Commun. 
2013;4:2056. 
131. Satoh K, Hata M, Yokota H. A novel member of the leucine-rich 
repeat superfamily induced in rat astrocytes by β-amyloid. 
Biochemical and biophysical research communications. 
2002;290:756-762. 
132. Kobe B, Kajava AV. The leucine-rich repeat as a protein 
recognition motif. Curr Opin Struct Biol. 2001;11:725-732. 
133. Pruitt KD, Harrow J, Harte RA et al. The consensus coding 
sequence (CCDS) project: Identifying a common protein-coding 
gene set for the human and mouse genomes. Genome Res. 
2009;19:1316-1323. 
134. Consortium U. Update on activities at the Universal Protein 
Resource (UniProt) in 2013. Nucleic Acids Res. 2013;41:D43-7. 
135. PSIPRED Sequence analysis results for job ID:28778bd6-703b-
11e2-84bc-00163e110593/NM_LRRC15. 
http://bioinf.cs.ucl.ac.uk/psipred/  6/2/2013. 
136. Nugent T, Jones DT. Transmembrane protein topology prediction 
using support vector machines. BMC Bioinformatics. 
2009;10:159. 
137. CCDS NCBI Report for CCDS46984.1 LRRC15 
www.ncbi.nlm.nih.gov/CCDS,  06/02/2013 




139. Reynolds PA, Smolen GA, Palmer RE et al. Identification of a 
DNA-binding site and transcriptional target for the EWS-
WT1(+KTS) oncoprotein. Genes Dev. 2003;17:2094-2107. 
140. Soule HD, Vazquez J, Long A, Albert S, Brennan M. A human 
cell line from a pleural effusion derived from a breast carcinoma. 
Journal of the National Cancer Institute. 1973;51:1409-1416. 
141. The Cancer Genome Atlas. http://tcga-­‐data.nci.nih.gov/tcga/,	  	  
2/9/2011 
142. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human 
breast tumours. Nature. 2000;406:747-752. 
143. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns 
of breast carcinomas distinguish tumor subclasses with clinical 
implications. P Natl Acad Sci Usa. 2001;98:10869-10874. 
144. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of 
breast tumor subtypes in independent gene expression data sets. P 
Natl Acad Sci Usa. 2003;100:8418-8423. 
145. Zhao H, Langerød A, Ji Y et al. Different gene expression patterns 
in invasive lobular and ductal carcinomas of the breast. Molecular 
biology of the cell. 2004;15:2523-2536. 
146. Radvanyi L, Singh-Sandhu D, Gallichan S et al. The gene 
associated with trichorhinophalangeal syndrome in humans is 




147. Richardson AL, Wang ZC, De Nicolo A et al. X chromosomal 
abnormalities in basal-like human breast cancer. Cancer Cell. 
2006;9:121-132. 
148. Turashvili G, Bouchal J, Baumforth K et al. Novel markers for 
differentiation of lobular and ductal invasive breast carcinomas by 
laser microdissection and microarray analysis. BMC Cancer. 
2007;7:55. 
149. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells 
within tumour stroma promote breast cancer metastasis. Nature. 
2007;449:557-563. 
150. Finak G, Bertos N, Pepin F et al. Stromal gene expression predicts 
clinical outcome in breast cancer. Nat Med. 2008;14:518-527. 
151. Gluck S, Ross JS, Royce M et al. TP53 genomics predict higher 
clinical and pathologic tumor response in operable early-stage 
breast cancer treated with docetaxel-capecitabine +/- trastuzumab. 
Breast Cancer Res Treat. 2011 
152. Satoh K, Hata M, Yokota H. High lib mRNA expression in breast 
carcinomas. DNA Res. 2004;11:199-203. 
153. Satoh K, Hata M, Shimizu T et al. Lib, transcriptionally induced 
in senile plaque-associated astrocytes, promotes glial migration 
through extracellular matrix. Biochem Biophys Res Commun. 
2005;335:631-636. 
154. Klein A, Olendrowitz C, Schmutzler R et al. Identification of 




155. Cailleau R, Olivé M, Cruciger QVJ. Long-term human breast 
carcinoma cell lines of metastatic origin: preliminary 
characterization. In vitro. 1978;14:911-915. 
156. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, 
Joyce MJ. Establishment and characterization of three new 
continuous cell lines derived from human breast carcinomas. 
Cancer research. 1978;38:3352-3364. 
157. Keydar I, Chen L, Karby S et al. Establishment and 
characterization of a cell line of human breast carcinoma origin. 
European Journal of Cancer (1965). 1979;15:659-670. 
158. Lasfargues EY, Coutinho WG, Redfield ES. Isolation of two 
human tumor epithelial cell lines from solid breast carcinomas. 
Journal of the National Cancer Institute. 1978;61:967-978. 
159. Trempe GL. Human breast cancer in culture. Recent Results 
Cancer Res. 1976;33-41. 
160. Soule HD, Maloney TM, Wolman SR et al. Isolation and 
characterization of a spontaneously immortalized human breast 
epithelial cell line, MCF-10. Cancer research. 1990;50:6075-6086. 
161. CCDS NCBI. Report for CCDS28099.1 Lrrc15. 
www.ncbi.nlm.nih.gov/CCDS  27/08/2013 
162. Reilly RF, Ellison DH. Mammalian distal tubule: physiology, 




163. Deen PM, Verdijk MA, Knoers NV et al. Requirement of human 
renal water channel aquaporin-2 for vasopressin-dependent 
concentration of urine. Science. 1994;264:92-95. 
164. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley 
DR. Reactive stroma in human prostate cancer induction of 
myofibroblast phenotype and extracellular matrix remodeling. 
Clinical Cancer Research. 2002;8:2912-2923. 
165. Sanna PP, Williamson RA, De Logu A, Bloom FE, Burton DR. 
Directed selection of recombinant human monoclonal antibodies 
to herpes simplex virus glycoproteins from phage display libraries. 
Proceedings of the National Academy of Sciences. 1995;92:6439-
6443. 
166. Stiller M, Green RE, Ronan M et al. Patterns of nucleotide 
misincorporations during enzymatic amplification and direct 
large-scale sequencing of ancient DNA. Proceedings of the 
National Academy of Sciences. 2006;103:13578-13584. 
167. Vodnik M, Zager U, Strukelj B, Lunder M. Phage display: 
selecting straws instead of a needle from a haystack. Molecules. 
2011;16:790-817. 
168. Gupta S, Thirstrup D, Jarvis TC et al. Rapid histochemistry using 
slow off-rate modified aptamers with anionic competition. Appl 
Immunohistochem Mol Morphol. 2011;19:273-278. 
169. Hartmann LC, Keeney GL, Lingle WL et al. Folate receptor 
overexpression is associated with poor outcome in breast cancer. 
Int J Cancer. 2007;121:938-942. 
 
References 256 
170. Kalli KR, Oberg AL, Keeney GL et al. Folate receptor alpha as a 
tumor target in epithelial ovarian cancer. Gynecol Oncol. 
2008;108:619-626. 
171. Miotti S, Canevari S, Menard S et al. Characterization of human 
ovarian carcinoma-associated antigens defined by novel 
monoclonal antibodies with tumor-restricted specificity. Int J 
Cancer. 1987;39:297-303. 
172. Sadasivan E, Rothenberg SP. The complete amino acid sequence 
of a human folate binding protein from KB cells determined from 
the cDNA. Journal of Biological Chemistry. 1989;264:5806-5811. 
173. Elwood PC. Molecular cloning and characterization of the human 
folate-binding protein cDNA from placenta and malignant tissue 
culture (KB) cells. Journal of Biological Chemistry. 
1989;264:14893-14901. 
174. Rothberg KG, Ying YS, Kolhouse JF, Kamen BA, Anderson RG. 
The glycophospholipid-linked folate receptor internalizes folate 
without entering the clathrin-coated pit endocytic pathway. J Cell 
Biol. 1990;110:637-649. 
175. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-
binding protein is a marker for ovarian cancer. Cancer Research. 
1991;51:5329-5338. 
176. Elwood PC, Nachmanoff K, Saikawa Y et al. The divergent 
5'termini of the α human folate receptor (hFR) mRNAs originate 
from two tissue-specific promoters and alternative splicing: 




177. Borjel AK, Yngve A, Sjostrom M, Nilsson TK. Novel mutations 
in the 5'-UTR of the FOLR1 gene. Clin Chem Lab Med. 
2006;44:161-167. 
178. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of 
folate receptor isoforms in normal and malignant tissues in vivo 
and in established cell lines. Physiologic and clinical implications. 
Cancer. 1994;73:2432-2443. 
179. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. 
Folate receptor expression in carcinomas and normal tissues 
determined by a quantitative radioligand binding assay. Anal 
Biochem. 2005;338:284-293. 
180. O'Shannessy DJ, Yu G, Smale R et al. Folate receptor alpha 
expression in lung cancer: diagnostic and prognostic significance. 
Oncotarget. 2012;3:414. 
181. O’Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu Y-S. 
Folate receptor alpha (FRA) expression in breast cancer: 
identification of a new molecular subtype and association with 
triple negative disease. SpringerPlus. 2012;1:1-9. 
182. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. 
Overexpression of folate binding protein in ovarian cancers. Int J 
Cancer. 1997;74:193-198. 
183. Konner J, Bell-McGuinn K, Sabbatini PJ et al. Farletuzumab, a 
Humanized Monoclonal Antibody against Folate Receptor Alpha, 




184. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. 
Farletuzumab (a monoclonal antibody against folate receptor 
alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol 
Oncol. 2013;129:452-458. 
185. ClinicalTrials.gov NIH US. A Safety and Efficacy Study of 
Farletuzumab in Subjects With Adenocarcinoma of the Lung. 
2010 
186. Leamon CP, Low PS. Delivery of macromolecules into living 
cells: a method that exploits folate receptor endocytosis. Proc Natl 
Acad Sci U S A. 1991;88:5572-5576. 
187. van Dam GM, Themelis G, Crane LM et al. Intraoperative tumor-
specific fluorescence imaging in ovarian cancer by folate receptor-
alpha targeting: first in-human results. Nat Med. 2011 
188. Naumann RW, Coleman RL, Burger RA et al. PRECEDENT: A 
Randomized Phase II Trial Comparing Vintafolide (EC145) and 
Pegylated Liposomal Doxorubicin (PLD) in Combination Versus 
PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. J 
Clin Oncol. 2013 
189. Merck. Study for Women With Platinum Resistant Ovarian 
Cancer Evaluating EC145 in Combination With Doxil® 
(PROCEED). 2010 
190. Setua S, Menon D, Asok A, Nair S, Koyakutty M. Folate receptor 
targeted, rare-earth oxide nanocrystals for bi-modal fluorescence 




191. Zheng Y, Song X, Darby M et al. Preparation and characterization 
of folate-poly(ethylene glycol)-grafted-trimethylchitosan for 
intracellular transport of protein through folate receptor-mediated 
endocytosis. J Biotechnol. 2010;145:47-53. 
192. Toffoli G, Corona G, Tolusso B et al. Resistance to methotrexate 
in SKOV-3 cell lines after chronic exposure to carbamazepine is 
associated with a decreased expression of folate receptor. Int J 
Cancer. 2000;85:683-690. 
193. Gartler SM. Apparent HeLa cell contamination of human 
heteroploid cell lines. 1968 
194. Fogh J, Wright WC, Loveless JD. Absence of HeLa cell 
contamination in 169 cell lines derived from human tumors. 
Journal of the National Cancer institute. 1977;58:209-214. 
195. Nelson-Rees WA, Daniels DW, Flandermeyer RR. Cross-
contamination of cells in culture. Science. 1981;212:446-452. 
196. Alivisatos AP. Semiconductor clusters, nanocrystals, and quantum 
dots. Science. 1996;271:933. 
197. Chan WC. Quantum Dot Bioconjugates for Ultrasensitive 
Nonisotopic Detection. Science. 1998;281:2016-2018. 
198. Dothager RS, Goiffon RJ, Jackson E, Harpstrite S, Piwnica-
Worms D. Cerenkov radiation energy transfer (CRET) imaging: a 
novel method for optical imaging of PET isotopes in biological 
systems. PLoS One. 2010;5:e13300. 
199. Maldonado CR, Gomez-Blanco N, Jauregui-Osoro M, Brunton 
VG, Yate L, Mareque-Rivas JC. QD-filled micelles which 
 
References 260 
combine SPECT and optical imaging with light-induced activation 
of a platinum(IV) prodrug for anticancer applications. Chem 
Commun (Camb). 2013;49:3985-3987. 
200. Reuters. Endocyte Inc (ECYT.O). www.reuters.com/finance/  
01/11/2013 
201. Leamon CP, Parker MA, Vlahov IR et al. Synthesis and 
Biological Evaluation of EC20:  A New Folate-Derived, Tc-Based 
Radiopharmaceutical. Bioconjugate Chem. 2002;13:1200-1210. 
202. Sega EI, Low PS. Tumor detection using folate receptor-targeted 
imaging agents. Cancer Metastasis Rev. 2008;27:655-664. 
203. Ross TL, Honer M, Muller C, Groehn V, Schibli R, Ametamey 
SM. A new 18F-labeled folic acid derivative with improved 
properties for the PET imaging of folate receptor-positive tumors. 
J Nucl Med. 2010;51:1756-1762. 
204. Fani M, Tamma ML, Nicolas GP et al. In vivo imaging of folate 
receptor positive tumor xenografts using novel 68Ga-NODAGA-
folate conjugates. Mol Pharm. 2012;9:1136-1145. 
205. Winter G. Phage display sequencing. 10/10/12 
206. Coussens LM, Fingleton B, Matrisian LM. Matrix 
metalloproteinase inhibitors and cancer: trials and tribulations. 
Science. 2002;295:2387-2392. 
207. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in 




208. Rundhaug JE. Matrix Metalloproteinases, Angiogenesis, and 
Cancer Commentary re: AC Lockhart et al., Reduction of Wound 
Angiogenesis in Patients Treated with BMS-275291, a Broad 
Spectrum Matrix Metalloproteinase Inhibitor. Clin. Cancer Res., 
9: 00–00, 2003. Clinical Cancer Research. 2003;9:551-554. 
209. Gilead  http://www.gilead.com/research/pipeline 03/11/2013 
210. Niedzwiecki. Patterns of MMP-2 and MMP-9 expression in 
human cancer cell lines. Oncol Rep. 2009;21 
211. Bendardaf R, Buhmeida A, Hilska M et al. MMP-9 (gelatinase B) 
expression is associated with disease-free survival and disease-
specific survival in colorectal cancer patients. Cancer Invest. 
2010;28:38-43. 
212. Zheng H, Takahashi H, Murai Y et al. Expressions of MMP-2, 
MMP-9 and VEGF are closely linked to growth, invasion, 
metastasis and angiogenesis of gastric carcinoma. Anticancer 
research. 2006;26:3579-3583. 
213. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, 
Eskelinen MJ, Kosma V-M. Expression of matrix 
metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a 
special reference to activator protein-2, HER2, and prognosis. 
Clinical Cancer Research. 2004;10:7621-7628. 
214. Kim HG, Kim JY, Han EH et al. Metallothionein-2A 
overexpression increases the expression of matrix 




215. Ramos-DeSimone N. Activation of Matrix Metalloproteinase-9 
(MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade 
Enhances Tumor Cell Invasion. Journal of Biological Chemistry. 
1999;274:13066-13076. 
216. Galardy RE, Cassabonne ME, Giese C et al. Low Molecular 
Weight Inhibitors in Corneal Ulcerationa. Annals of the New York 
Academy of Sciences. 1994;732:315-323. 
217. Levin JI, Chen J, Du M et al. The discovery of anthranilic acid-
Based MMP inhibitors. Part 2: SAR of the 5-position and P1-1 
groups. Bioorganic & medicinal chemistry letters. 2001;11:2189-
2192. 
218. Calderwood DA, Campbell ID, Critchley DR. Talins and kindlins: 
partners in integrin-mediated adhesion. Nat Rev Mol Cell Biol. 
2013;14:503-517. 
219. Sin S, Bonin F, Petit V et al. Role of the focal adhesion protein 
kindlin-1 in breast cancer growth and lung metastasis. J Natl 
Cancer Inst. 2011;103:1323-1337. 
220. Kupai K, Szucs G, Cseh S et al. Matrix metalloproteinase activity 
assays: Importance of zymography. J Pharmacol Toxicol Methods. 
2010;61:205-209. 
221. Graber ML, DiLillo DC, Friedman BL, Pastoriza-Munoz E. 
Characteristics of fluoroprobes for measuring intracellular pH. 
Anal Biochem. 1986;156:202-212. 
 
References 263 
222. Csiba L, Paschen W, Hossmann K-A. A topographic quantitative 
method for measuring brain tissue pH under physiological and 
pathophysiological conditions. Brain research. 1983;289:334-337. 
223. O'Reilly RA, Aggeler PM, Leong LS. Studies on the coumarin 
anticoagulant drugs: the pharmacodynamics of warfarin in man. 
Journal of clinical investigation. 1963;42:1542. 
224. Gold L, Janjic N, Jarvis T et al. Aptamers and the RNA world, 
past and present. Cold Spring Harb Perspect Biol. 2012;4 
225. Lounkine E, Keiser MJ, Whitebread S et al. Large-scale prediction 
and testing of drug activity on side-effect targets. Nature. 
2012;486:361-367. 
226. Epenetos AA, Mather S, Granowska M et al. Targeting of iodine-
123-labelled tumour-associated monoclonal antibodies to ovarian, 
breast, and gastrointestinal tumours. The Lancet. 1982;320:999-
1004. 
227. Gaykema SB, Brouwers AH, Hovenga S, Lub-de Hooge MN, de 
Vries EG, Schroder CP. Zirconium-89-trastuzumab positron 
emission tomography as a tool to solve a clinical dilemma in a 
patient with breast cancer. J Clin Oncol. 2012;30:e74-5. 
228. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics 
and pharmacodynamics. J Pharm Sci. 2004;93:2645-2668. 
229. Wallberg H, Grafstrom J, Cheng Q et al. HER2-positive tumors 
imaged within 1 hour using a site-specifically 11C-labeled Sel-
tagged affibody molecule. J Nucl Med. 2012;53:1446-1453. 
 
References 264 
230. Fleuren ED, Versleijen-Jonkers YM, Heskamp S et al. The 
strength of small: improved targeting of insulin-like growth factor-
1 receptor (IGF-1R) with F(ab')(2)-R1507 fragments in Ewing 
sarcomas. Eur J Cancer. 2013;49:2851-2858. 
231. Paganelli G, Riva P, Deleide G et al. In vivo labelling of 
biotinylated monoclonal antibodies by radioactive avidin: a 
strategy to increase tumor radiolocalization. International Journal 
of Cancer. 1988;41:121-125. 
232. Sharkey RM, Cardillo TM, Rossi EA et al. Signal amplification in 
molecular imaging by pretargeting a multivalent, bispecific 
antibody. Nat Med. 2005;11:1250-1255. 
233. Serres S, Soto MS, Hamilton A et al. Molecular MRI enables early 
and sensitive detection of brain metastases. Proc Natl Acad Sci U 
S A. 2012;109:6674-6679. 
234. Finn OJ. Cancer immunology. New England Journal of Medicine. 
2008;358:2704-2715. 
235. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J 
Nucl Med. 2008;49:1735-1738. 
236. Pubchem. Fluciclatide. http://pubchem.ncbi.nlm.nih.gov/ 12/04/14 
237. United States Adopted Name Council. FLUCICLATIDE F18. 
www.ama-assn.org/resources/doc/usan/fluciclatide-f-18.pdf,  
12/04/14 
238. Vandooren J, Geurts N, Martens E, Van den Steen PE, 
Opdenakker G. Zymography methods for visualizing hydrolytic 
enzymes. Nat Methods. 2013;10:211-220. 
 
References 265 
239. Savariar EN, Felsen CN, Nashi N et al. Real-time in vivo 
molecular detection of primary tumors and metastases with 
ratiometric activatable cell-penetrating peptides. Cancer Res. 
2013;73:855-864. 
240. Weissleder R, Pittet MJ. Imaging in the era of molecular 
oncology. Nature. 2008;452:580-589. 
241. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX 
family in cancer. Nat Rev Cancer. 2012;12:540-552. 
242. Erler JT, Bennewith KL, Nicolau M et al. Lysyl oxidase is 
essential for hypoxia-induced metastasis. Nature. 2006;440:1222-
1226. 
243. Fogelgren B, Polgar N, Szauter KM et al. Cellular fibronectin 
binds to lysyl oxidase with high affinity and is critical for its 
proteolytic activation. J Biol Chem. 2005;280:24690-24697. 
244. Chua F, Laurent GJ. Neutrophil elastase: mediator of extracellular 
matrix destruction and accumulation. Proc Am Thorac Soc. 
2006;3:424-427. 
245. Gregory AD, Houghton AM. Tumor-associated neutrophils: new 
targets for cancer therapy. Cancer Res. 2011;71:2411-2416. 




Index of Figures 266 
Index of Figures 
FIGURE 1.	   Principles of Computed Tomography 8	  
FIGURE 2.	   Principles of Positron Emission Tomography 14	  
FIGURE 3.	   CT Guided Biopsy of a Pulmonary Hilar Mass 17	  
FIGURE 4.	   A Quenched Pair of Fluorophores are Revealed 
Following Separation 23	  
FIGURE 5.	   Selection and Amplification of an Aptamer Library 24	  
FIGURE 6.	   Selection and Elution of a Phage Display Peptide Library 
26	  
FIGURE 7.	   Crystallographic Structure of an Aptamer Binding 
Cyanocobalamin 27	  
FIGURE 8.	   Emission Spectrum of the Folate Conjugated Quantum 
Dots 69	  
FIGURE 9.	   Quantum Dot Fluoresence Detected Using the Flow 
Cytometer 70	  
FIGURE 10.	   Bacteriophage Plaques in Cultures of Escherichia Coli 
72	  
FIGURE 11.	   Sandwich Immunosorbent Fluorescent Assay 81	  
FIGURE 12.	   A Test 2nd-Stage Amplification PCR 87	  
FIGURE 13.	   Predicted Structural Domains in the LRRC15 Protein 100	  
FIGURE 14.	   Predicted Structural Domains in the LRRC15 Protein (2) 
100	  
FIGURE 15.	   Western Blot and Immunofluorescent Detection of 
Tagged LRRC15 101	  
FIGURE 16.	   Oncomine Meta-analysis of Gene Transcription in 
Breast Cancer 102	  
FIGURE 17.	   Screening of Six Test Antibodies Raised to Peptides in 
LRRC15 105	  
 
Index of Figures 267 
FIGURE 18.	   Western Blot Detection of LRRC15_HA by a Novel 
Antibody 106	  
FIGURE 19.	   Immunofluorescence of LRRC15_HA Using a Novel 
Antibody 107	  
FIGURE 20.	   Western Blot to Assess Sensitivity of the New LRRC15 
Antibody 109	  
FIGURE 21.	   Non-Detection of LRRC15 Protein in Breast-Cancer Cell 
Lines 110	  
FIGURE 22.	   Detection of LRRC15 mRNA in Breast-Cancer Cell 
Lines 111	  
FIGURE 23.	   Quantification of LRRC15 mRNA in 3 Human Breast 
Cell-Lines 112	  
FIGURE 24.	   Human LRRC15 Amino acid Sequence, and Murine 
Homologue 113	  
FIGURE 25.	   Western Blot of Murine Tissue Lysates, LRRC15 
Antibody 115	  
FIGURE 26.	   LRRC15 Antibody Staining in FFPE Murine Liver 117	  
FIGURE 27.	   LRRC15 Antibody Staining in FFPE Murine Lung 118	  
FIGURE 28.	   LRRC15 Antibody Staining in FFPE Murine Fat Pad 119	  
FIGURE 29.	   LRRC15 Antibody Staining in FFPE Murine Breast 
Cancer 120	  
FIGURE 30.	   LRRC15 Antibody Staining in FFPE Murine Breast 
Cancer 2 121	  
FIGURE 31.	   LRRC15 Antibody Staining in FFPE Murine Breast 
Cancer 3 122	  
FIGURE 32.	   LRRC15 Antibody Staining in FFPE Murine Breast 
Cancer 4 123	  
FIGURE 33.	   LRRC15 Antibody Staining in FFPE Murine Kidney 124	  
FIGURE 34.	   Location of Lrrc15 in murine Kidney - Triple stain 125	  
 
Index of Figures 268 
FIGURE 35.	   LRRC15 Immunohistochemistry in Human Breast-
cancer samples 127	  
FIGURE 36.	   Western Blot of LRRC15_HA Expression and 
Immunoprecipitation 133	  
FIGURE 37.	   Sequencing of LRRC15 Affinity Selected Peptide 
Libraries 136	  
FIGURE 38.	   Confocal Fluorescent Microscopy, LRRC15 Peptide 1 
138	  
FIGURE 39.	   Confocal Fluorescent Microscopy, LRRC15 Peptide 2 
139	  
FIGURE 40.	   Plate-based Assay of LRRC15 Peptide 1 and 2 Binding 
140	  
FIGURE 41.	   Plate-based Assay of Peptide Binding at Lower 
Concentrations 141	  
FIGURE 42.	   Peptide Array Test of LRRC15_HA Binding 142	  
FIGURE 43.	   Sequencing of LRRC15 Affinity Selected Aptamer 
Libraries 145	  
FIGURE 44.	   Confocal Fluorescent Microscopy of Test Aptamer 
Binding to Cells 146	  
FIGURE 45.	   Binding of Selected Libraries to Immunosorbed 
LRRC15_HA 148	  
FIGURE 46.	   DNA Microarray Test of LRRC15 Binding 149	  
FIGURE 47.	   Base Composition in Aptamer Sequencing 151	  
FIGURE 48.	   Sequence Tagged FOLR1 in a Mammalian Expression 
Vector 158	  
FIGURE 49.	   Recombinant FOLR1 Transcription and Expression 160	  
FIGURE 50.	   Recombinant FOLR1 Expression by Flow Cytometry 
161	  
FIGURE 51.	   Flow Cytometry with Carboxyfluorescein Labelled 
Folate 163	  
 
Index of Figures 269 
FIGURE 52.	   Flow Cytometry with Folate Conjugated Quantum Dots 
165	  
FIGURE 53.	   Live-cell Staining by a Folic Acid Quantum Dot 
Compound 166	  
FIGURE 54.	   Sequencing Of Whole-Cell Affinity Selected Peptide 
Libraries 168	  
FIGURE 55.	   Sequencing Of Whole-Cell FOLR1 Selected Aptamer 
Libraries 170	  
FIGURE 56.	   Probe Fluorescent Response using Recombinant Human 
MMPs (1) 178	  
FIGURE 57.	   Probe Fluorescent Response using 30nM rh MMPs 179	  
FIGURE 58.	   D-Amino acid Control Probe with Recombinant Human 
MMP-9 180	  
FIGURE 59.	   Fluorescent Response with Fragments of Murine Tissue 
181	  
FIGURE 60.	   Fluorescent Response with Fragments Of Murine Tissue 
(Continued) 182	  
FIGURE 61.	   Comparison Between Kidney, Tumour, and Fat pad 
Responses 183	  
FIGURE 62.	   Probe Activation by Lysates of Murine Kidney and Liver 
184	  
FIGURE 63.	   Probe Activation by Fat Pad and Breast Tumour (1) 187	  
FIGURE 64.	   Probe Activation by Fat Pad and Breast Tumour (2) 188	  
FIGURE 65.	   Activation by Tumour - Effect of Kindlin-1 Deletion (1) 
190	  
FIGURE 66.	   Activation by Tumour - Effect of Kindlin-1 Deletion (2) 
191	  
FIGURE 67.	   Rate of Fluorescence Increase against Total Protein 192	  
FIGURE 68.	   Rate of Fluorescence Increase in hr MMP-9 Controls 
against Date 194	  
 
Index of Figures 270 
FIGURE 69.	   Mmp-2, 3, 9 and 13 mRNA Detection in Lysates of 
Murine Tissues 196	  
FIGURE 70.	   Mmp-2 and 3 Immunohistochemistry Murine Kidney 198	  
FIGURE 71.	   Mmp-9 IHC in Murine Lung 199	  
FIGURE 72.	   Mmp-13 IHC in Murine Kidney 200	  
FIGURE 73.	   Mmp-2 and 3 IHC in a PyMT Breast Tumour 201	  
FIGURE 74.	   Mmp-9 and 13 IHC in a PyMT Breast Tumour 202	  
FIGURE 75.	   Mmp-2 and 3 IHC in a Second PyMT Breast Tumour 
203	  
FIGURE 76.	   Mmp-9 and 13 IHC in a Second PyMT Breast Tumour 
204	  
FIGURE 77.	   Mmp-2 and 3 IHC in a NIC Pten -/+ Breast Tumour 205	  
FIGURE 78.	   Mmp-9 and 13 IHC in a NIC Pten -/+ Breast Tumour 206	  
FIGURE 79.	   Mmp-2 and 3 IHC in a Second NIC Pten -/+ Breast 
Tumour 207	  
FIGURE 80.	   Mmp-9 and 13 IHC in a Second NIC Pten -/+ Breast 
Tumour 208	  
FIGURE 81.	   Proteinase Activity in Murine Tissue Lysates, by Gelatin 
Zymography 210	  
FIGURE 82.	   Fluciclatide structural diagrams 225	  
 
